id	sid	tid	token	lemma	pos
dpc-6169	1	1	dermatology	dermatology	NOUN
dpc-6169	1	2	:	:	PUNCT
dpc-6169	1	3	practical	practical	ADJ
dpc-6169	1	4	and	and	CCONJ
dpc-6169	1	5	conceptual	conceptual	ADJ
dpc-6169	1	6	original	original	ADJ
dpc-6169	1	7	article	article	NOUN
dpc-6169	1	8	|	|	ADV
dpc-6169	1	9	dermatol	dermatol	ADJ
dpc-6169	1	10	pract	pract	NOUN
dpc-6169	1	11	concept	concept	NOUN
dpc-6169	1	12	.	.	PUNCT
dpc-6169	2	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	2	2	1	1	NUM
dpc-6169	2	3	predictors	predictor	NOUN
dpc-6169	2	4	of	of	ADP
dpc-6169	2	5	early	early	ADJ
dpc-6169	2	6	response	response	NOUN
dpc-6169	2	7	and	and	CCONJ
dpc-6169	2	8	relapse	relapse	NOUN
dpc-6169	2	9	in	in	ADP
dpc-6169	2	10	chronic	chronic	ADJ
dpc-6169	2	11	spontaneous	spontaneous	ADJ
dpc-6169	2	12	urticaria	urticaria	NOUN
dpc-6169	2	13	treated	treat	VERB
dpc-6169	2	14	with	with	ADP
dpc-6169	2	15	omalizumab	omalizumab	NOUN
dpc-6169	2	16	:	:	PUNCT
dpc-6169	2	17	the	the	DET
dpc-6169	2	18	role	role	NOUN
dpc-6169	2	19	of	of	ADP
dpc-6169	2	20	age	age	NOUN
dpc-6169	2	21	,	,	PUNCT
dpc-6169	2	22	sex	sex	NOUN
dpc-6169	2	23	,	,	PUNCT
dpc-6169	2	24	disease	disease	NOUN
dpc-6169	2	25	duration	duration	NOUN
dpc-6169	2	26	,	,	PUNCT
dpc-6169	2	27	and	and	CCONJ
dpc-6169	2	28	uas7	uas7	PROPN
dpc-6169	2	29	mehmet	mehmet	PROPN
dpc-6169	2	30	enes	enes	PROPN
dpc-6169	2	31	güner1	güner1	PROPN
dpc-6169	2	32	,	,	PUNCT
dpc-6169	2	33	perihan	perihan	PROPN
dpc-6169	2	34	öztürk2	öztürk2	NOUN
dpc-6169	2	35	,	,	PUNCT
dpc-6169	2	36	ozan	ozan	PROPN
dpc-6169	2	37	can	can	AUX
dpc-6169	2	38	yaray2	yaray2	NOUN
dpc-6169	2	39	,	,	PUNCT
dpc-6169	2	40	esra	esra	PROPN
dpc-6169	2	41	merve	merve	PROPN
dpc-6169	2	42	evran	evran	PROPN
dpc-6169	2	43	kılıç2	kılıç2	PROPN
dpc-6169	2	44	,	,	PUNCT
dpc-6169	2	45	mine	mine	NOUN
dpc-6169	2	46	müjde	müjde	NOUN
dpc-6169	2	47	kuş2	kuş2	PROPN
dpc-6169	2	48	1	1	NUM
dpc-6169	2	49	department	department	NOUN
dpc-6169	2	50	of	of	ADP
dpc-6169	2	51	dermatology	dermatology	NOUN
dpc-6169	2	52	,	,	PUNCT
dpc-6169	2	53	besni	besni	VERB
dpc-6169	2	54	state	state	NOUN
dpc-6169	2	55	hospital	hospital	NOUN
dpc-6169	2	56	,	,	PUNCT
dpc-6169	2	57	besni	besni	NOUN
dpc-6169	2	58	,	,	PUNCT
dpc-6169	2	59	adiyaman	adiyaman	NOUN
dpc-6169	2	60	,	,	PUNCT
dpc-6169	2	61	turkey	turkey	PROPN
dpc-6169	2	62	2	2	NUM
dpc-6169	2	63	department	department	NOUN
dpc-6169	2	64	of	of	ADP
dpc-6169	2	65	dermatology	dermatology	NOUN
dpc-6169	2	66	,	,	PUNCT
dpc-6169	2	67	kahramanmaras	kahramanmaras	PROPN
dpc-6169	2	68	sutcu	sutcu	PROPN
dpc-6169	2	69	imam	imam	PROPN
dpc-6169	2	70	university	university	PROPN
dpc-6169	2	71	,	,	PUNCT
dpc-6169	2	72	kahramanmaras	kahramanmaras	PROPN
dpc-6169	2	73	,	,	PUNCT
dpc-6169	2	74	turkey	turkey	NOUN
dpc-6169	2	75	key	key	ADJ
dpc-6169	2	76	words	word	NOUN
dpc-6169	2	77	:	:	PUNCT
dpc-6169	2	78	omalizumab	omalizumab	NOUN
dpc-6169	2	79	,	,	PUNCT
dpc-6169	2	80	relapse	relapse	NOUN
dpc-6169	2	81	,	,	PUNCT
dpc-6169	2	82	chronic	chronic	ADJ
dpc-6169	2	83	spontaneous	spontaneous	ADJ
dpc-6169	2	84	urticaria	urticaria	NOUN
dpc-6169	2	85	,	,	PUNCT
dpc-6169	2	86	sex	sex	NOUN
dpc-6169	2	87	,	,	PUNCT
dpc-6169	2	88	age	age	NOUN
dpc-6169	2	89	citation	citation	NOUN
dpc-6169	2	90	:	:	PUNCT
dpc-6169	2	91	güner	güner	NOUN
dpc-6169	2	92	me	i	PRON
dpc-6169	2	93	,	,	PUNCT
dpc-6169	2	94	öztürk	öztürk	NOUN
dpc-6169	2	95	p	p	NOUN
dpc-6169	2	96	,	,	PUNCT
dpc-6169	2	97	yaray	yaray	ADJ
dpc-6169	2	98	oc	oc	NOUN
dpc-6169	2	99	,	,	PUNCT
dpc-6169	2	100	evran	evran	PROPN
dpc-6169	2	101	kılıç	kılıç	PROPN
dpc-6169	2	102	em	em	PRON
dpc-6169	2	103	,	,	PUNCT
dpc-6169	2	104	kuş	kuş	PROPN
dpc-6169	2	105	mm	mm	PROPN
dpc-6169	2	106	.	.	PUNCT
dpc-6169	2	107	predictors	predictor	NOUN
dpc-6169	2	108	of	of	ADP
dpc-6169	2	109	early	early	ADJ
dpc-6169	2	110	response	response	NOUN
dpc-6169	2	111	and	and	CCONJ
dpc-6169	2	112	relapse	relapse	NOUN
dpc-6169	2	113	in	in	ADP
dpc-6169	2	114	chronic	chronic	ADJ
dpc-6169	2	115	spontaneous	spontaneous	ADJ
dpc-6169	2	116	urticaria	urticaria	NOUN
dpc-6169	2	117	treated	treat	VERB
dpc-6169	2	118	with	with	ADP
dpc-6169	2	119	omalizumab	omalizumab	NOUN
dpc-6169	2	120	:	:	PUNCT
dpc-6169	2	121	the	the	DET
dpc-6169	2	122	role	role	NOUN
dpc-6169	2	123	of	of	ADP
dpc-6169	2	124	age	age	NOUN
dpc-6169	2	125	,	,	PUNCT
dpc-6169	2	126	sex	sex	NOUN
dpc-6169	2	127	,	,	PUNCT
dpc-6169	2	128	disease	disease	NOUN
dpc-6169	2	129	duration	duration	NOUN
dpc-6169	2	130	,	,	PUNCT
dpc-6169	2	131	and	and	CCONJ
dpc-6169	2	132	uas7	uas7	NOUN
dpc-6169	2	133	.	.	PUNCT
dpc-6169	3	1	dermatol	dermatol	NOUN
dpc-6169	3	2	pract	pract	PROPN
dpc-6169	3	3	concept	concept	NOUN
dpc-6169	3	4	.	.	PUNCT
dpc-6169	4	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	4	2	.	.	PUNCT
dpc-6169	5	1	doi	doi	PROPN
dpc-6169	5	2	:	:	PUNCT
dpc-6169	5	3	https://doi.org/10.5826/dpc.1504a6169	https://doi.org/10.5826/dpc.1504a6169	PROPN
dpc-6169	5	4	accepted	accept	VERB
dpc-6169	5	5	:	:	PUNCT
dpc-6169	5	6	july	july	PROPN
dpc-6169	5	7	17	17	NUM
dpc-6169	5	8	,	,	PUNCT
dpc-6169	5	9	2025	2025	NUM
dpc-6169	5	10	;	;	PUNCT
dpc-6169	5	11	published	publish	VERB
dpc-6169	5	12	:	:	PUNCT
dpc-6169	6	1	october	october	PROPN
dpc-6169	6	2	2025	2025	NUM
dpc-6169	6	3	copyright	copyright	NOUN
dpc-6169	6	4	:	:	PUNCT
dpc-6169	6	5	©	©	PROPN
dpc-6169	6	6	2025	2025	NUM
dpc-6169	6	7	güner	güner	NOUN
dpc-6169	6	8	et	et	PROPN
dpc-6169	6	9	al	al	PROPN
dpc-6169	6	10	.	.	PUNCT
dpc-6169	7	1	this	this	PRON
dpc-6169	7	2	is	be	AUX
dpc-6169	7	3	an	an	DET
dpc-6169	7	4	open	open	ADJ
dpc-6169	7	5	-	-	PUNCT
dpc-6169	7	6	access	access	NOUN
dpc-6169	7	7	article	article	NOUN
dpc-6169	7	8	distributed	distribute	VERB
dpc-6169	7	9	under	under	ADP
dpc-6169	7	10	the	the	DET
dpc-6169	7	11	terms	term	NOUN
dpc-6169	7	12	of	of	ADP
dpc-6169	7	13	the	the	DET
dpc-6169	7	14	creative	creative	ADJ
dpc-6169	7	15	commons	common	NOUN
dpc-6169	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-6169	7	17	license	license	NOUN
dpc-6169	7	18	(	(	PUNCT
dpc-6169	7	19	by	by	ADP
dpc-6169	7	20	-	-	PUNCT
dpc-6169	7	21	nc-4.0	nc-4.0	NOUN
dpc-6169	7	22	)	)	PUNCT
dpc-6169	7	23	,	,	PUNCT
dpc-6169	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-6169	7	25	,	,	PUNCT
dpc-6169	7	26	which	which	PRON
dpc-6169	7	27	permits	permit	VERB
dpc-6169	7	28	unrestricted	unrestricted	ADJ
dpc-6169	7	29	noncommercial	noncommercial	ADJ
dpc-6169	7	30	use	use	NOUN
dpc-6169	7	31	,	,	PUNCT
dpc-6169	7	32	distribution	distribution	NOUN
dpc-6169	7	33	,	,	PUNCT
dpc-6169	7	34	and	and	CCONJ
dpc-6169	7	35	reproduction	reproduction	NOUN
dpc-6169	7	36	in	in	ADP
dpc-6169	7	37	any	any	DET
dpc-6169	7	38	medium	medium	NOUN
dpc-6169	7	39	,	,	PUNCT
dpc-6169	7	40	provided	provide	VERB
dpc-6169	7	41	the	the	DET
dpc-6169	7	42	original	original	ADJ
dpc-6169	7	43	authors	author	NOUN
dpc-6169	7	44	and	and	CCONJ
dpc-6169	7	45	source	source	NOUN
dpc-6169	7	46	are	be	AUX
dpc-6169	7	47	credited	credit	VERB
dpc-6169	7	48	.	.	PUNCT
dpc-6169	8	1	funding	funding	NOUN
dpc-6169	8	2	:	:	PUNCT
dpc-6169	8	3	none	none	NOUN
dpc-6169	8	4	.	.	PUNCT
dpc-6169	9	1	competing	compete	VERB
dpc-6169	9	2	interests	interest	NOUN
dpc-6169	9	3	:	:	PUNCT
dpc-6169	9	4	none	none	NOUN
dpc-6169	9	5	.	.	PUNCT
dpc-6169	10	1	authorship	authorship	NOUN
dpc-6169	10	2	:	:	PUNCT
dpc-6169	10	3	all	all	DET
dpc-6169	10	4	authors	author	NOUN
dpc-6169	10	5	have	have	AUX
dpc-6169	10	6	contributed	contribute	VERB
dpc-6169	10	7	significantly	significantly	ADV
dpc-6169	10	8	to	to	ADP
dpc-6169	10	9	this	this	DET
dpc-6169	10	10	publication	publication	NOUN
dpc-6169	10	11	.	.	PUNCT
dpc-6169	11	1	corresponding	correspond	VERB
dpc-6169	11	2	author	author	NOUN
dpc-6169	11	3	:	:	PUNCT
dpc-6169	11	4	mehmet	mehmet	PROPN
dpc-6169	11	5	enes	enes	PROPN
dpc-6169	11	6	güner	güner	PROPN
dpc-6169	11	7	,	,	PUNCT
dpc-6169	11	8	md	md	PROPN
dpc-6169	11	9	.	.	PROPN
dpc-6169	11	10	department	department	PROPN
dpc-6169	11	11	of	of	ADP
dpc-6169	11	12	dermatology	dermatology	NOUN
dpc-6169	11	13	,	,	PUNCT
dpc-6169	11	14	besni	besni	VERB
dpc-6169	11	15	state	state	NOUN
dpc-6169	11	16	hospital	hospital	NOUN
dpc-6169	11	17	,	,	PUNCT
dpc-6169	11	18	besni	besni	NOUN
dpc-6169	11	19	,	,	PUNCT
dpc-6169	11	20	adiyaman	adiyaman	NOUN
dpc-6169	11	21	,	,	PUNCT
dpc-6169	11	22	turkey	turkey	PROPN
dpc-6169	11	23	.	.	PUNCT
dpc-6169	12	1	email	email	NOUN
dpc-6169	12	2	:	:	PUNCT
dpc-6169	12	3	mehmetenesguner171@hotmail.com	mehmetenesguner171@hotmail.com	X
dpc-6169	12	4	orcid	orcid	NOUN
dpc-6169	13	1	i	i	NOUN
dpc-6169	13	2	d	d	NOUN
dpc-6169	13	3	:	:	PUNCT
dpc-6169	13	4	https://orcid.org/0000-0001-5424-4674	https://orcid.org/0000-0001-5424-4674	X
dpc-6169	13	5	introduction	introduction	NOUN
dpc-6169	13	6	:	:	PUNCT
dpc-6169	13	7	omalizumab	omalizumab	NOUN
dpc-6169	13	8	is	be	AUX
dpc-6169	13	9	an	an	DET
dpc-6169	13	10	established	establish	VERB
dpc-6169	13	11	treatment	treatment	NOUN
dpc-6169	13	12	for	for	ADP
dpc-6169	13	13	chronic	chronic	ADJ
dpc-6169	13	14	spontaneous	spontaneous	ADJ
dpc-6169	13	15	urticaria	urticaria	NOUN
dpc-6169	13	16	(	(	PUNCT
dpc-6169	13	17	csu	csu	PROPN
dpc-6169	13	18	)	)	PUNCT
dpc-6169	13	19	,	,	PUNCT
dpc-6169	13	20	yet	yet	CCONJ
dpc-6169	13	21	variability	variability	NOUN
dpc-6169	13	22	in	in	ADP
dpc-6169	13	23	therapeutic	therapeutic	ADJ
dpc-6169	13	24	response	response	NOUN
dpc-6169	13	25	remains	remain	VERB
dpc-6169	13	26	a	a	DET
dpc-6169	13	27	clinical	clinical	ADJ
dpc-6169	13	28	challenge	challenge	NOUN
dpc-6169	13	29	.	.	PUNCT
dpc-6169	14	1	identifying	identify	VERB
dpc-6169	14	2	baseline	baseline	ADJ
dpc-6169	14	3	predictors	predictor	NOUN
dpc-6169	14	4	of	of	ADP
dpc-6169	14	5	early	early	ADJ
dpc-6169	14	6	response	response	NOUN
dpc-6169	14	7	may	may	AUX
dpc-6169	14	8	help	help	VERB
dpc-6169	14	9	optimize	optimize	VERB
dpc-6169	14	10	patient	patient	ADJ
dpc-6169	14	11	selection	selection	NOUN
dpc-6169	14	12	and	and	CCONJ
dpc-6169	14	13	management	management	NOUN
dpc-6169	14	14	strategies	strategy	NOUN
dpc-6169	14	15	.	.	PUNCT
dpc-6169	15	1	objectives	objective	NOUN
dpc-6169	15	2	:	:	PUNCT
dpc-6169	15	3	to	to	PART
dpc-6169	15	4	evaluate	evaluate	VERB
dpc-6169	15	5	the	the	DET
dpc-6169	15	6	predictive	predictive	ADJ
dpc-6169	15	7	value	value	NOUN
dpc-6169	15	8	of	of	ADP
dpc-6169	15	9	age	age	NOUN
dpc-6169	15	10	,	,	PUNCT
dpc-6169	15	11	sex	sex	NOUN
dpc-6169	15	12	,	,	PUNCT
dpc-6169	15	13	baseline	baseline	ADJ
dpc-6169	15	14	disease	disease	NOUN
dpc-6169	15	15	severity	severity	NOUN
dpc-6169	15	16	,	,	PUNCT
dpc-6169	15	17	and	and	CCONJ
dpc-6169	15	18	disease	disease	NOUN
dpc-6169	15	19	duration	duration	NOUN
dpc-6169	15	20	for	for	ADP
dpc-6169	15	21	early	early	ADJ
dpc-6169	15	22	response	response	NOUN
dpc-6169	15	23	to	to	ADP
dpc-6169	15	24	omalizumab	omalizumab	NOUN
dpc-6169	15	25	and	and	CCONJ
dpc-6169	15	26	to	to	PART
dpc-6169	15	27	assess	assess	VERB
dpc-6169	15	28	their	their	PRON
dpc-6169	15	29	relationship	relationship	NOUN
dpc-6169	15	30	with	with	ADP
dpc-6169	15	31	relapse	relapse	NOUN
dpc-6169	15	32	risk	risk	NOUN
dpc-6169	15	33	.	.	PUNCT
dpc-6169	16	1	methods	method	NOUN
dpc-6169	16	2	:	:	PUNCT
dpc-6169	16	3	this	this	DET
dpc-6169	16	4	retrospective	retrospective	ADJ
dpc-6169	16	5	study	study	NOUN
dpc-6169	16	6	included	include	VERB
dpc-6169	16	7	274	274	NUM
dpc-6169	16	8	patients	patient	NOUN
dpc-6169	16	9	with	with	ADP
dpc-6169	16	10	csu	csu	PROPN
dpc-6169	16	11	treated	treat	VERB
dpc-6169	16	12	with	with	ADP
dpc-6169	16	13	omalizumab	omalizumab	NOUN
dpc-6169	16	14	between	between	ADP
dpc-6169	16	15	2011	2011	NUM
dpc-6169	16	16	and	and	CCONJ
dpc-6169	16	17	2024	2024	NUM
dpc-6169	16	18	.	.	PUNCT
dpc-6169	17	1	early	early	ADJ
dpc-6169	17	2	response	response	NOUN
dpc-6169	17	3	was	be	AUX
dpc-6169	17	4	defined	define	VERB
dpc-6169	17	5	as	as	ADP
dpc-6169	17	6	achieving	achieve	VERB
dpc-6169	17	7	a	a	DET
dpc-6169	17	8	uas7	uas7	ADJ
dpc-6169	17	9	score	score	NOUN
dpc-6169	17	10	<	<	X
dpc-6169	17	11	7	7	NUM
dpc-6169	17	12	at	at	ADP
dpc-6169	17	13	one	one	NUM
dpc-6169	17	14	month	month	NOUN
dpc-6169	17	15	.	.	PUNCT
dpc-6169	18	1	baseline	baseline	PROPN
dpc-6169	18	2	variables	variable	NOUN
dpc-6169	18	3	included	include	VERB
dpc-6169	18	4	age	age	NOUN
dpc-6169	18	5	,	,	PUNCT
dpc-6169	18	6	sex	sex	NOUN
dpc-6169	18	7	,	,	PUNCT
dpc-6169	18	8	uas7	uas7	NOUN
dpc-6169	18	9	,	,	PUNCT
dpc-6169	18	10	and	and	CCONJ
dpc-6169	18	11	disease	disease	NOUN
dpc-6169	18	12	duration	duration	NOUN
dpc-6169	18	13	.	.	PUNCT
dpc-6169	19	1	binary	binary	ADJ
dpc-6169	19	2	logistic	logistic	ADJ
dpc-6169	19	3	regression	regression	NOUN
dpc-6169	19	4	and	and	CCONJ
dpc-6169	19	5	roc	roc	PROPN
dpc-6169	19	6	curve	curve	NOUN
dpc-6169	19	7	analyses	analysis	NOUN
dpc-6169	19	8	were	be	AUX
dpc-6169	19	9	conducted	conduct	VERB
dpc-6169	19	10	to	to	PART
dpc-6169	19	11	identify	identify	VERB
dpc-6169	19	12	independent	independent	ADJ
dpc-6169	19	13	predictors	predictor	NOUN
dpc-6169	19	14	of	of	ADP
dpc-6169	19	15	early	early	ADJ
dpc-6169	19	16	response	response	NOUN
dpc-6169	19	17	.	.	PUNCT
dpc-6169	20	1	results	result	NOUN
dpc-6169	20	2	:	:	PUNCT
dpc-6169	20	3	among	among	ADP
dpc-6169	20	4	274	274	NUM
dpc-6169	20	5	patients	patient	NOUN
dpc-6169	20	6	(	(	PUNCT
dpc-6169	20	7	mean	mean	VERB
dpc-6169	20	8	age	age	NOUN
dpc-6169	20	9	42.96±15.54	42.96±15.54	NUM
dpc-6169	20	10	years	year	NOUN
dpc-6169	20	11	;	;	PUNCT
dpc-6169	20	12	66.4	66.4	NUM
dpc-6169	20	13	%	%	NOUN
dpc-6169	20	14	female	female	NOUN
dpc-6169	20	15	)	)	PUNCT
dpc-6169	20	16	,	,	PUNCT
dpc-6169	20	17	early	early	ADJ
dpc-6169	20	18	response	response	NOUN
dpc-6169	20	19	was	be	AUX
dpc-6169	20	20	achieved	achieve	VERB
dpc-6169	20	21	in	in	ADP
dpc-6169	20	22	37.6	37.6	NUM
dpc-6169	20	23	%	%	NOUN
dpc-6169	20	24	.	.	PUNCT
dpc-6169	21	1	early	early	ADJ
dpc-6169	21	2	responders	responder	NOUN
dpc-6169	21	3	had	have	VERB
dpc-6169	21	4	significantly	significantly	ADV
dpc-6169	21	5	lower	low	ADJ
dpc-6169	21	6	baseline	baseline	ADJ
dpc-6169	21	7	uas7	uas7	NOUN
dpc-6169	21	8	and	and	CCONJ
dpc-6169	21	9	shorter	short	ADJ
dpc-6169	21	10	disease	disease	NOUN
dpc-6169	21	11	duration	duration	NOUN
dpc-6169	21	12	(	(	PUNCT
dpc-6169	21	13	both	both	DET
dpc-6169	21	14	p<0.001	p<0.001	X
dpc-6169	21	15	)	)	PUNCT
dpc-6169	21	16	.	.	PUNCT
dpc-6169	22	1	logistic	logistic	ADJ
dpc-6169	22	2	regression	regression	NOUN
dpc-6169	22	3	confirmed	confirm	VERB
dpc-6169	22	4	both	both	DET
dpc-6169	22	5	variables	variable	NOUN
dpc-6169	22	6	as	as	ADP
dpc-6169	22	7	independent	independent	ADJ
dpc-6169	22	8	predictors	predictor	NOUN
dpc-6169	22	9	.	.	PUNCT
dpc-6169	23	1	age	age	NOUN
dpc-6169	23	2	and	and	CCONJ
dpc-6169	23	3	sex	sex	NOUN
dpc-6169	23	4	were	be	AUX
dpc-6169	23	5	not	not	PART
dpc-6169	23	6	independently	independently	ADV
dpc-6169	23	7	associated	associate	VERB
dpc-6169	23	8	with	with	ADP
dpc-6169	23	9	early	early	ADJ
dpc-6169	23	10	response	response	NOUN
dpc-6169	23	11	,	,	PUNCT
dpc-6169	23	12	although	although	SCONJ
dpc-6169	23	13	univariate	univariate	ADJ
dpc-6169	23	14	analysis	analysis	NOUN
dpc-6169	23	15	showed	show	VERB
dpc-6169	23	16	a	a	DET
dpc-6169	23	17	higher	high	ADJ
dpc-6169	23	18	early	early	ADJ
dpc-6169	23	19	response	response	NOUN
dpc-6169	23	20	rate	rate	NOUN
dpc-6169	23	21	in	in	ADP
dpc-6169	23	22	patients	patient	NOUN
dpc-6169	23	23	aged	age	VERB
dpc-6169	23	24	<	<	X
dpc-6169	23	25	45	45	NUM
dpc-6169	23	26	years	year	NOUN
dpc-6169	23	27	.	.	PUNCT
dpc-6169	24	1	roc	roc	NOUN
dpc-6169	24	2	analysis	analysis	NOUN
dpc-6169	24	3	demonstrated	demonstrate	VERB
dpc-6169	24	4	strong	strong	ADJ
dpc-6169	24	5	inverse	inverse	NOUN
dpc-6169	24	6	abstract	abstract	ADJ
dpc-6169	24	7	2	2	NUM
dpc-6169	24	8	original	original	ADJ
dpc-6169	24	9	article	article	NOUN
dpc-6169	24	10	|	|	ADV
dpc-6169	24	11	dermatol	dermatol	ADJ
dpc-6169	24	12	pract	pract	NOUN
dpc-6169	24	13	concept	concept	NOUN
dpc-6169	24	14	.	.	PUNCT
dpc-6169	25	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	25	2	predictive	predictive	ADJ
dpc-6169	25	3	value	value	NOUN
dpc-6169	25	4	for	for	ADP
dpc-6169	25	5	uas7	uas7	NOUN
dpc-6169	25	6	(	(	PUNCT
dpc-6169	25	7	auc=0.917	auc=0.917	NOUN
dpc-6169	25	8	)	)	PUNCT
dpc-6169	25	9	and	and	CCONJ
dpc-6169	25	10	disease	disease	NOUN
dpc-6169	25	11	duration	duration	NOUN
dpc-6169	25	12	(	(	PUNCT
dpc-6169	25	13	auc=0.940	auc=0.940	NOUN
dpc-6169	25	14	)	)	PUNCT
dpc-6169	25	15	.	.	PUNCT
dpc-6169	26	1	relapse	relapse	NOUN
dpc-6169	26	2	risk	risk	NOUN
dpc-6169	26	3	was	be	AUX
dpc-6169	26	4	significantly	significantly	ADV
dpc-6169	26	5	lower	low	ADJ
dpc-6169	26	6	in	in	ADP
dpc-6169	26	7	females	female	NOUN
dpc-6169	26	8	and	and	CCONJ
dpc-6169	26	9	patients	patient	NOUN
dpc-6169	26	10	aged	age	VERB
dpc-6169	26	11	<	<	X
dpc-6169	26	12	45	45	NUM
dpc-6169	26	13	years	year	NOUN
dpc-6169	26	14	.	.	PUNCT
dpc-6169	27	1	conclusions	conclusion	NOUN
dpc-6169	27	2	:	:	PUNCT
dpc-6169	27	3	lower	low	ADJ
dpc-6169	27	4	baseline	baseline	VERB
dpc-6169	27	5	uas7	uas7	NOUN
dpc-6169	27	6	and	and	CCONJ
dpc-6169	27	7	shorter	short	ADJ
dpc-6169	27	8	disease	disease	NOUN
dpc-6169	27	9	duration	duration	NOUN
dpc-6169	27	10	independently	independently	ADV
dpc-6169	27	11	predict	predict	VERB
dpc-6169	27	12	early	early	ADJ
dpc-6169	27	13	response	response	NOUN
dpc-6169	27	14	to	to	ADP
dpc-6169	27	15	omalizumab	omalizumab	NOUN
dpc-6169	27	16	.	.	PUNCT
dpc-6169	28	1	younger	young	ADJ
dpc-6169	28	2	age	age	NOUN
dpc-6169	28	3	and	and	CCONJ
dpc-6169	28	4	female	female	ADJ
dpc-6169	28	5	sex	sex	NOUN
dpc-6169	28	6	may	may	AUX
dpc-6169	28	7	be	be	AUX
dpc-6169	28	8	associated	associate	VERB
dpc-6169	28	9	with	with	ADP
dpc-6169	28	10	lower	low	ADJ
dpc-6169	28	11	relapse	relapse	NOUN
dpc-6169	28	12	risk	risk	NOUN
dpc-6169	28	13	.	.	PUNCT
dpc-6169	29	1	these	these	DET
dpc-6169	29	2	findings	finding	NOUN
dpc-6169	29	3	support	support	VERB
dpc-6169	29	4	earlier	early	ADV
dpc-6169	29	5	therapeutic	therapeutic	ADJ
dpc-6169	29	6	intervention	intervention	NOUN
dpc-6169	29	7	in	in	ADP
dpc-6169	29	8	patients	patient	NOUN
dpc-6169	29	9	with	with	ADP
dpc-6169	29	10	lower	low	ADJ
dpc-6169	29	11	disease	disease	NOUN
dpc-6169	29	12	burden	burden	NOUN
dpc-6169	29	13	to	to	PART
dpc-6169	29	14	improve	improve	VERB
dpc-6169	29	15	outcomes	outcome	NOUN
dpc-6169	29	16	.	.	PUNCT
dpc-6169	30	1	introduction	introduction	NOUN
dpc-6169	30	2	urticaria	urticaria	NOUN
dpc-6169	30	3	is	be	AUX
dpc-6169	30	4	a	a	DET
dpc-6169	30	5	condition	condition	NOUN
dpc-6169	30	6	characterized	characterize	VERB
dpc-6169	30	7	by	by	ADP
dpc-6169	30	8	the	the	DET
dpc-6169	30	9	presence	presence	NOUN
dpc-6169	30	10	of	of	ADP
dpc-6169	30	11	wheals	wheal	NOUN
dpc-6169	30	12	,	,	PUNCT
dpc-6169	30	13	angioedema	angioedema	VERB
dpc-6169	30	14	,	,	PUNCT
dpc-6169	30	15	or	or	CCONJ
dpc-6169	30	16	both	both	DET
dpc-6169	30	17	[	[	X
dpc-6169	30	18	1	1	NUM
dpc-6169	30	19	]	]	PUNCT
dpc-6169	30	20	.	.	PUNCT
dpc-6169	31	1	its	its	PRON
dpc-6169	31	2	prevalence	prevalence	NOUN
dpc-6169	31	3	in	in	ADP
dpc-6169	31	4	females	female	NOUN
dpc-6169	31	5	is	be	AUX
dpc-6169	31	6	2	2	NUM
dpc-6169	31	7	–	–	PUNCT
dpc-6169	31	8	4	4	NUM
dpc-6169	31	9	times	time	NOUN
dpc-6169	31	10	higher	high	ADJ
dpc-6169	31	11	than	than	ADP
dpc-6169	31	12	in	in	ADP
dpc-6169	31	13	males	male	NOUN
dpc-6169	31	14	[	[	X
dpc-6169	31	15	2	2	NUM
dpc-6169	31	16	]	]	PUNCT
dpc-6169	31	17	.	.	PUNCT
dpc-6169	32	1	chronic	chronic	ADJ
dpc-6169	32	2	urticaria	urticaria	NOUN
dpc-6169	32	3	is	be	AUX
dpc-6169	32	4	defined	define	VERB
dpc-6169	32	5	as	as	ADP
dpc-6169	32	6	urticaria	urticaria	NOUN
dpc-6169	32	7	persisting	persist	VERB
dpc-6169	32	8	for	for	ADP
dpc-6169	32	9	more	more	ADJ
dpc-6169	32	10	than	than	ADP
dpc-6169	32	11	six	six	NUM
dpc-6169	32	12	weeks	week	NOUN
dpc-6169	32	13	.	.	PUNCT
dpc-6169	33	1	[	[	X
dpc-6169	33	2	1	1	NUM
dpc-6169	33	3	]	]	PUNCT
dpc-6169	33	4	chronic	chronic	ADJ
dpc-6169	33	5	spontaneous	spontaneous	ADJ
dpc-6169	33	6	urticaria	urticaria	NOUN
dpc-6169	33	7	(	(	PUNCT
dpc-6169	33	8	csu	csu	PROPN
dpc-6169	33	9	)	)	PUNCT
dpc-6169	33	10	is	be	AUX
dpc-6169	33	11	characterized	characterize	VERB
dpc-6169	33	12	by	by	ADP
dpc-6169	33	13	the	the	DET
dpc-6169	33	14	spontaneous	spontaneous	ADJ
dpc-6169	33	15	occurrence	occurrence	NOUN
dpc-6169	33	16	of	of	ADP
dpc-6169	33	17	symptoms	symptom	NOUN
dpc-6169	33	18	lasting	last	VERB
dpc-6169	33	19	longer	long	ADV
dpc-6169	33	20	than	than	ADP
dpc-6169	33	21	six	six	NUM
dpc-6169	33	22	weeks	week	NOUN
dpc-6169	33	23	.	.	PUNCT
dpc-6169	34	1	in	in	ADP
dpc-6169	34	2	csu	csu	PROPN
dpc-6169	34	3	,	,	PUNCT
dpc-6169	34	4	lesions	lesion	NOUN
dpc-6169	34	5	typically	typically	ADV
dpc-6169	34	6	appear	appear	VERB
dpc-6169	34	7	without	without	ADP
dpc-6169	34	8	a	a	DET
dpc-6169	34	9	specific	specific	ADJ
dpc-6169	34	10	trigger	trigger	NOUN
dpc-6169	34	11	.	.	PUNCT
dpc-6169	35	1	csu	csu	PROPN
dpc-6169	35	2	is	be	AUX
dpc-6169	35	3	most	most	ADV
dpc-6169	35	4	commonly	commonly	ADV
dpc-6169	35	5	observed	observe	VERB
dpc-6169	35	6	between	between	ADP
dpc-6169	35	7	the	the	DET
dpc-6169	35	8	ages	age	NOUN
dpc-6169	35	9	of	of	ADP
dpc-6169	35	10	20	20	NUM
dpc-6169	35	11	and	and	CCONJ
dpc-6169	35	12	40	40	NUM
dpc-6169	35	13	years	year	NOUN
dpc-6169	35	14	,	,	PUNCT
dpc-6169	35	15	with	with	ADP
dpc-6169	35	16	the	the	DET
dpc-6169	35	17	disease	disease	NOUN
dpc-6169	35	18	duration	duration	NOUN
dpc-6169	35	19	ranging	ranging	NOUN
dpc-6169	35	20	between	between	ADP
dpc-6169	35	21	one	one	NUM
dpc-6169	35	22	and	and	CCONJ
dpc-6169	35	23	five	five	NUM
dpc-6169	35	24	years	year	NOUN
dpc-6169	35	25	in	in	ADP
dpc-6169	35	26	most	most	ADJ
dpc-6169	35	27	patients	patient	NOUN
dpc-6169	35	28	[	[	X
dpc-6169	35	29	3	3	NUM
dpc-6169	35	30	]	]	PUNCT
dpc-6169	35	31	.	.	PUNCT
dpc-6169	36	1	second	second	ADJ
dpc-6169	36	2	-	-	PUNCT
dpc-6169	36	3	generation	generation	NOUN
dpc-6169	36	4	antihistamines	antihistamine	NOUN
dpc-6169	36	5	are	be	AUX
dpc-6169	36	6	the	the	DET
dpc-6169	36	7	first	first	ADJ
dpc-6169	36	8	-	-	PUNCT
dpc-6169	36	9	line	line	NOUN
dpc-6169	36	10	treatment	treatment	NOUN
dpc-6169	36	11	,	,	PUNCT
dpc-6169	36	12	but	but	CCONJ
dpc-6169	36	13	in	in	ADP
dpc-6169	36	14	patients	patient	NOUN
dpc-6169	36	15	who	who	PRON
dpc-6169	36	16	do	do	AUX
dpc-6169	36	17	not	not	PART
dpc-6169	36	18	respond	respond	VERB
dpc-6169	36	19	even	even	ADV
dpc-6169	36	20	after	after	ADP
dpc-6169	36	21	dose	dose	NOUN
dpc-6169	36	22	escalation	escalation	NOUN
dpc-6169	36	23	up	up	ADP
dpc-6169	36	24	to	to	PART
dpc-6169	36	25	four	four	NUM
dpc-6169	36	26	times	time	NOUN
dpc-6169	36	27	the	the	DET
dpc-6169	36	28	standard	standard	PROPN
dpc-6169	36	29	dose	dose	PROPN
dpc-6169	36	30	,	,	PUNCT
dpc-6169	36	31	omalizumab	omalizumab	NOUN
dpc-6169	36	32	is	be	AUX
dpc-6169	36	33	added	add	VERB
dpc-6169	36	34	to	to	ADP
dpc-6169	36	35	the	the	DET
dpc-6169	36	36	treatment	treatment	NOUN
dpc-6169	36	37	regimen	regiman	NOUN
dpc-6169	37	1	[	[	X
dpc-6169	37	2	1	1	NUM
dpc-6169	37	3	]	]	PUNCT
dpc-6169	37	4	.	.	PUNCT
dpc-6169	38	1	omalizumab	omalizumab	NOUN
dpc-6169	38	2	is	be	AUX
dpc-6169	38	3	a	a	DET
dpc-6169	38	4	monoclonal	monoclonal	NOUN
dpc-6169	38	5	anti	anti	ADJ
dpc-6169	38	6	-	-	ADJ
dpc-6169	38	7	ige	ige	ADJ
dpc-6169	38	8	antibody	antibody	NOUN
dpc-6169	38	9	used	use	VERB
dpc-6169	38	10	in	in	ADP
dpc-6169	38	11	the	the	DET
dpc-6169	38	12	treatment	treatment	NOUN
dpc-6169	38	13	of	of	ADP
dpc-6169	38	14	asthma	asthma	NOUN
dpc-6169	38	15	,	,	PUNCT
dpc-6169	38	16	allergic	allergic	ADJ
dpc-6169	38	17	rhinitis	rhinitis	NOUN
dpc-6169	38	18	,	,	PUNCT
dpc-6169	38	19	and	and	CCONJ
dpc-6169	38	20	chronic	chronic	ADJ
dpc-6169	38	21	urticaria	urticaria	NOUN
dpc-6169	38	22	[	[	X
dpc-6169	38	23	4	4	NUM
dpc-6169	38	24	]	]	PUNCT
dpc-6169	38	25	.	.	PUNCT
dpc-6169	39	1	omalizumab	omalizumab	NOUN
dpc-6169	39	2	is	be	AUX
dpc-6169	39	3	now	now	ADV
dpc-6169	39	4	a	a	DET
dpc-6169	39	5	well	well	ADV
dpc-6169	39	6	-	-	PUNCT
dpc-6169	39	7	established	establish	VERB
dpc-6169	39	8	and	and	CCONJ
dpc-6169	39	9	highly	highly	ADV
dpc-6169	39	10	effective	effective	ADJ
dpc-6169	39	11	therapeutic	therapeutic	ADJ
dpc-6169	39	12	agent	agent	NOUN
dpc-6169	39	13	for	for	ADP
dpc-6169	39	14	patients	patient	NOUN
dpc-6169	39	15	with	with	ADP
dpc-6169	39	16	moderate	moderate	ADJ
dpc-6169	39	17	-	-	PUNCT
dpc-6169	39	18	to	to	ADP
dpc-6169	39	19	-	-	PUNCT
dpc-6169	39	20	severe	severe	ADJ
dpc-6169	39	21	chronic	chronic	ADJ
dpc-6169	39	22	spontaneous	spontaneous	ADJ
dpc-6169	39	23	urticaria	urticaria	NOUN
dpc-6169	39	24	(	(	PUNCT
dpc-6169	39	25	csu	csu	PROPN
dpc-6169	39	26	)	)	PUNCT
dpc-6169	39	27	.	.	PUNCT
dpc-6169	40	1	both	both	DET
dpc-6169	40	2	pivotal	pivotal	ADJ
dpc-6169	40	3	randomized	randomize	VERB
dpc-6169	40	4	controlled	control	VERB
dpc-6169	40	5	trials	trial	NOUN
dpc-6169	40	6	and	and	CCONJ
dpc-6169	40	7	real	real	ADJ
dpc-6169	40	8	-	-	PUNCT
dpc-6169	40	9	world	world	NOUN
dpc-6169	40	10	observational	observational	ADJ
dpc-6169	40	11	studies	study	NOUN
dpc-6169	40	12	have	have	AUX
dpc-6169	40	13	consistently	consistently	ADV
dpc-6169	40	14	demonstrated	demonstrate	VERB
dpc-6169	40	15	omalizumab	omalizumab	NOUN
dpc-6169	40	16	’s	’s	PART
dpc-6169	40	17	capacity	capacity	NOUN
dpc-6169	40	18	to	to	PART
dpc-6169	40	19	achieve	achieve	VERB
dpc-6169	40	20	disease	disease	NOUN
dpc-6169	40	21	control	control	NOUN
dpc-6169	40	22	in	in	ADP
dpc-6169	40	23	a	a	DET
dpc-6169	40	24	substantial	substantial	ADJ
dpc-6169	40	25	proportion	proportion	NOUN
dpc-6169	40	26	of	of	ADP
dpc-6169	40	27	patients	patient	NOUN
dpc-6169	40	28	.	.	PUNCT
dpc-6169	41	1	a	a	DET
dpc-6169	41	2	meta	meta	ADJ
dpc-6169	41	3	-	-	PUNCT
dpc-6169	41	4	analysis	analysis	NOUN
dpc-6169	41	5	encompassing	encompass	VERB
dpc-6169	41	6	45	45	NUM
dpc-6169	41	7	studies	study	NOUN
dpc-6169	41	8	and	and	CCONJ
dpc-6169	41	9	1,158	1,158	NUM
dpc-6169	41	10	individuals	individual	NOUN
dpc-6169	41	11	with	with	ADP
dpc-6169	41	12	csu	csu	PROPN
dpc-6169	41	13	reported	report	VERB
dpc-6169	41	14	that	that	SCONJ
dpc-6169	41	15	approximately	approximately	ADV
dpc-6169	41	16	72	72	NUM
dpc-6169	41	17	%	%	NOUN
dpc-6169	41	18	of	of	ADP
dpc-6169	41	19	patients	patient	NOUN
dpc-6169	41	20	achieved	achieve	VERB
dpc-6169	41	21	complete	complete	ADJ
dpc-6169	41	22	symptom	symptom	NOUN
dpc-6169	41	23	resolution	resolution	NOUN
dpc-6169	41	24	with	with	ADP
dpc-6169	41	25	omalizumab	omalizumab	NOUN
dpc-6169	41	26	[	[	X
dpc-6169	41	27	5	5	NUM
dpc-6169	41	28	]	]	PUNCT
dpc-6169	41	29	.	.	PUNCT
dpc-6169	42	1	nonetheless	nonetheless	ADV
dpc-6169	42	2	,	,	PUNCT
dpc-6169	42	3	response	response	NOUN
dpc-6169	42	4	rates	rate	NOUN
dpc-6169	42	5	vary	vary	VERB
dpc-6169	42	6	,	,	PUNCT
dpc-6169	42	7	and	and	CCONJ
dpc-6169	42	8	nearly	nearly	ADV
dpc-6169	42	9	one	one	NUM
dpc-6169	42	10	third	third	NOUN
dpc-6169	42	11	of	of	ADP
dpc-6169	42	12	patients	patient	NOUN
dpc-6169	42	13	do	do	AUX
dpc-6169	42	14	not	not	PART
dpc-6169	42	15	achieve	achieve	VERB
dpc-6169	42	16	adequate	adequate	ADJ
dpc-6169	42	17	clinical	clinical	ADJ
dpc-6169	42	18	benefit	benefit	NOUN
dpc-6169	42	19	[	[	X
dpc-6169	42	20	6	6	NUM
dpc-6169	42	21	]	]	PUNCT
dpc-6169	42	22	.	.	PUNCT
dpc-6169	43	1	furthermore	furthermore	ADV
dpc-6169	43	2	,	,	PUNCT
dpc-6169	43	3	among	among	ADP
dpc-6169	43	4	responders	responder	NOUN
dpc-6169	43	5	,	,	PUNCT
dpc-6169	43	6	there	there	PRON
dpc-6169	43	7	is	be	VERB
dpc-6169	43	8	notable	notable	ADJ
dpc-6169	43	9	variability	variability	NOUN
dpc-6169	43	10	in	in	ADP
dpc-6169	43	11	the	the	DET
dpc-6169	43	12	timing	timing	NOUN
dpc-6169	43	13	and	and	CCONJ
dpc-6169	43	14	extent	extent	NOUN
dpc-6169	43	15	of	of	ADP
dpc-6169	43	16	improvement	improvement	NOUN
dpc-6169	43	17	.	.	PUNCT
dpc-6169	44	1	some	some	DET
dpc-6169	44	2	patients	patient	NOUN
dpc-6169	44	3	experience	experience	VERB
dpc-6169	44	4	rapid	rapid	ADJ
dpc-6169	44	5	relief	relief	NOUN
dpc-6169	44	6	of	of	ADP
dpc-6169	44	7	itching	itching	NOUN
dpc-6169	44	8	and	and	CCONJ
dpc-6169	44	9	hives	hive	NOUN
dpc-6169	44	10	within	within	ADP
dpc-6169	44	11	the	the	DET
dpc-6169	44	12	first	first	ADJ
dpc-6169	44	13	four	four	NUM
dpc-6169	44	14	weeks	week	NOUN
dpc-6169	44	15	of	of	ADP
dpc-6169	44	16	therapy	therapy	NOUN
dpc-6169	44	17	,	,	PUNCT
dpc-6169	44	18	whereas	whereas	SCONJ
dpc-6169	44	19	others	other	NOUN
dpc-6169	44	20	require	require	VERB
dpc-6169	44	21	2–3	2–3	NUM
dpc-6169	44	22	months	month	NOUN
dpc-6169	44	23	or	or	CCONJ
dpc-6169	44	24	longer	long	ADV
dpc-6169	44	25	to	to	PART
dpc-6169	44	26	achieve	achieve	VERB
dpc-6169	44	27	well	well	ADV
dpc-6169	44	28	-	-	PUNCT
dpc-6169	44	29	controlled	control	VERB
dpc-6169	44	30	disease	disease	NOUN
dpc-6169	45	1	[	[	X
dpc-6169	45	2	7	7	NUM
dpc-6169	45	3	]	]	PUNCT
dpc-6169	45	4	.	.	PUNCT
dpc-6169	46	1	this	this	DET
dpc-6169	46	2	heterogeneity	heterogeneity	NOUN
dpc-6169	46	3	in	in	ADP
dpc-6169	46	4	patient	patient	ADJ
dpc-6169	46	5	responses	response	NOUN
dpc-6169	46	6	,	,	PUNCT
dpc-6169	46	7	both	both	PRON
dpc-6169	46	8	in	in	ADP
dpc-6169	46	9	terms	term	NOUN
dpc-6169	46	10	of	of	ADP
dpc-6169	46	11	efficacy	efficacy	NOUN
dpc-6169	46	12	and	and	CCONJ
dpc-6169	46	13	speed	speed	NOUN
dpc-6169	46	14	of	of	ADP
dpc-6169	46	15	onset	onset	NOUN
dpc-6169	46	16	,	,	PUNCT
dpc-6169	46	17	underscores	underscore	VERB
dpc-6169	46	18	the	the	DET
dpc-6169	46	19	need	need	NOUN
dpc-6169	46	20	to	to	PART
dpc-6169	46	21	better	well	ADV
dpc-6169	46	22	understand	understand	VERB
dpc-6169	46	23	which	which	PRON
dpc-6169	46	24	patients	patient	NOUN
dpc-6169	46	25	are	be	AUX
dpc-6169	46	26	likely	likely	ADJ
dpc-6169	46	27	to	to	PART
dpc-6169	46	28	benefit	benefit	VERB
dpc-6169	46	29	from	from	ADP
dpc-6169	46	30	omalizumab	omalizumab	NOUN
dpc-6169	46	31	quickly	quickly	ADV
dpc-6169	46	32	,	,	PUNCT
dpc-6169	46	33	which	which	PRON
dpc-6169	46	34	may	may	AUX
dpc-6169	46	35	respond	respond	VERB
dpc-6169	46	36	only	only	ADV
dpc-6169	46	37	later	later	ADV
dpc-6169	46	38	or	or	CCONJ
dpc-6169	46	39	partially	partially	ADV
dpc-6169	46	40	,	,	PUNCT
dpc-6169	46	41	and	and	CCONJ
dpc-6169	46	42	which	which	PRON
dpc-6169	46	43	may	may	AUX
dpc-6169	46	44	fail	fail	VERB
dpc-6169	46	45	to	to	PART
dpc-6169	46	46	respond	respond	VERB
dpc-6169	46	47	at	at	ADV
dpc-6169	46	48	all	all	ADV
dpc-6169	46	49	.	.	PUNCT
dpc-6169	47	1	given	give	VERB
dpc-6169	47	2	the	the	DET
dpc-6169	47	3	variable	variable	ADJ
dpc-6169	47	4	outcomes	outcome	NOUN
dpc-6169	47	5	with	with	ADP
dpc-6169	47	6	omalizumab	omalizumab	NOUN
dpc-6169	47	7	,	,	PUNCT
dpc-6169	47	8	researchers	researcher	NOUN
dpc-6169	47	9	have	have	AUX
dpc-6169	47	10	sought	seek	VERB
dpc-6169	47	11	to	to	PART
dpc-6169	47	12	identify	identify	VERB
dpc-6169	47	13	baseline	baseline	ADJ
dpc-6169	47	14	patient	patient	ADJ
dpc-6169	47	15	factors	factor	NOUN
dpc-6169	47	16	that	that	PRON
dpc-6169	47	17	predict	predict	VERB
dpc-6169	47	18	treatment	treatment	NOUN
dpc-6169	47	19	response	response	NOUN
dpc-6169	47	20	.	.	PUNCT
dpc-6169	48	1	demographic	demographic	ADJ
dpc-6169	48	2	factors	factor	NOUN
dpc-6169	48	3	such	such	ADJ
dpc-6169	48	4	as	as	ADP
dpc-6169	48	5	age	age	NOUN
dpc-6169	48	6	and	and	CCONJ
dpc-6169	48	7	sex	sex	NOUN
dpc-6169	48	8	have	have	AUX
dpc-6169	48	9	been	be	AUX
dpc-6169	48	10	evaluated	evaluate	VERB
dpc-6169	48	11	,	,	PUNCT
dpc-6169	48	12	but	but	CCONJ
dpc-6169	48	13	findings	finding	NOUN
dpc-6169	48	14	remain	remain	VERB
dpc-6169	48	15	inconclusive	inconclusive	ADJ
dpc-6169	48	16	.	.	PUNCT
dpc-6169	49	1	csu	csu	PROPN
dpc-6169	49	2	occurs	occur	VERB
dpc-6169	49	3	across	across	ADP
dpc-6169	49	4	all	all	DET
dpc-6169	49	5	adult	adult	NOUN
dpc-6169	49	6	age	age	NOUN
dpc-6169	49	7	groups	group	NOUN
dpc-6169	49	8	,	,	PUNCT
dpc-6169	49	9	with	with	ADP
dpc-6169	49	10	a	a	DET
dpc-6169	49	11	slight	slight	ADJ
dpc-6169	49	12	female	female	ADJ
dpc-6169	49	13	predominance	predominance	NOUN
dpc-6169	49	14	,	,	PUNCT
dpc-6169	49	15	yet	yet	CCONJ
dpc-6169	49	16	sex	sex	NOUN
dpc-6169	49	17	has	have	AUX
dpc-6169	49	18	not	not	PART
dpc-6169	49	19	emerged	emerge	VERB
dpc-6169	49	20	as	as	ADP
dpc-6169	49	21	a	a	DET
dpc-6169	49	22	consistent	consistent	ADJ
dpc-6169	49	23	predictor	predictor	NOUN
dpc-6169	49	24	of	of	ADP
dpc-6169	49	25	omalizumab	omalizumab	NOUN
dpc-6169	49	26	efficacy	efficacy	NOUN
dpc-6169	49	27	[	[	X
dpc-6169	49	28	5	5	NUM
dpc-6169	49	29	]	]	PUNCT
dpc-6169	49	30	.	.	PUNCT
dpc-6169	50	1	similarly	similarly	ADV
dpc-6169	50	2	,	,	PUNCT
dpc-6169	50	3	the	the	DET
dpc-6169	50	4	influence	influence	NOUN
dpc-6169	50	5	of	of	ADP
dpc-6169	50	6	age	age	NOUN
dpc-6169	50	7	on	on	ADP
dpc-6169	50	8	treatment	treatment	NOUN
dpc-6169	50	9	outcomes	outcome	NOUN
dpc-6169	50	10	is	be	AUX
dpc-6169	50	11	unclear	unclear	ADJ
dpc-6169	50	12	.	.	PUNCT
dpc-6169	51	1	some	some	DET
dpc-6169	51	2	real	real	ADJ
dpc-6169	51	3	-	-	PUNCT
dpc-6169	51	4	world	world	NOUN
dpc-6169	51	5	data	datum	NOUN
dpc-6169	51	6	suggest	suggest	VERB
dpc-6169	51	7	that	that	SCONJ
dpc-6169	51	8	older	old	ADJ
dpc-6169	51	9	patients	patient	NOUN
dpc-6169	51	10	may	may	AUX
dpc-6169	51	11	achieve	achieve	VERB
dpc-6169	51	12	higher	high	ADJ
dpc-6169	51	13	rates	rate	NOUN
dpc-6169	51	14	of	of	ADP
dpc-6169	51	15	disease	disease	NOUN
dpc-6169	51	16	control	control	NOUN
dpc-6169	51	17	with	with	ADP
dpc-6169	51	18	omalizumab	omalizumab	NOUN
dpc-6169	51	19	[	[	X
dpc-6169	51	20	8	8	NUM
dpc-6169	51	21	]	]	PUNCT
dpc-6169	51	22	,	,	PUNCT
dpc-6169	51	23	whereas	whereas	SCONJ
dpc-6169	51	24	other	other	ADJ
dpc-6169	51	25	studies	study	NOUN
dpc-6169	51	26	report	report	VERB
dpc-6169	51	27	no	no	DET
dpc-6169	51	28	significant	significant	ADJ
dpc-6169	51	29	age	age	NOUN
dpc-6169	51	30	difference	difference	NOUN
dpc-6169	51	31	between	between	ADP
dpc-6169	51	32	responders	responder	NOUN
dpc-6169	51	33	and	and	CCONJ
dpc-6169	51	34	non	non	NOUN
dpc-6169	51	35	-	-	NOUN
dpc-6169	51	36	responders	responder	NOUN
dpc-6169	51	37	[	[	X
dpc-6169	51	38	5	5	NUM
dpc-6169	51	39	]	]	PUNCT
dpc-6169	51	40	.	.	PUNCT
dpc-6169	52	1	disease	disease	NOUN
dpc-6169	52	2	severity	severity	NOUN
dpc-6169	52	3	at	at	ADP
dpc-6169	52	4	baseline	baseline	PROPN
dpc-6169	52	5	has	have	AUX
dpc-6169	52	6	also	also	ADV
dpc-6169	52	7	been	be	AUX
dpc-6169	52	8	examined	examine	VERB
dpc-6169	52	9	as	as	ADP
dpc-6169	52	10	a	a	DET
dpc-6169	52	11	potential	potential	ADJ
dpc-6169	52	12	predictor	predictor	NOUN
dpc-6169	52	13	of	of	ADP
dpc-6169	52	14	outcome	outcome	NOUN
dpc-6169	52	15	.	.	PUNCT
dpc-6169	53	1	the	the	DET
dpc-6169	53	2	urticaria	urticaria	NOUN
dpc-6169	53	3	activity	activity	NOUN
dpc-6169	53	4	score	score	NOUN
dpc-6169	53	5	(	(	PUNCT
dpc-6169	53	6	uas7	uas7	PROPN
dpc-6169	53	7	)	)	PUNCT
dpc-6169	53	8	,	,	PUNCT
dpc-6169	53	9	a	a	DET
dpc-6169	53	10	7	7	NUM
dpc-6169	53	11	-	-	PUNCT
dpc-6169	53	12	day	day	NOUN
dpc-6169	53	13	composite	composite	ADJ
dpc-6169	53	14	itch	itch	NOUN
dpc-6169	53	15	and	and	CCONJ
dpc-6169	53	16	hive	hive	NOUN
dpc-6169	53	17	severity	severity	NOUN
dpc-6169	53	18	score	score	NOUN
dpc-6169	53	19	,	,	PUNCT
dpc-6169	53	20	is	be	AUX
dpc-6169	53	21	often	often	ADV
dpc-6169	53	22	used	use	VERB
dpc-6169	53	23	to	to	PART
dpc-6169	53	24	quantify	quantify	VERB
dpc-6169	53	25	baseline	baseline	NOUN
dpc-6169	53	26	disease	disease	NOUN
dpc-6169	53	27	activity	activity	NOUN
dpc-6169	53	28	.	.	PUNCT
dpc-6169	54	1	there	there	PRON
dpc-6169	54	2	is	be	VERB
dpc-6169	54	3	evidence	evidence	NOUN
dpc-6169	54	4	that	that	SCONJ
dpc-6169	54	5	patients	patient	NOUN
dpc-6169	54	6	with	with	ADP
dpc-6169	54	7	more	more	ADV
dpc-6169	54	8	severe	severe	ADJ
dpc-6169	54	9	baseline	baseline	NOUN
dpc-6169	54	10	uas7	uas7	PROPN
dpc-6169	54	11	scores	score	NOUN
dpc-6169	54	12	tend	tend	VERB
dpc-6169	54	13	to	to	PART
dpc-6169	54	14	have	have	VERB
dpc-6169	54	15	poorer	poor	ADJ
dpc-6169	54	16	treatment	treatment	NOUN
dpc-6169	54	17	responses	response	NOUN
dpc-6169	54	18	to	to	ADP
dpc-6169	54	19	omalizumab	omalizumab	NOUN
dpc-6169	54	20	.	.	PUNCT
dpc-6169	55	1	in	in	ADP
dpc-6169	55	2	a	a	DET
dpc-6169	55	3	real	real	ADJ
dpc-6169	55	4	-	-	PUNCT
dpc-6169	55	5	world	world	NOUN
dpc-6169	55	6	cohort	cohort	NOUN
dpc-6169	55	7	,	,	PUNCT
dpc-6169	55	8	non	non	NOUN
dpc-6169	55	9	-	-	NOUN
dpc-6169	55	10	responders	responder	NOUN
dpc-6169	55	11	had	have	VERB
dpc-6169	55	12	significantly	significantly	ADV
dpc-6169	55	13	higher	high	ADJ
dpc-6169	55	14	median	median	ADJ
dpc-6169	55	15	baseline	baseline	NOUN
dpc-6169	55	16	uas7	uas7	PROPN
dpc-6169	55	17	than	than	SCONJ
dpc-6169	55	18	did	do	VERB
dpc-6169	55	19	responders	responder	NOUN
dpc-6169	55	20	,	,	PUNCT
dpc-6169	55	21	and	and	CCONJ
dpc-6169	55	22	a	a	DET
dpc-6169	55	23	baseline	baseline	NOUN
dpc-6169	55	24	uas7	uas7	NOUN
dpc-6169	55	25	above	above	ADP
dpc-6169	55	26	~30	~30	X
dpc-6169	55	27	was	be	AUX
dpc-6169	55	28	found	find	VERB
dpc-6169	55	29	to	to	PART
dpc-6169	55	30	predict	predict	VERB
dpc-6169	55	31	non	non	ADJ
dpc-6169	55	32	-	-	NOUN
dpc-6169	55	33	response	response	NOUN
dpc-6169	55	34	with	with	ADP
dpc-6169	55	35	moderate	moderate	ADJ
dpc-6169	55	36	accuracy	accuracy	NOUN
dpc-6169	56	1	[	[	X
dpc-6169	56	2	5	5	NUM
dpc-6169	56	3	]	]	PUNCT
dpc-6169	56	4	.	.	PUNCT
dpc-6169	57	1	another	another	DET
dpc-6169	57	2	factor	factor	NOUN
dpc-6169	57	3	of	of	ADP
dpc-6169	57	4	interest	interest	NOUN
dpc-6169	57	5	is	be	AUX
dpc-6169	57	6	the	the	DET
dpc-6169	57	7	duration	duration	NOUN
dpc-6169	57	8	of	of	ADP
dpc-6169	57	9	csu	csu	PROPN
dpc-6169	57	10	prior	prior	ADV
dpc-6169	57	11	to	to	ADP
dpc-6169	57	12	starting	start	VERB
dpc-6169	57	13	omalizumab	omalizumab	NOUN
dpc-6169	57	14	.	.	PUNCT
dpc-6169	58	1	long	long	ADV
dpc-6169	58	2	-	-	PUNCT
dpc-6169	58	3	standing	stand	VERB
dpc-6169	58	4	disease	disease	NOUN
dpc-6169	58	5	might	might	AUX
dpc-6169	58	6	reflect	reflect	VERB
dpc-6169	58	7	a	a	DET
dpc-6169	58	8	more	more	ADV
dpc-6169	58	9	entrenched	entrenched	ADJ
dpc-6169	58	10	or	or	CCONJ
dpc-6169	58	11	treatment	treatment	NOUN
dpc-6169	58	12	-	-	PUNCT
dpc-6169	58	13	resistant	resistant	ADJ
dpc-6169	58	14	urticaria	urticaria	NOUN
dpc-6169	58	15	endotype	endotype	NOUN
dpc-6169	58	16	,	,	PUNCT
dpc-6169	58	17	potentially	potentially	ADV
dpc-6169	58	18	influencing	influence	VERB
dpc-6169	58	19	outcomes	outcome	NOUN
dpc-6169	58	20	.	.	PUNCT
dpc-6169	59	1	some	some	DET
dpc-6169	59	2	investigations	investigation	NOUN
dpc-6169	59	3	have	have	AUX
dpc-6169	59	4	noted	note	VERB
dpc-6169	59	5	that	that	SCONJ
dpc-6169	59	6	longer	long	ADJ
dpc-6169	59	7	disease	disease	NOUN
dpc-6169	59	8	duration	duration	NOUN
dpc-6169	59	9	is	be	AUX
dpc-6169	59	10	associated	associate	VERB
dpc-6169	59	11	with	with	ADP
dpc-6169	59	12	an	an	DET
dpc-6169	59	13	elevated	elevated	ADJ
dpc-6169	59	14	risk	risk	NOUN
dpc-6169	59	15	of	of	ADP
dpc-6169	59	16	relapse	relapse	NOUN
dpc-6169	59	17	after	after	ADP
dpc-6169	59	18	stopping	stop	VERB
dpc-6169	59	19	omalizumab	omalizumab	NOUN
dpc-6169	60	1	[	[	X
dpc-6169	60	2	9	9	NUM
dpc-6169	60	3	]	]	PUNCT
dpc-6169	60	4	.	.	PUNCT
dpc-6169	61	1	determining	determine	VERB
dpc-6169	61	2	predictors	predictor	NOUN
dpc-6169	61	3	of	of	ADP
dpc-6169	61	4	early	early	ADJ
dpc-6169	61	5	response	response	NOUN
dpc-6169	61	6	and	and	CCONJ
dpc-6169	61	7	of	of	ADP
dpc-6169	61	8	relapse	relapse	NOUN
dpc-6169	61	9	risk	risk	NOUN
dpc-6169	61	10	is	be	AUX
dpc-6169	61	11	of	of	ADP
dpc-6169	61	12	high	high	ADJ
dpc-6169	61	13	clinical	clinical	ADJ
dpc-6169	61	14	relevance	relevance	NOUN
dpc-6169	61	15	in	in	ADP
dpc-6169	61	16	the	the	DET
dpc-6169	61	17	management	management	NOUN
dpc-6169	61	18	of	of	ADP
dpc-6169	61	19	csu	csu	PROPN
dpc-6169	61	20	.	.	PUNCT
dpc-6169	62	1	identifying	identify	VERB
dpc-6169	62	2	patients	patient	NOUN
dpc-6169	62	3	likely	likely	ADJ
dpc-6169	62	4	to	to	PART
dpc-6169	62	5	respond	respond	VERB
dpc-6169	62	6	quickly	quickly	ADV
dpc-6169	62	7	to	to	ADP
dpc-6169	62	8	omalizumab	omalizumab	NOUN
dpc-6169	62	9	could	could	AUX
dpc-6169	62	10	enable	enable	VERB
dpc-6169	62	11	clinicians	clinician	NOUN
dpc-6169	62	12	to	to	PART
dpc-6169	62	13	optimize	optimize	VERB
dpc-6169	62	14	treatment	treatment	NOUN
dpc-6169	62	15	plans	plan	NOUN
dpc-6169	62	16	,	,	PUNCT
dpc-6169	62	17	for	for	ADP
dpc-6169	62	18	instance	instance	NOUN
dpc-6169	62	19	,	,	PUNCT
dpc-6169	62	20	by	by	ADP
dpc-6169	62	21	continuing	continue	VERB
dpc-6169	62	22	therapy	therapy	NOUN
dpc-6169	62	23	in	in	ADP
dpc-6169	62	24	those	those	PRON
dpc-6169	62	25	showing	show	VERB
dpc-6169	62	26	early	early	ADJ
dpc-6169	62	27	improvement	improvement	NOUN
dpc-6169	62	28	or	or	CCONJ
dpc-6169	62	29	considering	consider	VERB
dpc-6169	62	30	alternative	alternative	ADJ
dpc-6169	62	31	strategies	strategy	NOUN
dpc-6169	62	32	in	in	ADP
dpc-6169	62	33	those	those	PRON
dpc-6169	62	34	predicted	predict	VERB
dpc-6169	62	35	to	to	PART
dpc-6169	62	36	respond	respond	VERB
dpc-6169	62	37	poorly	poorly	ADV
dpc-6169	62	38	.	.	PUNCT
dpc-6169	63	1	early	early	ADJ
dpc-6169	63	2	identification	identification	NOUN
dpc-6169	63	3	of	of	ADP
dpc-6169	63	4	likely	likely	ADJ
dpc-6169	63	5	non	non	NOUN
dpc-6169	63	6	-	-	NOUN
dpc-6169	63	7	responders	responder	NOUN
dpc-6169	63	8	may	may	AUX
dpc-6169	63	9	spare	spare	VERB
dpc-6169	63	10	patients	patient	NOUN
dpc-6169	63	11	prolonged	prolong	VERB
dpc-6169	63	12	ineffective	ineffective	ADJ
dpc-6169	63	13	treatment	treatment	NOUN
dpc-6169	63	14	and	and	CCONJ
dpc-6169	63	15	help	help	VERB
dpc-6169	63	16	guide	guide	VERB
dpc-6169	63	17	the	the	DET
dpc-6169	63	18	use	use	NOUN
dpc-6169	63	19	of	of	ADP
dpc-6169	63	20	adjunctive	adjunctive	ADJ
dpc-6169	63	21	therapies	therapy	NOUN
dpc-6169	63	22	.	.	PUNCT
dpc-6169	64	1	in	in	ADP
dpc-6169	64	2	light	light	NOUN
dpc-6169	64	3	of	of	ADP
dpc-6169	64	4	the	the	DET
dpc-6169	64	5	above	above	NOUN
dpc-6169	64	6	,	,	PUNCT
dpc-6169	64	7	the	the	DET
dpc-6169	64	8	present	present	ADJ
dpc-6169	64	9	study	study	NOUN
dpc-6169	64	10	aimed	aim	VERB
dpc-6169	64	11	to	to	PART
dpc-6169	64	12	systematically	systematically	ADV
dpc-6169	64	13	evaluate	evaluate	VERB
dpc-6169	64	14	the	the	DET
dpc-6169	64	15	impact	impact	NOUN
dpc-6169	64	16	of	of	ADP
dpc-6169	64	17	four	four	NUM
dpc-6169	64	18	key	key	ADJ
dpc-6169	64	19	patient	patient	ADJ
dpc-6169	64	20	factors	factor	NOUN
dpc-6169	64	21	(	(	PUNCT
dpc-6169	64	22	age	age	NOUN
dpc-6169	64	23	,	,	PUNCT
dpc-6169	64	24	sex	sex	NOUN
dpc-6169	64	25	,	,	PUNCT
dpc-6169	64	26	baseline	baseline	VERB
dpc-6169	64	27	uas7	uas7	NOUN
dpc-6169	64	28	,	,	PUNCT
dpc-6169	64	29	and	and	CCONJ
dpc-6169	64	30	disease	disease	NOUN
dpc-6169	64	31	duration	duration	NOUN
dpc-6169	64	32	)	)	PUNCT
dpc-6169	64	33	on	on	ADP
dpc-6169	64	34	outcomes	outcome	NOUN
dpc-6169	64	35	of	of	ADP
dpc-6169	64	36	omalizumab	omalizumab	NOUN
dpc-6169	64	37	therapy	therapy	NOUN
dpc-6169	64	38	in	in	ADP
dpc-6169	64	39	csu	csu	PROPN
dpc-6169	64	40	.	.	PUNCT
dpc-6169	65	1	specifically	specifically	ADV
dpc-6169	65	2	,	,	PUNCT
dpc-6169	65	3	we	we	PRON
dpc-6169	65	4	sought	seek	VERB
dpc-6169	65	5	to	to	PART
dpc-6169	65	6	determine	determine	VERB
dpc-6169	65	7	whether	whether	SCONJ
dpc-6169	65	8	any	any	PRON
dpc-6169	65	9	of	of	ADP
dpc-6169	65	10	these	these	DET
dpc-6169	65	11	baseline	baseline	ADJ
dpc-6169	65	12	characteristics	characteristic	NOUN
dpc-6169	65	13	predict	predict	VERB
dpc-6169	65	14	an	an	DET
dpc-6169	65	15	early	early	ADJ
dpc-6169	65	16	treatment	treatment	NOUN
dpc-6169	65	17	response	response	NOUN
dpc-6169	65	18	to	to	ADP
dpc-6169	65	19	omalizumab	omalizumab	NOUN
dpc-6169	65	20	,	,	PUNCT
dpc-6169	65	21	and	and	CCONJ
dpc-6169	65	22	whether	whether	SCONJ
dpc-6169	65	23	they	they	PRON
dpc-6169	65	24	influence	influence	VERB
dpc-6169	65	25	the	the	DET
dpc-6169	65	26	risk	risk	NOUN
dpc-6169	65	27	of	of	ADP
dpc-6169	65	28	relapse	relapse	NOUN
dpc-6169	65	29	after	after	ADP
dpc-6169	65	30	omalizumab	omalizumab	NOUN
dpc-6169	65	31	discontinuation	discontinuation	NOUN
dpc-6169	65	32	.	.	PUNCT
dpc-6169	66	1	by	by	ADP
dpc-6169	66	2	clarifying	clarify	VERB
dpc-6169	66	3	the	the	DET
dpc-6169	66	4	role	role	NOUN
dpc-6169	66	5	of	of	ADP
dpc-6169	66	6	age	age	NOUN
dpc-6169	66	7	,	,	PUNCT
dpc-6169	66	8	sex	sex	NOUN
dpc-6169	66	9	,	,	PUNCT
dpc-6169	66	10	initial	initial	ADJ
dpc-6169	66	11	disease	disease	NOUN
dpc-6169	66	12	severity	severity	NOUN
dpc-6169	66	13	,	,	PUNCT
dpc-6169	66	14	and	and	CCONJ
dpc-6169	66	15	disease	disease	NOUN
dpc-6169	66	16	chronicity	chronicity	NOUN
dpc-6169	66	17	in	in	ADP
dpc-6169	66	18	early	early	ADJ
dpc-6169	66	19	efficacy	efficacy	NOUN
dpc-6169	66	20	and	and	CCONJ
dpc-6169	66	21	post	post	ADJ
dpc-6169	66	22	-	-	ADJ
dpc-6169	66	23	treatment	treatment	ADJ
dpc-6169	66	24	relapse	relapse	NOUN
dpc-6169	66	25	,	,	PUNCT
dpc-6169	66	26	this	this	DET
dpc-6169	66	27	study	study	NOUN
dpc-6169	66	28	may	may	AUX
dpc-6169	66	29	help	help	VERB
dpc-6169	66	30	refine	refine	VERB
dpc-6169	66	31	our	our	PRON
dpc-6169	66	32	ability	ability	NOUN
dpc-6169	66	33	to	to	PART
dpc-6169	66	34	personalize	personalize	VERB
dpc-6169	66	35	csu	csu	NOUN
dpc-6169	66	36	treatment	treatment	NOUN
dpc-6169	66	37	and	and	CCONJ
dpc-6169	66	38	improve	improve	VERB
dpc-6169	66	39	long	long	ADJ
dpc-6169	66	40	-	-	PUNCT
dpc-6169	66	41	term	term	NOUN
dpc-6169	66	42	management	management	NOUN
dpc-6169	66	43	strategies	strategy	NOUN
dpc-6169	66	44	.	.	PUNCT
dpc-6169	67	1	original	original	ADJ
dpc-6169	67	2	article	article	NOUN
dpc-6169	67	3	|	|	ADV
dpc-6169	67	4	dermatol	dermatol	ADJ
dpc-6169	67	5	pract	pract	NOUN
dpc-6169	67	6	concept	concept	NOUN
dpc-6169	67	7	.	.	PUNCT
dpc-6169	68	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	68	2	3	3	NUM
dpc-6169	68	3	methods	method	NOUN
dpc-6169	68	4	ethical	ethical	ADJ
dpc-6169	68	5	approval	approval	NOUN
dpc-6169	68	6	for	for	ADP
dpc-6169	68	7	this	this	DET
dpc-6169	68	8	study	study	NOUN
dpc-6169	68	9	was	be	AUX
dpc-6169	68	10	obtained	obtain	VERB
dpc-6169	68	11	from	from	ADP
dpc-6169	68	12	the	the	DET
dpc-6169	68	13	clinical	clinical	ADJ
dpc-6169	68	14	research	research	NOUN
dpc-6169	68	15	ethics	ethic	NOUN
dpc-6169	68	16	committee	committee	PROPN
dpc-6169	68	17	(	(	PUNCT
dpc-6169	68	18	date	date	NOUN
dpc-6169	68	19	:	:	PUNCT
dpc-6169	68	20	17.02.25	17.02.25	NUM
dpc-6169	68	21	,	,	PUNCT
dpc-6169	68	22	session	session	NOUN
dpc-6169	68	23	no	no	NOUN
dpc-6169	68	24	:	:	SYM
dpc-6169	68	25	2025/06	2025/06	NUM
dpc-6169	68	26	,	,	PUNCT
dpc-6169	68	27	decision	decision	NOUN
dpc-6169	68	28	no	no	NOUN
dpc-6169	68	29	:	:	PUNCT
dpc-6169	68	30	13	13	NUM
dpc-6169	68	31	)	)	PUNCT
dpc-6169	68	32	.	.	PUNCT
dpc-6169	69	1	this	this	DET
dpc-6169	69	2	retrospective	retrospective	ADJ
dpc-6169	69	3	study	study	NOUN
dpc-6169	69	4	included	include	VERB
dpc-6169	69	5	patients	patient	NOUN
dpc-6169	69	6	diagnosed	diagnose	VERB
dpc-6169	69	7	with	with	ADP
dpc-6169	69	8	chronic	chronic	ADJ
dpc-6169	69	9	spontaneous	spontaneous	ADJ
dpc-6169	69	10	urticaria	urticaria	NOUN
dpc-6169	69	11	(	(	PUNCT
dpc-6169	69	12	csu	csu	PROPN
dpc-6169	69	13	)	)	PUNCT
dpc-6169	69	14	who	who	PRON
dpc-6169	69	15	presented	present	VERB
dpc-6169	69	16	to	to	ADP
dpc-6169	69	17	the	the	DET
dpc-6169	69	18	dermatology	dermatology	NOUN
dpc-6169	69	19	outpatient	outpatient	NOUN
dpc-6169	69	20	clinics	clinic	NOUN
dpc-6169	69	21	of	of	ADP
dpc-6169	69	22	our	our	PRON
dpc-6169	69	23	hospital	hospital	NOUN
dpc-6169	69	24	between	between	ADP
dpc-6169	69	25	june	june	PROPN
dpc-6169	69	26	2011	2011	NUM
dpc-6169	69	27	and	and	CCONJ
dpc-6169	69	28	january	january	PROPN
dpc-6169	69	29	2024	2024	NUM
dpc-6169	69	30	and	and	CCONJ
dpc-6169	69	31	who	who	PRON
dpc-6169	69	32	initiated	initiate	VERB
dpc-6169	69	33	omalizumab	omalizumab	NOUN
dpc-6169	69	34	treatment	treatment	NOUN
dpc-6169	69	35	.	.	PUNCT
dpc-6169	70	1	patient	patient	ADJ
dpc-6169	70	2	records	record	NOUN
dpc-6169	70	3	were	be	AUX
dpc-6169	70	4	reviewed	review	VERB
dpc-6169	70	5	to	to	PART
dpc-6169	70	6	extract	extract	VERB
dpc-6169	70	7	clinical	clinical	ADJ
dpc-6169	70	8	data	datum	NOUN
dpc-6169	70	9	.	.	PUNCT
dpc-6169	71	1	the	the	DET
dpc-6169	71	2	diagnosis	diagnosis	NOUN
dpc-6169	71	3	of	of	ADP
dpc-6169	71	4	csu	csu	PROPN
dpc-6169	71	5	and	and	CCONJ
dpc-6169	71	6	the	the	DET
dpc-6169	71	7	assessment	assessment	NOUN
dpc-6169	71	8	of	of	ADP
dpc-6169	71	9	disease	disease	NOUN
dpc-6169	71	10	activity	activity	NOUN
dpc-6169	71	11	were	be	AUX
dpc-6169	71	12	conducted	conduct	VERB
dpc-6169	71	13	in	in	ADP
dpc-6169	71	14	accordance	accordance	NOUN
dpc-6169	71	15	with	with	ADP
dpc-6169	71	16	the	the	DET
dpc-6169	71	17	eaaci	eaaci	NOUN
dpc-6169	71	18	/	/	SYM
dpc-6169	71	19	ga²len/	ga²len/	PROPN
dpc-6169	71	20	euroguiderm	euroguiderm	NOUN
dpc-6169	71	21	/	/	SYM
dpc-6169	71	22	apaaaci	apaaaci	NOUN
dpc-6169	71	23	guideline	guideline	NOUN
dpc-6169	71	24	for	for	ADP
dpc-6169	71	25	urticaria	urticaria	NOUN
dpc-6169	71	26	[	[	X
dpc-6169	71	27	1	1	NUM
dpc-6169	71	28	]	]	PUNCT
dpc-6169	71	29	.	.	PUNCT
dpc-6169	72	1	patients	patient	NOUN
dpc-6169	72	2	were	be	AUX
dpc-6169	72	3	eligible	eligible	ADJ
dpc-6169	72	4	for	for	ADP
dpc-6169	72	5	inclusion	inclusion	NOUN
dpc-6169	72	6	if	if	SCONJ
dpc-6169	72	7	they	they	PRON
dpc-6169	72	8	were	be	AUX
dpc-6169	72	9	over	over	ADP
dpc-6169	72	10	18	18	NUM
dpc-6169	72	11	years	year	NOUN
dpc-6169	72	12	of	of	ADP
dpc-6169	72	13	age	age	NOUN
dpc-6169	72	14	,	,	PUNCT
dpc-6169	72	15	had	have	VERB
dpc-6169	72	16	a	a	DET
dpc-6169	72	17	confirmed	confirm	VERB
dpc-6169	72	18	diagnosis	diagnosis	NOUN
dpc-6169	72	19	of	of	ADP
dpc-6169	72	20	csu	csu	PROPN
dpc-6169	72	21	,	,	PUNCT
dpc-6169	72	22	were	be	AUX
dpc-6169	72	23	treated	treat	VERB
dpc-6169	72	24	with	with	ADP
dpc-6169	72	25	omalizumab	omalizumab	NOUN
dpc-6169	72	26	,	,	PUNCT
dpc-6169	72	27	and	and	CCONJ
dpc-6169	72	28	had	have	AUX
dpc-6169	72	29	completed	complete	VERB
dpc-6169	72	30	at	at	ADP
dpc-6169	72	31	least	least	ADV
dpc-6169	72	32	16	16	NUM
dpc-6169	72	33	weeks	week	NOUN
dpc-6169	72	34	of	of	ADP
dpc-6169	72	35	therapy	therapy	NOUN
dpc-6169	72	36	without	without	ADP
dpc-6169	72	37	receiving	receive	VERB
dpc-6169	72	38	additional	additional	ADJ
dpc-6169	72	39	systemic	systemic	ADJ
dpc-6169	72	40	treatments	treatment	NOUN
dpc-6169	72	41	.	.	PUNCT
dpc-6169	73	1	patients	patient	NOUN
dpc-6169	73	2	with	with	ADP
dpc-6169	73	3	inducible	inducible	ADJ
dpc-6169	73	4	urticaria	urticaria	NOUN
dpc-6169	73	5	were	be	AUX
dpc-6169	73	6	excluded	exclude	VERB
dpc-6169	73	7	.	.	PUNCT
dpc-6169	74	1	disease	disease	NOUN
dpc-6169	74	2	activity	activity	NOUN
dpc-6169	74	3	was	be	AUX
dpc-6169	74	4	evaluated	evaluate	VERB
dpc-6169	74	5	using	use	VERB
dpc-6169	74	6	the	the	DET
dpc-6169	74	7	urticaria	urticaria	NOUN
dpc-6169	74	8	activity	activity	NOUN
dpc-6169	74	9	score	score	NOUN
dpc-6169	74	10	over	over	ADP
dpc-6169	74	11	7	7	NUM
dpc-6169	74	12	days	day	NOUN
dpc-6169	74	13	(	(	PUNCT
dpc-6169	74	14	uas7	uas7	PROPN
dpc-6169	74	15	)	)	PUNCT
dpc-6169	74	16	,	,	PUNCT
dpc-6169	74	17	which	which	PRON
dpc-6169	74	18	assesses	assess	VERB
dpc-6169	74	19	the	the	DET
dpc-6169	74	20	severity	severity	NOUN
dpc-6169	74	21	of	of	ADP
dpc-6169	74	22	wheals	wheal	NOUN
dpc-6169	74	23	and	and	CCONJ
dpc-6169	74	24	pruritus	pruritus	NOUN
dpc-6169	74	25	.	.	PUNCT
dpc-6169	75	1	each	each	DET
dpc-6169	75	2	patient	patient	NOUN
dpc-6169	75	3	received	receive	VERB
dpc-6169	75	4	300	300	NUM
dpc-6169	75	5	mg	mg	NOUN
dpc-6169	75	6	of	of	ADP
dpc-6169	75	7	omalizumab	omalizumab	NOUN
dpc-6169	75	8	every	every	DET
dpc-6169	75	9	four	four	NUM
dpc-6169	75	10	weeks	week	NOUN
dpc-6169	75	11	for	for	ADP
dpc-6169	75	12	16	16	NUM
dpc-6169	75	13	weeks	week	NOUN
dpc-6169	75	14	.	.	PUNCT
dpc-6169	76	1	disease	disease	NOUN
dpc-6169	76	2	activity	activity	NOUN
dpc-6169	76	3	and	and	CCONJ
dpc-6169	76	4	the	the	DET
dpc-6169	76	5	therapeutic	therapeutic	ADJ
dpc-6169	76	6	effect	effect	NOUN
dpc-6169	76	7	of	of	ADP
dpc-6169	76	8	omalizumab	omalizumab	NOUN
dpc-6169	76	9	were	be	AUX
dpc-6169	76	10	evaluated	evaluate	VERB
dpc-6169	76	11	using	use	VERB
dpc-6169	76	12	uas7	uas7	PROPN
dpc-6169	76	13	measurements	measurement	NOUN
dpc-6169	76	14	at	at	ADP
dpc-6169	76	15	baseline	baseline	NOUN
dpc-6169	76	16	and	and	CCONJ
dpc-6169	76	17	at	at	ADP
dpc-6169	76	18	the	the	DET
dpc-6169	76	19	4th	4th	ADJ
dpc-6169	76	20	,	,	PUNCT
dpc-6169	76	21	8th	8th	ADJ
dpc-6169	76	22	,	,	PUNCT
dpc-6169	76	23	12th	12th	ADJ
dpc-6169	76	24	,	,	PUNCT
dpc-6169	76	25	and	and	CCONJ
dpc-6169	76	26	16th	16th	ADJ
dpc-6169	76	27	week	week	NOUN
dpc-6169	76	28	.	.	PUNCT
dpc-6169	77	1	patients	patient	NOUN
dpc-6169	77	2	were	be	AUX
dpc-6169	77	3	then	then	ADV
dpc-6169	77	4	categorized	categorize	VERB
dpc-6169	77	5	based	base	VERB
dpc-6169	77	6	on	on	ADP
dpc-6169	77	7	their	their	PRON
dpc-6169	77	8	response	response	NOUN
dpc-6169	77	9	to	to	ADP
dpc-6169	77	10	treatment	treatment	NOUN
dpc-6169	77	11	over	over	ADP
dpc-6169	77	12	the	the	DET
dpc-6169	77	13	16	16	NUM
dpc-6169	77	14	-	-	PUNCT
dpc-6169	77	15	week	week	NOUN
dpc-6169	77	16	period	period	NOUN
dpc-6169	77	17	.	.	PUNCT
dpc-6169	78	1	responders	responder	NOUN
dpc-6169	78	2	were	be	AUX
dpc-6169	78	3	defined	define	VERB
dpc-6169	78	4	as	as	ADP
dpc-6169	78	5	those	those	PRON
dpc-6169	78	6	with	with	ADP
dpc-6169	78	7	a	a	DET
dpc-6169	78	8	uas7	uas7	ADJ
dpc-6169	78	9	score	score	NOUN
dpc-6169	78	10	<	<	X
dpc-6169	78	11	7	7	NUM
dpc-6169	78	12	,	,	PUNCT
dpc-6169	78	13	whereas	whereas	SCONJ
dpc-6169	78	14	non	non	NOUN
dpc-6169	78	15	-	-	NOUN
dpc-6169	78	16	responders	responder	NOUN
dpc-6169	78	17	were	be	AUX
dpc-6169	78	18	those	those	PRON
dpc-6169	78	19	with	with	ADP
dpc-6169	78	20	a	a	DET
dpc-6169	78	21	uas7	uas7	ADJ
dpc-6169	78	22	score	score	NOUN
dpc-6169	78	23	of	of	ADP
dpc-6169	78	24	7	7	NUM
dpc-6169	78	25	or	or	CCONJ
dpc-6169	78	26	higher	high	ADJ
dpc-6169	78	27	.	.	PUNCT
dpc-6169	79	1	"	"	PUNCT
dpc-6169	79	2	early	early	ADJ
dpc-6169	79	3	response	response	NOUN
dpc-6169	79	4	"	"	PUNCT
dpc-6169	79	5	was	be	AUX
dpc-6169	79	6	defined	define	VERB
dpc-6169	79	7	as	as	ADP
dpc-6169	79	8	the	the	DET
dpc-6169	79	9	resolution	resolution	NOUN
dpc-6169	79	10	of	of	ADP
dpc-6169	79	11	csu	csu	PROPN
dpc-6169	79	12	symptoms	symptom	NOUN
dpc-6169	79	13	(	(	PUNCT
dpc-6169	79	14	uas7	uas7	PROPN
dpc-6169	79	15	<	<	X
dpc-6169	79	16	7	7	NUM
dpc-6169	79	17	)	)	PUNCT
dpc-6169	79	18	within	within	ADP
dpc-6169	79	19	the	the	DET
dpc-6169	79	20	first	first	ADJ
dpc-6169	79	21	four	four	NUM
dpc-6169	79	22	weeks	week	NOUN
dpc-6169	79	23	of	of	ADP
dpc-6169	79	24	omalizumab	omalizumab	NOUN
dpc-6169	79	25	treatment	treatment	NOUN
dpc-6169	79	26	[	[	X
dpc-6169	79	27	5	5	NUM
dpc-6169	79	28	]	]	PUNCT
dpc-6169	79	29	.	.	PUNCT
dpc-6169	80	1	after	after	ADP
dpc-6169	80	2	the	the	DET
dpc-6169	80	3	initial	initial	ADJ
dpc-6169	80	4	treatment	treatment	NOUN
dpc-6169	80	5	period	period	NOUN
dpc-6169	80	6	,	,	PUNCT
dpc-6169	80	7	patients	patient	NOUN
dpc-6169	80	8	were	be	AUX
dpc-6169	80	9	followed	follow	VERB
dpc-6169	80	10	for	for	ADP
dpc-6169	80	11	an	an	DET
dpc-6169	80	12	additional	additional	ADJ
dpc-6169	80	13	eight	eight	NUM
dpc-6169	80	14	weeks	week	NOUN
dpc-6169	80	15	to	to	PART
dpc-6169	80	16	monitor	monitor	VERB
dpc-6169	80	17	for	for	ADP
dpc-6169	80	18	relapse	relapse	NOUN
dpc-6169	80	19	,	,	PUNCT
dpc-6169	80	20	defined	define	VERB
dpc-6169	80	21	as	as	ADP
dpc-6169	80	22	the	the	DET
dpc-6169	80	23	need	need	NOUN
dpc-6169	80	24	to	to	PART
dpc-6169	80	25	reinitiate	reinitiate	VERB
dpc-6169	80	26	omalizumab	omalizumab	NOUN
dpc-6169	80	27	due	due	ADP
dpc-6169	80	28	to	to	ADP
dpc-6169	80	29	recurrence	recurrence	NOUN
dpc-6169	80	30	of	of	ADP
dpc-6169	80	31	csu	csu	PROPN
dpc-6169	80	32	symptoms	symptom	NOUN
dpc-6169	80	33	after	after	ADP
dpc-6169	80	34	discontinuation	discontinuation	NOUN
dpc-6169	80	35	.	.	PUNCT
dpc-6169	81	1	the	the	DET
dpc-6169	81	2	primary	primary	ADJ
dpc-6169	81	3	objective	objective	NOUN
dpc-6169	81	4	of	of	ADP
dpc-6169	81	5	the	the	DET
dpc-6169	81	6	study	study	NOUN
dpc-6169	81	7	was	be	AUX
dpc-6169	81	8	to	to	PART
dpc-6169	81	9	evaluate	evaluate	VERB
dpc-6169	81	10	early	early	ADJ
dpc-6169	81	11	response	response	NOUN
dpc-6169	81	12	and	and	CCONJ
dpc-6169	81	13	relapse	relapse	NOUN
dpc-6169	81	14	rates	rate	NOUN
dpc-6169	81	15	according	accord	VERB
dpc-6169	81	16	to	to	ADP
dpc-6169	81	17	age	age	NOUN
dpc-6169	81	18	and	and	CCONJ
dpc-6169	81	19	sex	sex	NOUN
dpc-6169	81	20	.	.	PUNCT
dpc-6169	82	1	secondary	secondary	ADJ
dpc-6169	82	2	analyses	analysis	NOUN
dpc-6169	82	3	explored	explore	VERB
dpc-6169	82	4	the	the	DET
dpc-6169	82	5	influence	influence	NOUN
dpc-6169	82	6	of	of	ADP
dpc-6169	82	7	baseline	baseline	NOUN
dpc-6169	82	8	uas7	uas7	NOUN
dpc-6169	82	9	and	and	CCONJ
dpc-6169	82	10	disease	disease	NOUN
dpc-6169	82	11	duration	duration	NOUN
dpc-6169	82	12	on	on	ADP
dpc-6169	82	13	treatment	treatment	NOUN
dpc-6169	82	14	outcomes	outcome	NOUN
dpc-6169	82	15	.	.	PUNCT
dpc-6169	83	1	statistical	statistical	ADJ
dpc-6169	83	2	analyses	analysis	NOUN
dpc-6169	83	3	statistical	statistical	ADJ
dpc-6169	83	4	analyses	analysis	NOUN
dpc-6169	83	5	were	be	AUX
dpc-6169	83	6	conducted	conduct	VERB
dpc-6169	83	7	using	use	VERB
dpc-6169	83	8	ibm	ibm	PROPN
dpc-6169	83	9	spss	spss	PROPN
dpc-6169	83	10	statistics	statistic	NOUN
dpc-6169	83	11	26	26	NUM
dpc-6169	83	12	.	.	PUNCT
dpc-6169	84	1	descriptive	descriptive	ADJ
dpc-6169	84	2	data	datum	NOUN
dpc-6169	84	3	are	be	AUX
dpc-6169	84	4	presented	present	VERB
dpc-6169	84	5	as	as	ADP
dpc-6169	84	6	n	n	NUM
dpc-6169	84	7	and	and	CCONJ
dpc-6169	84	8	%	%	NOUN
dpc-6169	84	9	for	for	ADP
dpc-6169	84	10	categorical	categorical	ADJ
dpc-6169	84	11	variables	variable	NOUN
dpc-6169	84	12	,	,	PUNCT
dpc-6169	84	13	and	and	CCONJ
dpc-6169	84	14	as	as	ADP
dpc-6169	84	15	mean	mean	NOUN
dpc-6169	84	16	±	±	NUM
dpc-6169	84	17	standard	standard	ADJ
dpc-6169	84	18	deviation	deviation	NOUN
dpc-6169	84	19	(	(	PUNCT
dpc-6169	84	20	mean±sd	mean±sd	NUM
dpc-6169	84	21	)	)	PUNCT
dpc-6169	84	22	for	for	ADP
dpc-6169	84	23	continuous	continuous	ADJ
dpc-6169	84	24	variables	variable	NOUN
dpc-6169	84	25	.	.	PUNCT
dpc-6169	85	1	the	the	DET
dpc-6169	85	2	kolmogorov	kolmogorov	PROPN
dpc-6169	85	3	–	–	PUNCT
dpc-6169	85	4	smirnov	smirnov	PROPN
dpc-6169	85	5	and	and	CCONJ
dpc-6169	85	6	shapiro	shapiro	PROPN
dpc-6169	85	7	–	–	PUNCT
dpc-6169	85	8	wilk	wilk	NOUN
dpc-6169	85	9	tests	test	NOUN
dpc-6169	85	10	were	be	AUX
dpc-6169	85	11	used	use	VERB
dpc-6169	85	12	to	to	PART
dpc-6169	85	13	assess	assess	VERB
dpc-6169	85	14	the	the	DET
dpc-6169	85	15	normality	normality	NOUN
dpc-6169	85	16	of	of	ADP
dpc-6169	85	17	continuous	continuous	ADJ
dpc-6169	85	18	variables	variable	NOUN
dpc-6169	85	19	.	.	PUNCT
dpc-6169	86	1	group	group	NOUN
dpc-6169	86	2	comparisons	comparison	NOUN
dpc-6169	86	3	were	be	AUX
dpc-6169	86	4	performed	perform	VERB
dpc-6169	86	5	using	use	VERB
dpc-6169	86	6	the	the	DET
dpc-6169	86	7	chi	chi	ADJ
dpc-6169	86	8	-	-	PUNCT
dpc-6169	86	9	square	square	ADJ
dpc-6169	86	10	test	test	NOUN
dpc-6169	86	11	for	for	ADP
dpc-6169	86	12	categorical	categorical	ADJ
dpc-6169	86	13	variables	variable	NOUN
dpc-6169	86	14	and	and	CCONJ
dpc-6169	86	15	the	the	DET
dpc-6169	86	16	mann	mann	PROPN
dpc-6169	86	17	–	–	PUNCT
dpc-6169	86	18	whitney	whitney	PROPN
dpc-6169	86	19	u	u	PROPN
dpc-6169	86	20	test	test	NOUN
dpc-6169	86	21	for	for	ADP
dpc-6169	86	22	non	non	ADJ
dpc-6169	86	23	-	-	ADJ
dpc-6169	86	24	normally	normally	ADV
dpc-6169	86	25	distributed	distribute	VERB
dpc-6169	86	26	continuous	continuous	ADJ
dpc-6169	86	27	variables	variable	NOUN
dpc-6169	86	28	.	.	PUNCT
dpc-6169	87	1	a	a	DET
dpc-6169	87	2	p	p	NOUN
dpc-6169	87	3	-	-	PUNCT
dpc-6169	87	4	value	value	NOUN
dpc-6169	87	5	of	of	ADP
dpc-6169	87	6	<	<	NOUN
dpc-6169	87	7	0.05	0.05	NUM
dpc-6169	87	8	was	be	AUX
dpc-6169	87	9	considered	consider	VERB
dpc-6169	87	10	statistically	statistically	ADV
dpc-6169	87	11	significant	significant	ADJ
dpc-6169	87	12	.	.	PUNCT
dpc-6169	88	1	binary	binary	ADJ
dpc-6169	88	2	logistic	logistic	ADJ
dpc-6169	88	3	regression	regression	NOUN
dpc-6169	88	4	analysis	analysis	NOUN
dpc-6169	88	5	was	be	AUX
dpc-6169	88	6	performed	perform	VERB
dpc-6169	88	7	to	to	PART
dpc-6169	88	8	identify	identify	VERB
dpc-6169	88	9	independent	independent	ADJ
dpc-6169	88	10	predictors	predictor	NOUN
dpc-6169	88	11	of	of	ADP
dpc-6169	88	12	early	early	ADJ
dpc-6169	88	13	treatment	treatment	NOUN
dpc-6169	88	14	response	response	NOUN
dpc-6169	88	15	,	,	PUNCT
dpc-6169	88	16	including	include	VERB
dpc-6169	88	17	baseline	baseline	NOUN
dpc-6169	88	18	uas7	uas7	NOUN
dpc-6169	88	19	,	,	PUNCT
dpc-6169	88	20	disease	disease	NOUN
dpc-6169	88	21	duration	duration	NOUN
dpc-6169	88	22	,	,	PUNCT
dpc-6169	88	23	age	age	NOUN
dpc-6169	88	24	group	group	NOUN
dpc-6169	88	25	(	(	PUNCT
dpc-6169	88	26	<	<	X
dpc-6169	88	27	45	45	NUM
dpc-6169	88	28	vs.	vs.	NOUN
dpc-6169	88	29	≥45	≥45	NUM
dpc-6169	88	30	years	year	NOUN
dpc-6169	88	31	)	)	PUNCT
dpc-6169	88	32	,	,	PUNCT
dpc-6169	88	33	and	and	CCONJ
dpc-6169	88	34	sex	sex	NOUN
dpc-6169	88	35	.	.	PUNCT
dpc-6169	89	1	results	result	NOUN
dpc-6169	89	2	are	be	AUX
dpc-6169	89	3	reported	report	VERB
dpc-6169	89	4	as	as	ADP
dpc-6169	89	5	odds	odd	NOUN
dpc-6169	89	6	ratios	ratio	NOUN
dpc-6169	89	7	(	(	PUNCT
dpc-6169	89	8	or	or	CCONJ
dpc-6169	89	9	)	)	PUNCT
dpc-6169	89	10	with	with	ADP
dpc-6169	89	11	95	95	NUM
dpc-6169	89	12	%	%	NOUN
dpc-6169	89	13	confidence	confidence	NOUN
dpc-6169	89	14	intervals	interval	NOUN
dpc-6169	89	15	(	(	PUNCT
dpc-6169	89	16	ci	ci	NOUN
dpc-6169	89	17	)	)	PUNCT
dpc-6169	89	18	.	.	PUNCT
dpc-6169	90	1	receiver	receiver	ADJ
dpc-6169	90	2	operating	operate	VERB
dpc-6169	90	3	characteristic	characteristic	NOUN
dpc-6169	90	4	(	(	PUNCT
dpc-6169	90	5	roc	roc	PROPN
dpc-6169	90	6	)	)	PUNCT
dpc-6169	90	7	curve	curve	NOUN
dpc-6169	90	8	analyses	analysis	NOUN
dpc-6169	90	9	were	be	AUX
dpc-6169	90	10	conducted	conduct	VERB
dpc-6169	90	11	to	to	PART
dpc-6169	90	12	evaluate	evaluate	VERB
dpc-6169	90	13	the	the	DET
dpc-6169	90	14	discriminatory	discriminatory	ADJ
dpc-6169	90	15	ability	ability	NOUN
dpc-6169	90	16	of	of	ADP
dpc-6169	90	17	baseline	baseline	NOUN
dpc-6169	90	18	uas7	uas7	NOUN
dpc-6169	90	19	and	and	CCONJ
dpc-6169	90	20	disease	disease	NOUN
dpc-6169	90	21	duration	duration	NOUN
dpc-6169	90	22	for	for	ADP
dpc-6169	90	23	predicting	predict	VERB
dpc-6169	90	24	early	early	ADJ
dpc-6169	90	25	response	response	NOUN
dpc-6169	90	26	.	.	PUNCT
dpc-6169	91	1	the	the	DET
dpc-6169	91	2	area	area	NOUN
dpc-6169	91	3	under	under	ADP
dpc-6169	91	4	the	the	DET
dpc-6169	91	5	curve	curve	NOUN
dpc-6169	91	6	(	(	PUNCT
dpc-6169	91	7	auc	auc	NOUN
dpc-6169	91	8	)	)	PUNCT
dpc-6169	91	9	and	and	CCONJ
dpc-6169	91	10	optimal	optimal	ADJ
dpc-6169	91	11	cutoff	cutoff	NOUN
dpc-6169	91	12	values	value	NOUN
dpc-6169	91	13	were	be	AUX
dpc-6169	91	14	calculated	calculate	VERB
dpc-6169	91	15	based	base	VERB
dpc-6169	91	16	on	on	ADP
dpc-6169	91	17	sensitivity	sensitivity	NOUN
dpc-6169	91	18	and	and	CCONJ
dpc-6169	91	19	specificity	specificity	NOUN
dpc-6169	91	20	metrics	metric	NOUN
dpc-6169	91	21	.	.	PUNCT
dpc-6169	92	1	results	result	VERB
dpc-6169	92	2	a	a	DET
dpc-6169	92	3	total	total	NOUN
dpc-6169	92	4	of	of	ADP
dpc-6169	92	5	274	274	NUM
dpc-6169	92	6	patients	patient	NOUN
dpc-6169	92	7	with	with	ADP
dpc-6169	92	8	chronic	chronic	ADJ
dpc-6169	92	9	spontaneous	spontaneous	ADJ
dpc-6169	92	10	urticaria	urticaria	NOUN
dpc-6169	92	11	(	(	PUNCT
dpc-6169	92	12	csu	csu	PROPN
dpc-6169	92	13	)	)	PUNCT
dpc-6169	92	14	undergoing	undergo	VERB
dpc-6169	92	15	omalizumab	omalizumab	NOUN
dpc-6169	92	16	treatment	treatment	NOUN
dpc-6169	92	17	were	be	AUX
dpc-6169	92	18	included	include	VERB
dpc-6169	92	19	in	in	ADP
dpc-6169	92	20	the	the	DET
dpc-6169	92	21	study	study	NOUN
dpc-6169	92	22	,	,	PUNCT
dpc-6169	92	23	with	with	ADP
dpc-6169	92	24	a	a	DET
dpc-6169	92	25	mean	mean	ADJ
dpc-6169	92	26	age	age	NOUN
dpc-6169	92	27	of	of	ADP
dpc-6169	92	28	42.96	42.96	NUM
dpc-6169	92	29	±	±	NUM
dpc-6169	92	30	15.54	15.54	NUM
dpc-6169	92	31	years	year	NOUN
dpc-6169	92	32	(	(	PUNCT
dpc-6169	92	33	min=18	min=18	PROPN
dpc-6169	92	34	,	,	PUNCT
dpc-6169	92	35	max=85	max=85	PROPN
dpc-6169	92	36	)	)	PUNCT
dpc-6169	92	37	.	.	PUNCT
dpc-6169	93	1	among	among	ADP
dpc-6169	93	2	these	these	PRON
dpc-6169	93	3	,	,	PUNCT
dpc-6169	93	4	92	92	NUM
dpc-6169	93	5	(	(	PUNCT
dpc-6169	93	6	33.6	33.6	NUM
dpc-6169	93	7	%	%	NOUN
dpc-6169	93	8	)	)	PUNCT
dpc-6169	93	9	were	be	AUX
dpc-6169	93	10	male	male	ADJ
dpc-6169	93	11	,	,	PUNCT
dpc-6169	93	12	and	and	CCONJ
dpc-6169	93	13	182	182	NUM
dpc-6169	93	14	(	(	PUNCT
dpc-6169	93	15	66.4	66.4	NUM
dpc-6169	93	16	%	%	NOUN
dpc-6169	93	17	)	)	PUNCT
dpc-6169	93	18	were	be	AUX
dpc-6169	93	19	female	female	ADJ
dpc-6169	93	20	.	.	PUNCT
dpc-6169	94	1	the	the	DET
dpc-6169	94	2	mean	mean	ADJ
dpc-6169	94	3	duration	duration	NOUN
dpc-6169	94	4	of	of	ADP
dpc-6169	94	5	omalizumab	omalizumab	NOUN
dpc-6169	94	6	treatment	treatment	NOUN
dpc-6169	94	7	among	among	ADP
dpc-6169	94	8	the	the	DET
dpc-6169	94	9	study	study	NOUN
dpc-6169	94	10	participants	participant	NOUN
dpc-6169	94	11	was	be	AUX
dpc-6169	94	12	found	find	VERB
dpc-6169	94	13	to	to	PART
dpc-6169	94	14	be	be	AUX
dpc-6169	94	15	35.63	35.63	NUM
dpc-6169	94	16	±	±	NUM
dpc-6169	94	17	27.78	27.78	NUM
dpc-6169	94	18	months	month	NOUN
dpc-6169	94	19	(	(	PUNCT
dpc-6169	94	20	min=3	min=3	NOUN
dpc-6169	94	21	,	,	PUNCT
dpc-6169	94	22	max=120	max=120	NOUN
dpc-6169	94	23	)	)	PUNCT
dpc-6169	94	24	.	.	PUNCT
dpc-6169	95	1	among	among	ADP
dpc-6169	95	2	the	the	DET
dpc-6169	95	3	patients	patient	NOUN
dpc-6169	95	4	,	,	PUNCT
dpc-6169	95	5	143	143	NUM
dpc-6169	95	6	(	(	PUNCT
dpc-6169	95	7	52.2	52.2	NUM
dpc-6169	95	8	%	%	NOUN
dpc-6169	95	9	)	)	PUNCT
dpc-6169	95	10	were	be	AUX
dpc-6169	95	11	still	still	ADV
dpc-6169	95	12	continuing	continue	VERB
dpc-6169	95	13	treatment	treatment	NOUN
dpc-6169	95	14	,	,	PUNCT
dpc-6169	95	15	while	while	SCONJ
dpc-6169	95	16	77	77	NUM
dpc-6169	95	17	patients	patient	NOUN
dpc-6169	95	18	(	(	PUNCT
dpc-6169	95	19	28.1	28.1	NUM
dpc-6169	95	20	%	%	NOUN
dpc-6169	95	21	)	)	PUNCT
dpc-6169	95	22	had	have	AUX
dpc-6169	95	23	discontinued	discontinue	VERB
dpc-6169	95	24	treatment	treatment	NOUN
dpc-6169	95	25	of	of	ADP
dpc-6169	95	26	their	their	PRON
dpc-6169	95	27	own	own	ADJ
dpc-6169	95	28	will	will	NOUN
dpc-6169	95	29	.	.	PUNCT
dpc-6169	96	1	the	the	DET
dpc-6169	96	2	number	number	NOUN
dpc-6169	96	3	of	of	ADP
dpc-6169	96	4	patients	patient	NOUN
dpc-6169	96	5	whose	whose	DET
dpc-6169	96	6	treatment	treatment	NOUN
dpc-6169	96	7	was	be	AUX
dpc-6169	96	8	discontinued	discontinue	VERB
dpc-6169	96	9	due	due	ADP
dpc-6169	96	10	to	to	ADP
dpc-6169	96	11	lack	lack	NOUN
dpc-6169	96	12	of	of	ADP
dpc-6169	96	13	efficacy	efficacy	NOUN
dpc-6169	96	14	was	be	AUX
dpc-6169	96	15	15	15	NUM
dpc-6169	96	16	(	(	PUNCT
dpc-6169	96	17	5.5	5.5	NUM
dpc-6169	96	18	%	%	NOUN
dpc-6169	96	19	)	)	PUNCT
dpc-6169	96	20	,	,	PUNCT
dpc-6169	96	21	while	while	SCONJ
dpc-6169	96	22	36	36	NUM
dpc-6169	96	23	patients	patient	NOUN
dpc-6169	96	24	(	(	PUNCT
dpc-6169	96	25	13.1	13.1	NUM
dpc-6169	96	26	%	%	NOUN
dpc-6169	96	27	)	)	PUNCT
dpc-6169	96	28	initially	initially	ADV
dpc-6169	96	29	responded	respond	VERB
dpc-6169	96	30	to	to	ADP
dpc-6169	96	31	treatment	treatment	NOUN
dpc-6169	96	32	but	but	CCONJ
dpc-6169	96	33	later	later	ADV
dpc-6169	96	34	discontinued	discontinue	VERB
dpc-6169	96	35	due	due	ADP
dpc-6169	96	36	to	to	ADP
dpc-6169	96	37	loss	loss	NOUN
dpc-6169	96	38	of	of	ADP
dpc-6169	96	39	effectiveness	effectiveness	NOUN
dpc-6169	96	40	.	.	PUNCT
dpc-6169	97	1	one	one	NUM
dpc-6169	97	2	patient	patient	NOUN
dpc-6169	97	3	discontinued	discontinue	VERB
dpc-6169	97	4	treatment	treatment	NOUN
dpc-6169	97	5	at	at	ADP
dpc-6169	97	6	the	the	DET
dpc-6169	97	7	fourth	fourth	ADJ
dpc-6169	97	8	month	month	NOUN
dpc-6169	97	9	due	due	ADP
dpc-6169	97	10	to	to	ADP
dpc-6169	97	11	generalized	generalized	ADJ
dpc-6169	97	12	numbness	numbness	NOUN
dpc-6169	97	13	and	and	CCONJ
dpc-6169	97	14	fatigue	fatigue	NOUN
dpc-6169	97	15	.	.	PUNCT
dpc-6169	98	1	another	another	DET
dpc-6169	98	2	patient	patient	NOUN
dpc-6169	98	3	discontinued	discontinue	VERB
dpc-6169	98	4	treatment	treatment	NOUN
dpc-6169	98	5	at	at	ADP
dpc-6169	98	6	the	the	DET
dpc-6169	98	7	fifth	fifth	ADJ
dpc-6169	98	8	month	month	NOUN
dpc-6169	98	9	due	due	ADP
dpc-6169	98	10	to	to	ADP
dpc-6169	98	11	a	a	DET
dpc-6169	98	12	7	7	NUM
dpc-6169	98	13	%	%	NOUN
dpc-6169	98	14	reduction	reduction	NOUN
dpc-6169	98	15	in	in	ADP
dpc-6169	98	16	body	body	NOUN
dpc-6169	98	17	weight	weight	NOUN
dpc-6169	98	18	.	.	PUNCT
dpc-6169	99	1	additionally	additionally	ADV
dpc-6169	99	2	,	,	PUNCT
dpc-6169	99	3	one	one	NUM
dpc-6169	99	4	patient	patient	NOUN
dpc-6169	99	5	developed	develop	VERB
dpc-6169	99	6	a	a	DET
dpc-6169	99	7	widespread	widespread	ADJ
dpc-6169	99	8	maculopapular	maculopapular	ADJ
dpc-6169	99	9	reaction	reaction	NOUN
dpc-6169	99	10	within	within	ADP
dpc-6169	99	11	24	24	NUM
dpc-6169	99	12	hours	hour	NOUN
dpc-6169	99	13	after	after	ADP
dpc-6169	99	14	the	the	DET
dpc-6169	99	15	fifth	fifth	ADJ
dpc-6169	99	16	dose	dose	NOUN
dpc-6169	99	17	,	,	PUNCT
dpc-6169	99	18	leading	lead	VERB
dpc-6169	99	19	to	to	ADP
dpc-6169	99	20	treatment	treatment	NOUN
dpc-6169	99	21	discontinuation	discontinuation	NOUN
dpc-6169	99	22	.	.	PUNCT
dpc-6169	100	1	another	another	DET
dpc-6169	100	2	patient	patient	NOUN
dpc-6169	100	3	experienced	experienced	ADJ
dpc-6169	100	4	palpitations	palpitation	NOUN
dpc-6169	100	5	starting	start	VERB
dpc-6169	100	6	from	from	ADP
dpc-6169	100	7	the	the	DET
dpc-6169	100	8	third	third	ADJ
dpc-6169	100	9	dose	dose	NOUN
dpc-6169	100	10	,	,	PUNCT
dpc-6169	100	11	necessitating	necessitate	VERB
dpc-6169	100	12	drug	drug	NOUN
dpc-6169	100	13	discontinuation	discontinuation	NOUN
dpc-6169	100	14	.	.	PUNCT
dpc-6169	101	1	the	the	DET
dpc-6169	101	2	total	total	ADJ
dpc-6169	101	3	number	number	NOUN
dpc-6169	101	4	of	of	ADP
dpc-6169	101	5	patients	patient	NOUN
dpc-6169	101	6	who	who	PRON
dpc-6169	101	7	discontinued	discontinue	VERB
dpc-6169	101	8	treatment	treatment	NOUN
dpc-6169	101	9	due	due	ADP
dpc-6169	101	10	to	to	ADP
dpc-6169	101	11	adverse	adverse	ADJ
dpc-6169	101	12	effects	effect	NOUN
dpc-6169	101	13	was	be	AUX
dpc-6169	101	14	four	four	NUM
dpc-6169	101	15	(	(	PUNCT
dpc-6169	101	16	1.45	1.45	NUM
dpc-6169	101	17	%	%	NOUN
dpc-6169	101	18	)	)	PUNCT
dpc-6169	101	19	.	.	PUNCT
dpc-6169	102	1	among	among	ADP
dpc-6169	102	2	these	these	PRON
dpc-6169	102	3	,	,	PUNCT
dpc-6169	102	4	two	two	NUM
dpc-6169	102	5	(	(	PUNCT
dpc-6169	102	6	0.74	0.74	NUM
dpc-6169	102	7	%	%	NOUN
dpc-6169	102	8	)	)	PUNCT
dpc-6169	102	9	were	be	AUX
dpc-6169	102	10	male	male	ADJ
dpc-6169	102	11	and	and	CCONJ
dpc-6169	102	12	two	two	NUM
dpc-6169	102	13	(	(	PUNCT
dpc-6169	102	14	0.74	0.74	NUM
dpc-6169	102	15	%	%	NOUN
dpc-6169	102	16	)	)	PUNCT
dpc-6169	102	17	were	be	AUX
dpc-6169	102	18	female	female	ADJ
dpc-6169	102	19	.	.	PUNCT
dpc-6169	103	1	the	the	DET
dpc-6169	103	2	mean	mean	ADJ
dpc-6169	103	3	age	age	NOUN
dpc-6169	103	4	of	of	ADP
dpc-6169	103	5	male	male	ADJ
dpc-6169	103	6	patients	patient	NOUN
dpc-6169	103	7	in	in	ADP
dpc-6169	103	8	the	the	DET
dpc-6169	103	9	study	study	NOUN
dpc-6169	103	10	was	be	AUX
dpc-6169	103	11	43.15	43.15	NUM
dpc-6169	103	12	±	±	NUM
dpc-6169	103	13	16.77	16.77	NUM
dpc-6169	103	14	years	year	NOUN
dpc-6169	103	15	,	,	PUNCT
dpc-6169	103	16	while	while	SCONJ
dpc-6169	103	17	that	that	PRON
dpc-6169	103	18	of	of	ADP
dpc-6169	103	19	female	female	ADJ
dpc-6169	103	20	patients	patient	NOUN
dpc-6169	103	21	was	be	AUX
dpc-6169	103	22	42.86	42.86	NUM
dpc-6169	103	23	±	±	NUM
dpc-6169	103	24	14.93	14.93	NUM
dpc-6169	103	25	years	year	NOUN
dpc-6169	103	26	.	.	PUNCT
dpc-6169	104	1	no	no	DET
dpc-6169	104	2	statistically	statistically	ADV
dpc-6169	104	3	significant	significant	ADJ
dpc-6169	104	4	difference	difference	NOUN
dpc-6169	104	5	was	be	AUX
dpc-6169	104	6	observed	observe	VERB
dpc-6169	104	7	between	between	ADP
dpc-6169	104	8	the	the	DET
dpc-6169	104	9	ages	age	NOUN
dpc-6169	104	10	of	of	ADP
dpc-6169	104	11	male	male	ADJ
dpc-6169	104	12	and	and	CCONJ
dpc-6169	104	13	female	female	ADJ
dpc-6169	104	14	patients	patient	NOUN
dpc-6169	104	15	(	(	PUNCT
dpc-6169	104	16	p=0.885	p=0.885	NOUN
dpc-6169	104	17	)	)	PUNCT
dpc-6169	104	18	.	.	PUNCT
dpc-6169	105	1	the	the	DET
dpc-6169	105	2	mean	mean	ADJ
dpc-6169	105	3	follow	follow	VERB
dpc-6169	105	4	-	-	PUNCT
dpc-6169	105	5	up	up	ADP
dpc-6169	105	6	duration	duration	NOUN
dpc-6169	105	7	for	for	ADP
dpc-6169	105	8	male	male	ADJ
dpc-6169	105	9	patients	patient	NOUN
dpc-6169	105	10	was	be	AUX
dpc-6169	105	11	35.52	35.52	NUM
dpc-6169	105	12	±	±	NUM
dpc-6169	105	13	29.70	29.70	NUM
dpc-6169	105	14	months	month	NOUN
dpc-6169	105	15	,	,	PUNCT
dpc-6169	105	16	whereas	whereas	SCONJ
dpc-6169	105	17	for	for	ADP
dpc-6169	105	18	female	female	ADJ
dpc-6169	105	19	patients	patient	NOUN
dpc-6169	105	20	,	,	PUNCT
dpc-6169	105	21	it	it	PRON
dpc-6169	105	22	was	be	AUX
dpc-6169	105	23	35.68	35.68	NUM
dpc-6169	105	24	±	±	NUM
dpc-6169	105	25	26.84	26.84	NUM
dpc-6169	105	26	months	month	NOUN
dpc-6169	105	27	.	.	PUNCT
dpc-6169	106	1	no	no	DET
dpc-6169	106	2	significant	significant	ADJ
dpc-6169	106	3	difference	difference	NOUN
dpc-6169	106	4	was	be	AUX
dpc-6169	106	5	found	find	VERB
dpc-6169	106	6	between	between	ADP
dpc-6169	106	7	the	the	DET
dpc-6169	106	8	sexes	sex	NOUN
dpc-6169	106	9	in	in	ADP
dpc-6169	106	10	terms	term	NOUN
dpc-6169	106	11	of	of	ADP
dpc-6169	106	12	follow	follow	VERB
dpc-6169	106	13	-	-	PUNCT
dpc-6169	106	14	up	up	ADP
dpc-6169	106	15	duration	duration	NOUN
dpc-6169	106	16	(	(	PUNCT
dpc-6169	106	17	p=0.964	p=0.964	X
dpc-6169	106	18	)	)	PUNCT
dpc-6169	106	19	.	.	PUNCT
dpc-6169	107	1	when	when	SCONJ
dpc-6169	107	2	evaluating	evaluate	VERB
dpc-6169	107	3	early	early	ADJ
dpc-6169	107	4	responders	responder	NOUN
dpc-6169	107	5	to	to	PART
dpc-6169	107	6	omalizumab	omalizumab	VERB
dpc-6169	107	7	treatment	treatment	NOUN
dpc-6169	107	8	based	base	VERB
dpc-6169	107	9	on	on	ADP
dpc-6169	107	10	sex	sex	NOUN
dpc-6169	107	11	,	,	PUNCT
dpc-6169	107	12	no	no	DET
dpc-6169	107	13	statistically	statistically	ADV
dpc-6169	107	14	significant	significant	ADJ
dpc-6169	107	15	difference	difference	NOUN
dpc-6169	107	16	was	be	AUX
dpc-6169	107	17	observed	observe	VERB
dpc-6169	107	18	between	between	ADP
dpc-6169	107	19	male	male	ADJ
dpc-6169	107	20	and	and	CCONJ
dpc-6169	107	21	female	female	ADJ
dpc-6169	107	22	patients	patient	NOUN
dpc-6169	107	23	in	in	ADP
dpc-6169	107	24	terms	term	NOUN
dpc-6169	107	25	of	of	ADP
dpc-6169	107	26	initial	initial	ADJ
dpc-6169	107	27	response	response	NOUN
dpc-6169	107	28	to	to	ADP
dpc-6169	107	29	the	the	DET
dpc-6169	107	30	first	first	ADJ
dpc-6169	107	31	dose	dose	PROPN
dpc-6169	107	32	(	(	PUNCT
dpc-6169	107	33	p=0.243	p=0.243	PROPN
dpc-6169	107	34	)	)	PUNCT
dpc-6169	107	35	(	(	PUNCT
dpc-6169	107	36	table	table	NOUN
dpc-6169	107	37	1	1	NUM
dpc-6169	107	38	)	)	PUNCT
dpc-6169	107	39	.	.	PUNCT
dpc-6169	108	1	4	4	NUM
dpc-6169	108	2	original	original	ADJ
dpc-6169	108	3	article	article	NOUN
dpc-6169	108	4	|	|	ADV
dpc-6169	108	5	dermatol	dermatol	ADJ
dpc-6169	108	6	pract	pract	NOUN
dpc-6169	108	7	concept	concept	NOUN
dpc-6169	108	8	.	.	PUNCT
dpc-6169	109	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	109	2	(	(	PUNCT
dpc-6169	109	3	or	or	CCONJ
dpc-6169	109	4	:	:	PUNCT
dpc-6169	109	5	0.761	0.761	NUM
dpc-6169	109	6	;	;	PUNCT
dpc-6169	109	7	95	95	NUM
dpc-6169	109	8	%	%	NOUN
dpc-6169	109	9	ci	ci	NOUN
dpc-6169	109	10	:	:	PUNCT
dpc-6169	109	11	0.697–0.831	0.697–0.831	NUM
dpc-6169	109	12	;	;	PUNCT
dpc-6169	109	13	p<0.001	p<0.001	X
dpc-6169	109	14	)	)	PUNCT
dpc-6169	109	15	were	be	AUX
dpc-6169	109	16	both	both	PRON
dpc-6169	109	17	independently	independently	ADV
dpc-6169	109	18	associated	associate	VERB
dpc-6169	109	19	with	with	ADP
dpc-6169	109	20	a	a	DET
dpc-6169	109	21	higher	high	ADJ
dpc-6169	109	22	likelihood	likelihood	NOUN
dpc-6169	109	23	of	of	ADP
dpc-6169	109	24	early	early	ADJ
dpc-6169	109	25	treatment	treatment	NOUN
dpc-6169	109	26	response	response	NOUN
dpc-6169	109	27	.	.	PUNCT
dpc-6169	110	1	in	in	ADP
dpc-6169	110	2	contrast	contrast	NOUN
dpc-6169	110	3	,	,	PUNCT
dpc-6169	110	4	sex	sex	NOUN
dpc-6169	110	5	(	(	PUNCT
dpc-6169	110	6	p=0.307	p=0.307	NOUN
dpc-6169	110	7	)	)	PUNCT
dpc-6169	110	8	and	and	CCONJ
dpc-6169	110	9	age	age	NOUN
dpc-6169	110	10	group	group	NOUN
dpc-6169	110	11	(	(	PUNCT
dpc-6169	110	12	<	<	X
dpc-6169	110	13	45	45	NUM
dpc-6169	110	14	vs.	vs.	NOUN
dpc-6169	110	15	≥45	≥45	NOUN
dpc-6169	110	16	years	year	NOUN
dpc-6169	110	17	,	,	PUNCT
dpc-6169	110	18	p=0.872	p=0.872	PUNCT
dpc-6169	110	19	)	)	PUNCT
dpc-6169	110	20	were	be	AUX
dpc-6169	110	21	not	not	PART
dpc-6169	110	22	independently	independently	ADV
dpc-6169	110	23	associated	associate	VERB
dpc-6169	110	24	with	with	ADP
dpc-6169	110	25	early	early	ADJ
dpc-6169	110	26	response	response	NOUN
dpc-6169	110	27	.	.	PUNCT
dpc-6169	111	1	notably	notably	ADV
dpc-6169	111	2	,	,	PUNCT
dpc-6169	111	3	in	in	ADP
dpc-6169	111	4	univariate	univariate	ADJ
dpc-6169	111	5	analysis	analysis	NOUN
dpc-6169	111	6	,	,	PUNCT
dpc-6169	111	7	patients	patient	NOUN
dpc-6169	111	8	under	under	ADP
dpc-6169	111	9	45	45	NUM
dpc-6169	111	10	years	year	NOUN
dpc-6169	111	11	of	of	ADP
dpc-6169	111	12	age	age	NOUN
dpc-6169	111	13	showed	show	VERB
dpc-6169	111	14	a	a	DET
dpc-6169	111	15	statistically	statistically	ADV
dpc-6169	111	16	significantly	significantly	ADV
dpc-6169	111	17	higher	high	ADJ
dpc-6169	111	18	likelihood	likelihood	NOUN
dpc-6169	111	19	of	of	ADP
dpc-6169	111	20	achieving	achieve	VERB
dpc-6169	111	21	early	early	ADJ
dpc-6169	111	22	response	response	NOUN
dpc-6169	111	23	compared	compare	VERB
dpc-6169	111	24	to	to	ADP
dpc-6169	111	25	those	those	PRON
dpc-6169	111	26	aged	age	VERB
dpc-6169	111	27	45	45	NUM
dpc-6169	111	28	years	year	NOUN
dpc-6169	111	29	or	or	CCONJ
dpc-6169	111	30	older	old	ADJ
dpc-6169	111	31	(	(	PUNCT
dpc-6169	111	32	p=0.01	p=0.01	NUM
dpc-6169	111	33	)	)	PUNCT
dpc-6169	111	34	.	.	PUNCT
dpc-6169	112	1	however	however	ADV
dpc-6169	112	2	,	,	PUNCT
dpc-6169	112	3	this	this	DET
dpc-6169	112	4	relationship	relationship	NOUN
dpc-6169	112	5	did	do	AUX
dpc-6169	112	6	not	not	PART
dpc-6169	112	7	persist	persist	VERB
dpc-6169	112	8	after	after	ADP
dpc-6169	112	9	adjusting	adjust	VERB
dpc-6169	112	10	for	for	ADP
dpc-6169	112	11	disease	disease	NOUN
dpc-6169	112	12	duration	duration	NOUN
dpc-6169	112	13	and	and	CCONJ
dpc-6169	112	14	baseline	baseline	NOUN
dpc-6169	112	15	uas7	uas7	NOUN
dpc-6169	112	16	in	in	ADP
dpc-6169	112	17	multivariate	multivariate	NOUN
dpc-6169	112	18	analysis	analysis	NOUN
dpc-6169	112	19	,	,	PUNCT
dpc-6169	112	20	suggesting	suggest	VERB
dpc-6169	112	21	the	the	DET
dpc-6169	112	22	apparent	apparent	ADJ
dpc-6169	112	23	age	age	NOUN
dpc-6169	112	24	effect	effect	NOUN
dpc-6169	112	25	may	may	AUX
dpc-6169	112	26	be	be	AUX
dpc-6169	112	27	mediated	mediate	VERB
dpc-6169	112	28	through	through	ADP
dpc-6169	112	29	these	these	DET
dpc-6169	112	30	clinical	clinical	ADJ
dpc-6169	112	31	variables	variable	NOUN
dpc-6169	112	32	.	.	PUNCT
dpc-6169	113	1	roc	roc	PROPN
dpc-6169	113	2	curve	curve	NOUN
dpc-6169	113	3	analysis	analysis	NOUN
dpc-6169	113	4	was	be	AUX
dpc-6169	113	5	performed	perform	VERB
dpc-6169	113	6	to	to	PART
dpc-6169	113	7	assess	assess	VERB
dpc-6169	113	8	the	the	DET
dpc-6169	113	9	ability	ability	NOUN
dpc-6169	113	10	of	of	ADP
dpc-6169	113	11	baseline	baseline	NOUN
dpc-6169	113	12	uas7	uas7	NOUN
dpc-6169	113	13	to	to	PART
dpc-6169	113	14	predict	predict	VERB
dpc-6169	113	15	early	early	ADJ
dpc-6169	113	16	response	response	NOUN
dpc-6169	113	17	to	to	ADP
dpc-6169	113	18	omalizumab	omalizumab	NOUN
dpc-6169	113	19	.	.	PUNCT
dpc-6169	114	1	the	the	DET
dpc-6169	114	2	area	area	NOUN
dpc-6169	114	3	under	under	ADP
dpc-6169	114	4	the	the	DET
dpc-6169	114	5	curve	curve	NOUN
dpc-6169	114	6	(	(	PUNCT
dpc-6169	114	7	auc	auc	NOUN
dpc-6169	114	8	)	)	PUNCT
dpc-6169	114	9	was	be	AUX
dpc-6169	114	10	0.083	0.083	NUM
dpc-6169	114	11	,	,	PUNCT
dpc-6169	114	12	indicating	indicate	VERB
dpc-6169	114	13	an	an	DET
dpc-6169	114	14	inverse	inverse	ADJ
dpc-6169	114	15	predictive	predictive	NOUN
dpc-6169	114	16	relationship	relationship	NOUN
dpc-6169	114	17	.	.	PUNCT
dpc-6169	115	1	interpreted	interpret	VERB
dpc-6169	115	2	in	in	ADP
dpc-6169	115	3	clinical	clinical	ADJ
dpc-6169	115	4	context	context	NOUN
dpc-6169	115	5	,	,	PUNCT
dpc-6169	115	6	this	this	PRON
dpc-6169	115	7	corresponds	correspond	VERB
dpc-6169	115	8	to	to	ADP
dpc-6169	115	9	an	an	DET
dpc-6169	115	10	auc	auc	NOUN
dpc-6169	115	11	of	of	ADP
dpc-6169	115	12	0.917	0.917	NUM
dpc-6169	115	13	for	for	ADP
dpc-6169	115	14	lower	low	ADJ
dpc-6169	115	15	baseline	baseline	ADJ
dpc-6169	115	16	uas7	uas7	NOUN
dpc-6169	115	17	predicting	predict	VERB
dpc-6169	115	18	early	early	ADJ
dpc-6169	115	19	response	response	NOUN
dpc-6169	115	20	.	.	PUNCT
dpc-6169	116	1	coordinate	coordinate	NOUN
dpc-6169	116	2	points	point	NOUN
dpc-6169	116	3	suggested	suggest	VERB
dpc-6169	116	4	that	that	SCONJ
dpc-6169	116	5	patients	patient	NOUN
dpc-6169	116	6	with	with	ADP
dpc-6169	116	7	baseline	baseline	ADJ
dpc-6169	116	8	uas7	uas7	ADJ
dpc-6169	116	9	values	value	NOUN
dpc-6169	116	10	below	below	ADP
dpc-6169	116	11	approximately	approximately	ADV
dpc-6169	116	12	10–12	10–12	NUM
dpc-6169	116	13	were	be	AUX
dpc-6169	116	14	most	most	ADV
dpc-6169	116	15	likely	likely	ADJ
dpc-6169	116	16	to	to	PART
dpc-6169	116	17	achieve	achieve	VERB
dpc-6169	116	18	early	early	ADJ
dpc-6169	116	19	response	response	NOUN
dpc-6169	116	20	,	,	PUNCT
dpc-6169	116	21	whereas	whereas	SCONJ
dpc-6169	116	22	those	those	PRON
dpc-6169	116	23	with	with	ADP
dpc-6169	116	24	scores	score	NOUN
dpc-6169	116	25	above	above	ADP
dpc-6169	116	26	20	20	NUM
dpc-6169	116	27	were	be	AUX
dpc-6169	116	28	highly	highly	ADV
dpc-6169	116	29	unlikely	unlikely	ADJ
dpc-6169	116	30	to	to	PART
dpc-6169	116	31	do	do	VERB
dpc-6169	116	32	so	so	ADV
dpc-6169	116	33	.	.	PUNCT
dpc-6169	117	1	roc	roc	PROPN
dpc-6169	117	2	curve	curve	NOUN
dpc-6169	117	3	analysis	analysis	NOUN
dpc-6169	117	4	was	be	AUX
dpc-6169	117	5	conducted	conduct	VERB
dpc-6169	117	6	to	to	PART
dpc-6169	117	7	assess	assess	VERB
dpc-6169	117	8	the	the	DET
dpc-6169	117	9	predictive	predictive	ADJ
dpc-6169	117	10	value	value	NOUN
dpc-6169	117	11	of	of	ADP
dpc-6169	117	12	disease	disease	NOUN
dpc-6169	117	13	duration	duration	NOUN
dpc-6169	117	14	for	for	ADP
dpc-6169	117	15	early	early	ADJ
dpc-6169	117	16	response	response	NOUN
dpc-6169	117	17	to	to	ADP
dpc-6169	117	18	omalizumab	omalizumab	NOUN
dpc-6169	117	19	.	.	PUNCT
dpc-6169	118	1	the	the	DET
dpc-6169	118	2	area	area	NOUN
dpc-6169	118	3	under	under	ADP
dpc-6169	118	4	the	the	DET
dpc-6169	118	5	curve	curve	NOUN
dpc-6169	118	6	(	(	PUNCT
dpc-6169	118	7	auc	auc	NOUN
dpc-6169	118	8	)	)	PUNCT
dpc-6169	118	9	was	be	AUX
dpc-6169	118	10	0.060	0.060	NUM
dpc-6169	118	11	,	,	PUNCT
dpc-6169	118	12	indicating	indicate	VERB
dpc-6169	118	13	an	an	DET
dpc-6169	118	14	inverse	inverse	NOUN
dpc-6169	118	15	association	association	NOUN
dpc-6169	118	16	.	.	PUNCT
dpc-6169	119	1	clinically	clinically	ADV
dpc-6169	119	2	,	,	PUNCT
dpc-6169	119	3	this	this	PRON
dpc-6169	119	4	corresponds	correspond	VERB
dpc-6169	119	5	to	to	ADP
dpc-6169	119	6	an	an	DET
dpc-6169	119	7	auc	auc	NOUN
dpc-6169	119	8	of	of	ADP
dpc-6169	119	9	0.940	0.940	NUM
dpc-6169	119	10	when	when	SCONJ
dpc-6169	119	11	interpreted	interpret	VERB
dpc-6169	119	12	for	for	ADP
dpc-6169	119	13	shorter	short	ADJ
dpc-6169	119	14	disease	disease	NOUN
dpc-6169	119	15	duration	duration	NOUN
dpc-6169	119	16	predicting	predict	VERB
dpc-6169	119	17	early	early	ADJ
dpc-6169	119	18	response	response	NOUN
dpc-6169	119	19	.	.	PUNCT
dpc-6169	120	1	coordinate	coordinate	NOUN
dpc-6169	120	2	analysis	analysis	NOUN
dpc-6169	120	3	suggested	suggest	VERB
dpc-6169	120	4	that	that	SCONJ
dpc-6169	120	5	a	a	DET
dpc-6169	120	6	disease	disease	NOUN
dpc-6169	120	7	duration	duration	NOUN
dpc-6169	120	8	of	of	ADP
dpc-6169	120	9	less	less	ADJ
dpc-6169	120	10	than	than	ADP
dpc-6169	120	11	six	six	NUM
dpc-6169	120	12	months	month	NOUN
dpc-6169	120	13	was	be	AUX
dpc-6169	120	14	associated	associate	VERB
dpc-6169	120	15	with	with	ADP
dpc-6169	120	16	the	the	DET
dpc-6169	120	17	highest	high	ADJ
dpc-6169	120	18	sensitivity	sensitivity	NOUN
dpc-6169	120	19	for	for	ADP
dpc-6169	120	20	early	early	ADJ
dpc-6169	120	21	treatment	treatment	NOUN
dpc-6169	120	22	response	response	NOUN
dpc-6169	120	23	,	,	PUNCT
dpc-6169	120	24	while	while	SCONJ
dpc-6169	120	25	durations	duration	NOUN
dpc-6169	120	26	exceeding	exceed	VERB
dpc-6169	120	27	12–15	12–15	NUM
dpc-6169	120	28	months	month	NOUN
dpc-6169	120	29	were	be	AUX
dpc-6169	120	30	increasingly	increasingly	ADV
dpc-6169	120	31	associated	associate	VERB
dpc-6169	120	32	with	with	ADP
dpc-6169	120	33	non	non	ADJ
dpc-6169	120	34	-	-	NOUN
dpc-6169	120	35	response	response	NOUN
dpc-6169	120	36	.	.	PUNCT
dpc-6169	121	1	discussion	discussion	NOUN
dpc-6169	121	2	in	in	ADP
dpc-6169	121	3	this	this	DET
dpc-6169	121	4	study	study	NOUN
dpc-6169	121	5	,	,	PUNCT
dpc-6169	121	6	we	we	PRON
dpc-6169	121	7	investigated	investigate	VERB
dpc-6169	121	8	the	the	DET
dpc-6169	121	9	impact	impact	NOUN
dpc-6169	121	10	of	of	ADP
dpc-6169	121	11	age	age	NOUN
dpc-6169	121	12	,	,	PUNCT
dpc-6169	121	13	sex	sex	NOUN
dpc-6169	121	14	,	,	PUNCT
dpc-6169	121	15	baseline	baseline	VERB
dpc-6169	121	16	uas7	uas7	NOUN
dpc-6169	121	17	,	,	PUNCT
dpc-6169	121	18	and	and	CCONJ
dpc-6169	121	19	disease	disease	NOUN
dpc-6169	121	20	duration	duration	NOUN
dpc-6169	121	21	on	on	ADP
dpc-6169	121	22	both	both	CCONJ
dpc-6169	121	23	early	early	ADJ
dpc-6169	121	24	response	response	NOUN
dpc-6169	121	25	and	and	CCONJ
dpc-6169	121	26	relapse	relapse	VERB
dpc-6169	121	27	risk	risk	NOUN
dpc-6169	121	28	in	in	ADP
dpc-6169	121	29	patients	patient	NOUN
dpc-6169	121	30	with	with	ADP
dpc-6169	121	31	chronic	chronic	ADJ
dpc-6169	121	32	spontaneous	spontaneous	ADJ
dpc-6169	121	33	urticaria	urticaria	NOUN
dpc-6169	121	34	treated	treat	VERB
dpc-6169	121	35	with	with	ADP
dpc-6169	121	36	omalizumab	omalizumab	NOUN
dpc-6169	121	37	.	.	PUNCT
dpc-6169	122	1	our	our	PRON
dpc-6169	122	2	findings	finding	NOUN
dpc-6169	122	3	revealed	reveal	VERB
dpc-6169	122	4	that	that	SCONJ
dpc-6169	122	5	lower	low	ADJ
dpc-6169	122	6	baseline	baseline	VERB
dpc-6169	122	7	uas7	uas7	PROPN
dpc-6169	122	8	scores	score	NOUN
dpc-6169	122	9	and	and	CCONJ
dpc-6169	122	10	shorter	short	ADJ
dpc-6169	122	11	disease	disease	NOUN
dpc-6169	122	12	duration	duration	NOUN
dpc-6169	122	13	were	be	AUX
dpc-6169	122	14	both	both	PRON
dpc-6169	122	15	independently	independently	ADV
dpc-6169	122	16	associated	associate	VERB
dpc-6169	122	17	with	with	ADP
dpc-6169	122	18	a	a	DET
dpc-6169	122	19	significantly	significantly	ADV
dpc-6169	122	20	higher	high	ADJ
dpc-6169	122	21	likelihood	likelihood	NOUN
dpc-6169	122	22	of	of	ADP
dpc-6169	122	23	early	early	ADJ
dpc-6169	122	24	response	response	NOUN
dpc-6169	122	25	,	,	PUNCT
dpc-6169	122	26	while	while	SCONJ
dpc-6169	122	27	age	age	NOUN
dpc-6169	122	28	and	and	CCONJ
dpc-6169	122	29	sex	sex	NOUN
dpc-6169	122	30	were	be	AUX
dpc-6169	122	31	not	not	PART
dpc-6169	122	32	significant	significant	ADJ
dpc-6169	122	33	predictors	predictor	NOUN
dpc-6169	122	34	in	in	ADP
dpc-6169	122	35	multivariate	multivariate	NOUN
dpc-6169	122	36	models	model	NOUN
dpc-6169	122	37	.	.	PUNCT
dpc-6169	123	1	however	however	ADV
dpc-6169	123	2	,	,	PUNCT
dpc-6169	123	3	in	in	ADP
dpc-6169	123	4	univariate	univariate	ADJ
dpc-6169	123	5	analysis	analysis	NOUN
dpc-6169	123	6	,	,	PUNCT
dpc-6169	123	7	patients	patient	NOUN
dpc-6169	123	8	younger	young	ADJ
dpc-6169	123	9	than	than	ADP
dpc-6169	123	10	45	45	NUM
dpc-6169	123	11	years	year	NOUN
dpc-6169	123	12	were	be	AUX
dpc-6169	123	13	more	more	ADV
dpc-6169	123	14	likely	likely	ADJ
dpc-6169	123	15	to	to	PART
dpc-6169	123	16	achieve	achieve	VERB
dpc-6169	123	17	early	early	ADJ
dpc-6169	123	18	response	response	NOUN
dpc-6169	123	19	.	.	PUNCT
dpc-6169	124	1	additionally	additionally	ADV
dpc-6169	124	2	,	,	PUNCT
dpc-6169	124	3	relapse	relapse	VERB
dpc-6169	124	4	among	among	ADP
dpc-6169	124	5	patients	patient	NOUN
dpc-6169	124	6	who	who	PRON
dpc-6169	124	7	did	do	AUX
dpc-6169	124	8	not	not	PART
dpc-6169	124	9	respond	respond	VERB
dpc-6169	124	10	to	to	ADP
dpc-6169	124	11	omalizumab	omalizumab	NOUN
dpc-6169	124	12	treatment	treatment	NOUN
dpc-6169	124	13	,	,	PUNCT
dpc-6169	124	14	12	12	NUM
dpc-6169	124	15	were	be	AUX
dpc-6169	124	16	male	male	ADJ
dpc-6169	124	17	,	,	PUNCT
dpc-6169	124	18	while	while	SCONJ
dpc-6169	124	19	25	25	NUM
dpc-6169	124	20	were	be	AUX
dpc-6169	124	21	female	female	ADJ
dpc-6169	124	22	.	.	PUNCT
dpc-6169	125	1	no	no	DET
dpc-6169	125	2	significant	significant	ADJ
dpc-6169	125	3	difference	difference	NOUN
dpc-6169	125	4	was	be	AUX
dpc-6169	125	5	found	find	VERB
dpc-6169	125	6	between	between	ADP
dpc-6169	125	7	the	the	DET
dpc-6169	125	8	sexes	sex	NOUN
dpc-6169	125	9	regarding	regard	VERB
dpc-6169	125	10	the	the	DET
dpc-6169	125	11	lack	lack	NOUN
dpc-6169	125	12	of	of	ADP
dpc-6169	125	13	treatment	treatment	NOUN
dpc-6169	125	14	response	response	NOUN
dpc-6169	125	15	to	to	ADP
dpc-6169	125	16	omalizumab	omalizumab	NOUN
dpc-6169	125	17	(	(	PUNCT
dpc-6169	125	18	p=0.874	p=0.874	NOUN
dpc-6169	125	19	)	)	PUNCT
dpc-6169	125	20	(	(	PUNCT
dpc-6169	125	21	table	table	NOUN
dpc-6169	125	22	1	1	NUM
dpc-6169	125	23	)	)	PUNCT
dpc-6169	125	24	.	.	PUNCT
dpc-6169	126	1	when	when	SCONJ
dpc-6169	126	2	evaluating	evaluate	VERB
dpc-6169	126	3	relapse	relapse	NOUN
dpc-6169	126	4	development	development	NOUN
dpc-6169	126	5	in	in	ADP
dpc-6169	126	6	patients	patient	NOUN
dpc-6169	126	7	monitored	monitor	VERB
dpc-6169	126	8	after	after	ADP
dpc-6169	126	9	16	16	NUM
dpc-6169	126	10	weeks	week	NOUN
dpc-6169	126	11	of	of	ADP
dpc-6169	126	12	omalizumab	omalizumab	NOUN
dpc-6169	126	13	treatment	treatment	NOUN
dpc-6169	126	14	,	,	PUNCT
dpc-6169	126	15	relapse	relapse	NOUN
dpc-6169	126	16	was	be	AUX
dpc-6169	126	17	observed	observe	VERB
dpc-6169	126	18	in	in	ADP
dpc-6169	126	19	42	42	NUM
dpc-6169	126	20	female	female	ADJ
dpc-6169	126	21	patients	patient	NOUN
dpc-6169	126	22	(	(	PUNCT
dpc-6169	126	23	23.1	23.1	NUM
dpc-6169	126	24	%	%	NOUN
dpc-6169	126	25	)	)	PUNCT
dpc-6169	126	26	and	and	CCONJ
dpc-6169	126	27	32	32	NUM
dpc-6169	126	28	male	male	ADJ
dpc-6169	126	29	patients	patient	NOUN
dpc-6169	126	30	(	(	PUNCT
dpc-6169	126	31	34.8	34.8	NUM
dpc-6169	126	32	%	%	NOUN
dpc-6169	126	33	)	)	PUNCT
dpc-6169	126	34	.	.	PUNCT
dpc-6169	127	1	the	the	DET
dpc-6169	127	2	relapse	relapse	NOUN
dpc-6169	127	3	rate	rate	NOUN
dpc-6169	127	4	during	during	ADP
dpc-6169	127	5	omalizumab	omalizumab	NOUN
dpc-6169	127	6	treatment	treatment	NOUN
dpc-6169	127	7	was	be	AUX
dpc-6169	127	8	found	find	VERB
dpc-6169	127	9	to	to	PART
dpc-6169	127	10	be	be	AUX
dpc-6169	127	11	significantly	significantly	ADV
dpc-6169	127	12	higher	high	ADJ
dpc-6169	127	13	in	in	ADP
dpc-6169	127	14	male	male	ADJ
dpc-6169	127	15	patients	patient	NOUN
dpc-6169	127	16	compared	compare	VERB
dpc-6169	127	17	to	to	ADP
dpc-6169	127	18	female	female	ADJ
dpc-6169	127	19	patients	patient	NOUN
dpc-6169	127	20	(	(	PUNCT
dpc-6169	127	21	p=0.02	p=0.02	NOUN
dpc-6169	127	22	)	)	PUNCT
dpc-6169	127	23	(	(	PUNCT
dpc-6169	127	24	table	table	NOUN
dpc-6169	127	25	1	1	NUM
dpc-6169	127	26	)	)	PUNCT
dpc-6169	127	27	.	.	PUNCT
dpc-6169	128	1	when	when	SCONJ
dpc-6169	128	2	patients	patient	NOUN
dpc-6169	128	3	who	who	PRON
dpc-6169	128	4	responded	respond	VERB
dpc-6169	128	5	early	early	ADV
dpc-6169	128	6	to	to	PART
dpc-6169	128	7	omalizumab	omalizumab	VERB
dpc-6169	128	8	treatment	treatment	NOUN
dpc-6169	128	9	and	and	CCONJ
dpc-6169	128	10	those	those	PRON
dpc-6169	128	11	who	who	PRON
dpc-6169	128	12	did	do	AUX
dpc-6169	128	13	not	not	PART
dpc-6169	128	14	were	be	AUX
dpc-6169	128	15	divided	divide	VERB
dpc-6169	128	16	into	into	ADP
dpc-6169	128	17	two	two	NUM
dpc-6169	128	18	groups	group	NOUN
dpc-6169	128	19	based	base	VERB
dpc-6169	128	20	on	on	ADP
dpc-6169	128	21	age	age	NOUN
dpc-6169	128	22	—	—	PUNCT
dpc-6169	128	23	under	under	ADP
dpc-6169	128	24	45	45	NUM
dpc-6169	128	25	years	year	NOUN
dpc-6169	128	26	and	and	CCONJ
dpc-6169	128	27	45	45	NUM
dpc-6169	128	28	years	year	NOUN
dpc-6169	128	29	or	or	CCONJ
dpc-6169	128	30	older	old	ADJ
dpc-6169	128	31	—	—	PUNCT
dpc-6169	128	32	a	a	DET
dpc-6169	128	33	significant	significant	ADJ
dpc-6169	128	34	difference	difference	NOUN
dpc-6169	128	35	was	be	AUX
dpc-6169	128	36	observed	observe	VERB
dpc-6169	128	37	in	in	ADP
dpc-6169	128	38	the	the	DET
dpc-6169	128	39	response	response	NOUN
dpc-6169	128	40	to	to	ADP
dpc-6169	128	41	the	the	DET
dpc-6169	128	42	first	first	ADJ
dpc-6169	128	43	dose	dose	NOUN
dpc-6169	128	44	in	in	ADP
dpc-6169	128	45	the	the	DET
dpc-6169	128	46	younger	young	ADJ
dpc-6169	128	47	age	age	NOUN
dpc-6169	128	48	group	group	NOUN
dpc-6169	128	49	compared	compare	VERB
dpc-6169	128	50	to	to	ADP
dpc-6169	128	51	the	the	DET
dpc-6169	128	52	older	old	ADJ
dpc-6169	128	53	age	age	NOUN
dpc-6169	128	54	group	group	NOUN
dpc-6169	128	55	(	(	PUNCT
dpc-6169	128	56	p=0.01	p=0.01	PROPN
dpc-6169	128	57	)	)	PUNCT
dpc-6169	128	58	.	.	PUNCT
dpc-6169	129	1	accordingly	accordingly	ADV
dpc-6169	129	2	,	,	PUNCT
dpc-6169	129	3	the	the	DET
dpc-6169	129	4	rate	rate	NOUN
dpc-6169	129	5	of	of	ADP
dpc-6169	129	6	benefiting	benefit	VERB
dpc-6169	129	7	from	from	ADP
dpc-6169	129	8	the	the	DET
dpc-6169	129	9	first	first	ADJ
dpc-6169	129	10	dose	dose	NOUN
dpc-6169	129	11	of	of	ADP
dpc-6169	129	12	omalizumab	omalizumab	NOUN
dpc-6169	129	13	was	be	AUX
dpc-6169	129	14	significantly	significantly	ADV
dpc-6169	129	15	higher	high	ADJ
dpc-6169	129	16	in	in	ADP
dpc-6169	129	17	patients	patient	NOUN
dpc-6169	129	18	under	under	ADP
dpc-6169	129	19	45	45	NUM
dpc-6169	129	20	years	year	NOUN
dpc-6169	129	21	of	of	ADP
dpc-6169	129	22	age	age	NOUN
dpc-6169	129	23	(	(	PUNCT
dpc-6169	129	24	table	table	NOUN
dpc-6169	129	25	2	2	NUM
dpc-6169	129	26	)	)	PUNCT
dpc-6169	129	27	.	.	PUNCT
dpc-6169	130	1	when	when	SCONJ
dpc-6169	130	2	female	female	ADJ
dpc-6169	130	3	patients	patient	NOUN
dpc-6169	130	4	who	who	PRON
dpc-6169	130	5	responded	respond	VERB
dpc-6169	130	6	early	early	ADV
dpc-6169	130	7	to	to	PART
dpc-6169	130	8	omalizumab	omalizumab	VERB
dpc-6169	130	9	treatment	treatment	NOUN
dpc-6169	130	10	and	and	CCONJ
dpc-6169	130	11	those	those	PRON
dpc-6169	130	12	who	who	PRON
dpc-6169	130	13	did	do	AUX
dpc-6169	130	14	not	not	PART
dpc-6169	130	15	were	be	AUX
dpc-6169	130	16	analyzed	analyze	VERB
dpc-6169	130	17	separately	separately	ADV
dpc-6169	130	18	by	by	ADP
dpc-6169	130	19	age	age	NOUN
dpc-6169	130	20	groups	group	NOUN
dpc-6169	130	21	,	,	PUNCT
dpc-6169	130	22	no	no	DET
dpc-6169	130	23	significant	significant	ADJ
dpc-6169	130	24	difference	difference	NOUN
dpc-6169	130	25	was	be	AUX
dpc-6169	130	26	found	find	VERB
dpc-6169	130	27	between	between	ADP
dpc-6169	130	28	the	the	DET
dpc-6169	130	29	two	two	NUM
dpc-6169	130	30	age	age	NOUN
dpc-6169	130	31	groups	group	NOUN
dpc-6169	130	32	in	in	ADP
dpc-6169	130	33	terms	term	NOUN
dpc-6169	130	34	of	of	ADP
dpc-6169	130	35	response	response	NOUN
dpc-6169	130	36	to	to	ADP
dpc-6169	130	37	the	the	DET
dpc-6169	130	38	first	first	ADJ
dpc-6169	130	39	dose	dose	PROPN
dpc-6169	130	40	(	(	PUNCT
dpc-6169	130	41	p=0.446	p=0.446	PROPN
dpc-6169	130	42	)	)	PUNCT
dpc-6169	130	43	(	(	PUNCT
dpc-6169	130	44	table	table	NOUN
dpc-6169	130	45	2	2	NUM
dpc-6169	130	46	)	)	PUNCT
dpc-6169	130	47	.	.	PUNCT
dpc-6169	131	1	when	when	SCONJ
dpc-6169	131	2	relapse	relapse	VERB
dpc-6169	131	3	development	development	NOUN
dpc-6169	131	4	after	after	ADP
dpc-6169	131	5	16	16	NUM
dpc-6169	131	6	weeks	week	NOUN
dpc-6169	131	7	of	of	ADP
dpc-6169	131	8	omalizumab	omalizumab	NOUN
dpc-6169	131	9	treatment	treatment	NOUN
dpc-6169	131	10	was	be	AUX
dpc-6169	131	11	evaluated	evaluate	VERB
dpc-6169	131	12	based	base	VERB
dpc-6169	131	13	on	on	ADP
dpc-6169	131	14	age	age	NOUN
dpc-6169	131	15	groups	group	NOUN
dpc-6169	131	16	,	,	PUNCT
dpc-6169	131	17	the	the	DET
dpc-6169	131	18	recurrence	recurrence	NOUN
dpc-6169	131	19	rate	rate	NOUN
dpc-6169	131	20	was	be	AUX
dpc-6169	131	21	found	find	VERB
dpc-6169	131	22	to	to	PART
dpc-6169	131	23	be	be	AUX
dpc-6169	131	24	significantly	significantly	ADV
dpc-6169	131	25	lower	low	ADJ
dpc-6169	131	26	in	in	ADP
dpc-6169	131	27	the	the	DET
dpc-6169	131	28	under	under	ADP
dpc-6169	131	29	45	45	NUM
dpc-6169	131	30	age	age	NOUN
dpc-6169	131	31	group	group	NOUN
dpc-6169	131	32	compared	compare	VERB
dpc-6169	131	33	to	to	ADP
dpc-6169	131	34	the	the	DET
dpc-6169	131	35	45	45	NUM
dpc-6169	131	36	years	year	NOUN
dpc-6169	131	37	and	and	CCONJ
dpc-6169	131	38	older	old	ADJ
dpc-6169	131	39	group	group	NOUN
dpc-6169	131	40	(	(	PUNCT
dpc-6169	131	41	p=0.016	p=0.016	PROPN
dpc-6169	131	42	)	)	PUNCT
dpc-6169	131	43	(	(	PUNCT
dpc-6169	131	44	table	table	NOUN
dpc-6169	131	45	2	2	NUM
dpc-6169	131	46	)	)	PUNCT
dpc-6169	131	47	.	.	PUNCT
dpc-6169	132	1	among	among	ADP
dpc-6169	132	2	the	the	DET
dpc-6169	132	3	274	274	NUM
dpc-6169	132	4	patients	patient	NOUN
dpc-6169	132	5	,	,	PUNCT
dpc-6169	132	6	103	103	NUM
dpc-6169	132	7	(	(	PUNCT
dpc-6169	132	8	37.6	37.6	NUM
dpc-6169	132	9	%	%	NOUN
dpc-6169	132	10	)	)	PUNCT
dpc-6169	132	11	achieved	achieve	VERB
dpc-6169	132	12	an	an	DET
dpc-6169	132	13	early	early	ADJ
dpc-6169	132	14	response	response	NOUN
dpc-6169	132	15	to	to	ADP
dpc-6169	132	16	omalizumab	omalizumab	NOUN
dpc-6169	132	17	as	as	SCONJ
dpc-6169	132	18	defined	define	VERB
dpc-6169	132	19	by	by	ADP
dpc-6169	132	20	a	a	DET
dpc-6169	132	21	uas7	uas7	NOUN
dpc-6169	132	22	<	<	X
dpc-6169	132	23	7	7	NUM
dpc-6169	132	24	at	at	ADP
dpc-6169	132	25	the	the	DET
dpc-6169	132	26	first	first	ADJ
dpc-6169	132	27	month	month	NOUN
dpc-6169	132	28	.	.	PUNCT
dpc-6169	133	1	patients	patient	NOUN
dpc-6169	133	2	who	who	PRON
dpc-6169	133	3	achieved	achieve	VERB
dpc-6169	133	4	an	an	DET
dpc-6169	133	5	early	early	ADJ
dpc-6169	133	6	response	response	NOUN
dpc-6169	133	7	had	have	VERB
dpc-6169	133	8	significantly	significantly	ADV
dpc-6169	133	9	lower	low	ADJ
dpc-6169	133	10	baseline	baseline	ADJ
dpc-6169	133	11	uas7	uas7	PROPN
dpc-6169	133	12	scores	score	NOUN
dpc-6169	133	13	compared	compare	VERB
dpc-6169	133	14	to	to	ADP
dpc-6169	133	15	non	non	NOUN
dpc-6169	133	16	-	-	NOUN
dpc-6169	133	17	responders	responder	NOUN
dpc-6169	133	18	(	(	PUNCT
dpc-6169	133	19	p<0.001	p<0.001	PROPN
dpc-6169	133	20	)	)	PUNCT
dpc-6169	133	21	.	.	PUNCT
dpc-6169	134	1	similarly	similarly	ADV
dpc-6169	134	2	,	,	PUNCT
dpc-6169	134	3	disease	disease	NOUN
dpc-6169	134	4	duration	duration	NOUN
dpc-6169	134	5	prior	prior	ADV
dpc-6169	134	6	to	to	ADP
dpc-6169	134	7	omalizumab	omalizumab	NOUN
dpc-6169	134	8	initiation	initiation	NOUN
dpc-6169	134	9	was	be	AUX
dpc-6169	134	10	significantly	significantly	ADV
dpc-6169	134	11	shorter	short	ADJ
dpc-6169	134	12	in	in	ADP
dpc-6169	134	13	early	early	ADJ
dpc-6169	134	14	responders	responder	NOUN
dpc-6169	134	15	compared	compare	VERB
dpc-6169	134	16	to	to	ADP
dpc-6169	134	17	non	non	NOUN
dpc-6169	134	18	-	-	NOUN
dpc-6169	134	19	responders	responder	NOUN
dpc-6169	134	20	(	(	PUNCT
dpc-6169	134	21	p<0.001	p<0.001	PROPN
dpc-6169	134	22	)	)	PUNCT
dpc-6169	134	23	.	.	PUNCT
dpc-6169	135	1	binary	binary	PROPN
dpc-6169	135	2	logistic	logistic	PROPN
dpc-6169	135	3	regression	regression	NOUN
dpc-6169	135	4	was	be	AUX
dpc-6169	135	5	performed	perform	VERB
dpc-6169	135	6	to	to	PART
dpc-6169	135	7	determine	determine	VERB
dpc-6169	135	8	whether	whether	SCONJ
dpc-6169	135	9	baseline	baseline	ADJ
dpc-6169	135	10	clinical	clinical	ADJ
dpc-6169	135	11	characteristics	characteristic	NOUN
dpc-6169	135	12	were	be	AUX
dpc-6169	135	13	independently	independently	ADV
dpc-6169	135	14	associated	associate	VERB
dpc-6169	135	15	with	with	ADP
dpc-6169	135	16	early	early	ADJ
dpc-6169	135	17	response	response	NOUN
dpc-6169	135	18	to	to	ADP
dpc-6169	135	19	omalizumab	omalizumab	NOUN
dpc-6169	135	20	(	(	PUNCT
dpc-6169	135	21	defined	define	VERB
dpc-6169	135	22	as	as	ADP
dpc-6169	135	23	uas7	uas7	NOUN
dpc-6169	135	24	<	<	X
dpc-6169	135	25	7	7	NUM
dpc-6169	135	26	at	at	ADP
dpc-6169	135	27	one	one	NUM
dpc-6169	135	28	month	month	NOUN
dpc-6169	135	29	)	)	PUNCT
dpc-6169	135	30	.	.	PUNCT
dpc-6169	136	1	the	the	DET
dpc-6169	136	2	model	model	NOUN
dpc-6169	136	3	was	be	AUX
dpc-6169	136	4	statistically	statistically	ADV
dpc-6169	136	5	significant	significant	ADJ
dpc-6169	136	6	(	(	PUNCT
dpc-6169	136	7	χ²	χ²	NOUN
dpc-6169	136	8	=	=	SYM
dpc-6169	136	9	277.765	277.765	NUM
dpc-6169	136	10	,	,	PUNCT
dpc-6169	136	11	p<0.001	p<0.001	PROPN
dpc-6169	136	12	)	)	PUNCT
dpc-6169	136	13	and	and	CCONJ
dpc-6169	136	14	demonstrated	demonstrate	VERB
dpc-6169	136	15	good	good	ADJ
dpc-6169	136	16	fit	fit	ADJ
dpc-6169	136	17	(	(	PUNCT
dpc-6169	136	18	hosmer	hosmer	NOUN
dpc-6169	136	19	–	–	PUNCT
dpc-6169	136	20	lemeshow	lemeshow	NOUN
dpc-6169	136	21	test	test	NOUN
dpc-6169	136	22	,	,	PUNCT
dpc-6169	136	23	p=0.788	p=0.788	NOUN
dpc-6169	136	24	)	)	PUNCT
dpc-6169	136	25	.	.	PUNCT
dpc-6169	137	1	lower	low	ADJ
dpc-6169	137	2	baseline	baseline	PROPN
dpc-6169	137	3	uas7	uas7	NOUN
dpc-6169	137	4	(	(	PUNCT
dpc-6169	137	5	odds	odd	NOUN
dpc-6169	137	6	ratio	ratio	NOUN
dpc-6169	137	7	(	(	PUNCT
dpc-6169	137	8	or	or	CCONJ
dpc-6169	137	9	):	):	PUNCT
dpc-6169	137	10	0.657	0.657	NUM
dpc-6169	137	11	;	;	PUNCT
dpc-6169	137	12	95	95	NUM
dpc-6169	137	13	%	%	NOUN
dpc-6169	137	14	ci	ci	NOUN
dpc-6169	137	15	:	:	PUNCT
dpc-6169	137	16	0.555–0.777	0.555–0.777	ADJ
dpc-6169	137	17	;	;	PUNCT
dpc-6169	137	18	p<0.001	p<0.001	X
dpc-6169	137	19	)	)	PUNCT
dpc-6169	137	20	and	and	CCONJ
dpc-6169	137	21	shorter	short	ADJ
dpc-6169	137	22	disease	disease	NOUN
dpc-6169	137	23	duration	duration	NOUN
dpc-6169	137	24	prior	prior	ADV
dpc-6169	137	25	to	to	ADP
dpc-6169	137	26	omalizumab	omalizumab	NOUN
dpc-6169	137	27	initiation	initiation	NOUN
dpc-6169	137	28	table	table	NOUN
dpc-6169	137	29	1	1	NUM
dpc-6169	137	30	.	.	PUNCT
dpc-6169	138	1	treatment	treatment	NOUN
dpc-6169	138	2	response	response	NOUN
dpc-6169	138	3	by	by	ADP
dpc-6169	138	4	sex	sex	NOUN
dpc-6169	138	5	.	.	PUNCT
dpc-6169	139	1	sex	sex	NOUN
dpc-6169	139	2	number	number	NOUN
dpc-6169	139	3	of	of	ADP
dpc-6169	139	4	patients	patient	NOUN
dpc-6169	139	5	number	number	NOUN
dpc-6169	139	6	of	of	ADP
dpc-6169	139	7	early	early	ADJ
dpc-6169	139	8	responders	responder	NOUN
dpc-6169	139	9	number	number	NOUN
dpc-6169	139	10	of	of	ADP
dpc-6169	139	11	non	non	NOUN
dpc-6169	139	12	-	-	NOUN
dpc-6169	139	13	responders	responder	NOUN
dpc-6169	139	14	relapse	relapse	VERB
dpc-6169	139	15	male	male	NOUN
dpc-6169	139	16	92	92	NUM
dpc-6169	139	17	39	39	NUM
dpc-6169	139	18	12	12	NUM
dpc-6169	139	19	32	32	NUM
dpc-6169	139	20	female	female	NOUN
dpc-6169	139	21	184	184	NUM
dpc-6169	139	22	64	64	NUM
dpc-6169	139	23	25	25	NUM
dpc-6169	139	24	42	42	NUM
dpc-6169	139	25	original	original	ADJ
dpc-6169	139	26	article	article	NOUN
dpc-6169	139	27	|	|	ADV
dpc-6169	139	28	dermatol	dermatol	ADJ
dpc-6169	139	29	pract	pract	NOUN
dpc-6169	139	30	concept	concept	NOUN
dpc-6169	139	31	.	.	PUNCT
dpc-6169	140	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	140	2	5	5	NUM
dpc-6169	140	3	however	however	ADV
dpc-6169	140	4	,	,	PUNCT
dpc-6169	140	5	when	when	SCONJ
dpc-6169	140	6	recurrence	recurrence	NOUN
dpc-6169	140	7	rates	rate	NOUN
dpc-6169	140	8	during	during	ADP
dpc-6169	140	9	omalizumab	omalizumab	NOUN
dpc-6169	140	10	treatment	treatment	NOUN
dpc-6169	140	11	were	be	AUX
dpc-6169	140	12	analyzed	analyze	VERB
dpc-6169	140	13	by	by	ADP
dpc-6169	140	14	sex	sex	NOUN
dpc-6169	140	15	,	,	PUNCT
dpc-6169	140	16	the	the	DET
dpc-6169	140	17	recurrence	recurrence	NOUN
dpc-6169	140	18	rate	rate	NOUN
dpc-6169	140	19	was	be	AUX
dpc-6169	140	20	found	find	VERB
dpc-6169	140	21	to	to	PART
dpc-6169	140	22	be	be	AUX
dpc-6169	140	23	significantly	significantly	ADV
dpc-6169	140	24	higher	high	ADJ
dpc-6169	140	25	in	in	ADP
dpc-6169	140	26	male	male	ADJ
dpc-6169	140	27	patients	patient	NOUN
dpc-6169	140	28	.	.	PUNCT
dpc-6169	141	1	in	in	ADP
dpc-6169	141	2	this	this	DET
dpc-6169	141	3	regard	regard	NOUN
dpc-6169	141	4	,	,	PUNCT
dpc-6169	141	5	our	our	PRON
dpc-6169	141	6	study	study	NOUN
dpc-6169	141	7	is	be	AUX
dpc-6169	141	8	consistent	consistent	ADJ
dpc-6169	141	9	with	with	ADP
dpc-6169	141	10	the	the	DET
dpc-6169	141	11	findings	finding	NOUN
dpc-6169	141	12	of	of	ADP
dpc-6169	141	13	sirufo	sirufo	PROPN
dpc-6169	141	14	et	et	PROPN
dpc-6169	141	15	al	al	PROPN
dpc-6169	141	16	.	.	PUNCT
dpc-6169	142	1	[	[	X
dpc-6169	142	2	11	11	NUM
dpc-6169	142	3	]	]	PUNCT
dpc-6169	142	4	,	,	PUNCT
dpc-6169	142	5	who	who	PRON
dpc-6169	142	6	suggested	suggest	VERB
dpc-6169	142	7	that	that	SCONJ
dpc-6169	142	8	this	this	DET
dpc-6169	142	9	difference	difference	NOUN
dpc-6169	142	10	may	may	AUX
dpc-6169	142	11	be	be	AUX
dpc-6169	142	12	related	relate	VERB
dpc-6169	142	13	to	to	ADP
dpc-6169	142	14	the	the	DET
dpc-6169	142	15	effects	effect	NOUN
dpc-6169	142	16	of	of	ADP
dpc-6169	142	17	female	female	ADJ
dpc-6169	142	18	hormones	hormone	NOUN
dpc-6169	142	19	on	on	ADP
dpc-6169	142	20	histamine	histamine	NOUN
dpc-6169	142	21	receptor	receptor	NOUN
dpc-6169	142	22	profiles	profile	NOUN
dpc-6169	142	23	and	and	CCONJ
dpc-6169	142	24	mast	mast	NOUN
dpc-6169	142	25	cells	cell	NOUN
dpc-6169	142	26	[	[	X
dpc-6169	142	27	11	11	NUM
dpc-6169	142	28	]	]	PUNCT
dpc-6169	142	29	.	.	PUNCT
dpc-6169	143	1	in	in	ADP
dpc-6169	143	2	a	a	DET
dpc-6169	143	3	study	study	NOUN
dpc-6169	143	4	by	by	ADP
dpc-6169	143	5	kitao	kitao	PROPN
dpc-6169	143	6	et	et	PROPN
dpc-6169	143	7	al	al	PROPN
dpc-6169	143	8	.	.	PUNCT
dpc-6169	144	1	[	[	X
dpc-6169	144	2	15	15	NUM
dpc-6169	144	3	]	]	PUNCT
dpc-6169	144	4	involving	involve	VERB
dpc-6169	144	5	52	52	NUM
dpc-6169	144	6	patients	patient	NOUN
dpc-6169	144	7	with	with	ADP
dpc-6169	144	8	chronic	chronic	ADJ
dpc-6169	144	9	urticaria	urticaria	NOUN
dpc-6169	144	10	receiving	receive	VERB
dpc-6169	144	11	omalizumab	omalizumab	NOUN
dpc-6169	144	12	,	,	PUNCT
dpc-6169	144	13	patients	patient	NOUN
dpc-6169	144	14	were	be	AUX
dpc-6169	144	15	divided	divide	VERB
dpc-6169	144	16	into	into	ADP
dpc-6169	144	17	two	two	NUM
dpc-6169	144	18	groups	group	NOUN
dpc-6169	144	19	—	—	PUNCT
dpc-6169	144	20	those	those	PRON
dpc-6169	144	21	aged	aged	ADJ
dpc-6169	144	22	over	over	ADP
dpc-6169	144	23	65	65	NUM
dpc-6169	144	24	and	and	CCONJ
dpc-6169	144	25	those	those	PRON
dpc-6169	144	26	under	under	ADP
dpc-6169	144	27	65	65	NUM
dpc-6169	144	28	—	—	PUNCT
dpc-6169	144	29	to	to	PART
dpc-6169	144	30	examine	examine	VERB
dpc-6169	144	31	the	the	DET
dpc-6169	144	32	drug	drug	NOUN
dpc-6169	144	33	’s	’s	PART
dpc-6169	144	34	effectiveness	effectiveness	NOUN
dpc-6169	144	35	.	.	PUNCT
dpc-6169	145	1	they	they	PRON
dpc-6169	145	2	found	find	VERB
dpc-6169	145	3	that	that	SCONJ
dpc-6169	145	4	treatment	treatment	NOUN
dpc-6169	145	5	response	response	NOUN
dpc-6169	145	6	was	be	AUX
dpc-6169	145	7	significantly	significantly	ADV
dpc-6169	145	8	reduced	reduce	VERB
dpc-6169	145	9	in	in	ADP
dpc-6169	145	10	patients	patient	NOUN
dpc-6169	145	11	over	over	ADP
dpc-6169	145	12	65	65	NUM
dpc-6169	145	13	years	year	NOUN
dpc-6169	145	14	of	of	ADP
dpc-6169	145	15	age	age	NOUN
dpc-6169	145	16	.	.	PUNCT
dpc-6169	146	1	similarly	similarly	ADV
dpc-6169	146	2	,	,	PUNCT
dpc-6169	146	3	korn	korn	PROPN
dpc-6169	146	4	et	et	PROPN
dpc-6169	146	5	al	al	PROPN
dpc-6169	146	6	.	.	PUNCT
dpc-6169	147	1	[	[	X
dpc-6169	147	2	16	16	NUM
dpc-6169	147	3	]	]	PUNCT
dpc-6169	147	4	conducted	conduct	VERB
dpc-6169	147	5	a	a	DET
dpc-6169	147	6	study	study	NOUN
dpc-6169	147	7	on	on	ADP
dpc-6169	147	8	174	174	NUM
dpc-6169	147	9	asthma	asthma	NOUN
dpc-6169	147	10	patients	patient	NOUN
dpc-6169	147	11	receiving	receive	VERB
dpc-6169	147	12	omalizumab	omalizumab	NOUN
dpc-6169	147	13	and	and	CCONJ
dpc-6169	147	14	found	find	VERB
dpc-6169	147	15	no	no	DET
dpc-6169	147	16	significant	significant	ADJ
dpc-6169	147	17	difference	difference	NOUN
dpc-6169	147	18	in	in	ADP
dpc-6169	147	19	treatment	treatment	NOUN
dpc-6169	147	20	response	response	NOUN
dpc-6169	147	21	between	between	ADP
dpc-6169	147	22	patients	patient	NOUN
dpc-6169	147	23	aged	age	VERB
dpc-6169	147	24	over	over	ADP
dpc-6169	147	25	50	50	NUM
dpc-6169	147	26	and	and	CCONJ
dpc-6169	147	27	those	those	PRON
dpc-6169	147	28	under	under	ADP
dpc-6169	147	29	50	50	NUM
dpc-6169	147	30	.	.	PUNCT
dpc-6169	148	1	additionally	additionally	ADV
dpc-6169	148	2	,	,	PUNCT
dpc-6169	148	3	ghazanfar	ghazanfar	ADV
dpc-6169	148	4	et	et	PROPN
dpc-6169	148	5	al	al	PROPN
dpc-6169	148	6	.	.	PUNCT
dpc-6169	149	1	[	[	X
dpc-6169	149	2	17	17	NUM
dpc-6169	149	3	]	]	PUNCT
dpc-6169	149	4	analyzed	analyze	VERB
dpc-6169	149	5	154	154	NUM
dpc-6169	149	6	urticaria	urticaria	NOUN
dpc-6169	149	7	patients	patient	NOUN
dpc-6169	149	8	and	and	CCONJ
dpc-6169	149	9	found	find	VERB
dpc-6169	149	10	no	no	DET
dpc-6169	149	11	association	association	NOUN
dpc-6169	149	12	between	between	ADP
dpc-6169	149	13	older	old	ADJ
dpc-6169	149	14	age	age	NOUN
dpc-6169	149	15	and	and	CCONJ
dpc-6169	149	16	treatment	treatment	NOUN
dpc-6169	149	17	response	response	NOUN
dpc-6169	149	18	.	.	PUNCT
dpc-6169	150	1	in	in	ADP
dpc-6169	150	2	our	our	PRON
dpc-6169	150	3	study	study	NOUN
dpc-6169	150	4	,	,	PUNCT
dpc-6169	150	5	when	when	SCONJ
dpc-6169	150	6	patients	patient	NOUN
dpc-6169	150	7	who	who	PRON
dpc-6169	150	8	benefited	benefit	VERB
dpc-6169	150	9	from	from	ADP
dpc-6169	150	10	the	the	DET
dpc-6169	150	11	first	first	ADJ
dpc-6169	150	12	dose	dose	NOUN
dpc-6169	150	13	of	of	ADP
dpc-6169	150	14	omalizumab	omalizumab	NOUN
dpc-6169	150	15	were	be	AUX
dpc-6169	150	16	compared	compare	VERB
dpc-6169	150	17	with	with	ADP
dpc-6169	150	18	those	those	PRON
dpc-6169	150	19	who	who	PRON
dpc-6169	150	20	did	do	VERB
dpc-6169	150	21	not	not	PART
dpc-6169	150	22	,	,	PUNCT
dpc-6169	150	23	dividing	divide	VERB
dpc-6169	150	24	them	they	PRON
dpc-6169	150	25	into	into	ADP
dpc-6169	150	26	two	two	NUM
dpc-6169	150	27	groups	group	NOUN
dpc-6169	150	28	based	base	VERB
dpc-6169	150	29	on	on	ADP
dpc-6169	150	30	age	age	NOUN
dpc-6169	150	31	(	(	PUNCT
dpc-6169	150	32	under	under	ADP
dpc-6169	150	33	45	45	NUM
dpc-6169	150	34	and	and	CCONJ
dpc-6169	150	35	45	45	NUM
dpc-6169	150	36	or	or	CCONJ
dpc-6169	150	37	older	old	ADJ
dpc-6169	150	38	)	)	PUNCT
dpc-6169	150	39	,	,	PUNCT
dpc-6169	150	40	the	the	DET
dpc-6169	150	41	proportion	proportion	NOUN
dpc-6169	150	42	of	of	ADP
dpc-6169	150	43	patients	patient	NOUN
dpc-6169	150	44	benefiting	benefit	VERB
dpc-6169	150	45	from	from	ADP
dpc-6169	150	46	the	the	DET
dpc-6169	150	47	first	first	ADJ
dpc-6169	150	48	dose	dose	NOUN
dpc-6169	150	49	was	be	AUX
dpc-6169	150	50	significantly	significantly	ADV
dpc-6169	150	51	higher	high	ADJ
dpc-6169	150	52	in	in	ADP
dpc-6169	150	53	those	those	PRON
dpc-6169	150	54	under	under	ADP
dpc-6169	150	55	45	45	NUM
dpc-6169	150	56	years	year	NOUN
dpc-6169	150	57	of	of	ADP
dpc-6169	150	58	age	age	NOUN
dpc-6169	150	59	.	.	PUNCT
dpc-6169	151	1	in	in	ADP
dpc-6169	151	2	this	this	DET
dpc-6169	151	3	aspect	aspect	NOUN
dpc-6169	151	4	,	,	PUNCT
dpc-6169	151	5	our	our	PRON
dpc-6169	151	6	findings	finding	NOUN
dpc-6169	151	7	are	be	AUX
dpc-6169	151	8	consistent	consistent	ADJ
dpc-6169	151	9	with	with	ADP
dpc-6169	151	10	the	the	DET
dpc-6169	151	11	study	study	NOUN
dpc-6169	151	12	by	by	ADP
dpc-6169	151	13	kitao	kitao	PROPN
dpc-6169	151	14	et	et	PROPN
dpc-6169	151	15	al	al	PROPN
dpc-6169	151	16	.	.	PUNCT
dpc-6169	152	1	[	[	X
dpc-6169	152	2	15	15	NUM
dpc-6169	152	3	]	]	PUNCT
dpc-6169	152	4	.	.	PUNCT
dpc-6169	153	1	furthermore	furthermore	ADV
dpc-6169	153	2	,	,	PUNCT
dpc-6169	153	3	in	in	ADP
dpc-6169	153	4	our	our	PRON
dpc-6169	153	5	study	study	NOUN
dpc-6169	153	6	,	,	PUNCT
dpc-6169	153	7	when	when	SCONJ
dpc-6169	153	8	relapse	relapse	NOUN
dpc-6169	153	9	development	development	NOUN
dpc-6169	153	10	was	be	AUX
dpc-6169	153	11	analyzed	analyze	VERB
dpc-6169	153	12	based	base	VERB
dpc-6169	153	13	on	on	ADP
dpc-6169	153	14	age	age	NOUN
dpc-6169	153	15	group	group	NOUN
dpc-6169	153	16	,	,	PUNCT
dpc-6169	153	17	the	the	DET
dpc-6169	153	18	recurrence	recurrence	NOUN
dpc-6169	153	19	rate	rate	NOUN
dpc-6169	153	20	was	be	AUX
dpc-6169	153	21	found	find	VERB
dpc-6169	153	22	to	to	PART
dpc-6169	153	23	be	be	AUX
dpc-6169	153	24	significantly	significantly	ADV
dpc-6169	153	25	lower	low	ADJ
dpc-6169	153	26	in	in	ADP
dpc-6169	153	27	the	the	DET
dpc-6169	153	28	under	under	ADP
dpc-6169	153	29	45	45	NUM
dpc-6169	153	30	age	age	NOUN
dpc-6169	153	31	group	group	NOUN
dpc-6169	153	32	compared	compare	VERB
dpc-6169	153	33	to	to	ADP
dpc-6169	153	34	the	the	DET
dpc-6169	153	35	45	45	NUM
dpc-6169	153	36	years	year	NOUN
dpc-6169	153	37	and	and	CCONJ
dpc-6169	153	38	older	old	ADJ
dpc-6169	153	39	group	group	NOUN
dpc-6169	153	40	.	.	PUNCT
dpc-6169	154	1	overall	overall	ADV
dpc-6169	154	2	,	,	PUNCT
dpc-6169	154	3	these	these	DET
dpc-6169	154	4	results	result	NOUN
dpc-6169	154	5	highlight	highlight	VERB
dpc-6169	154	6	that	that	SCONJ
dpc-6169	154	7	while	while	SCONJ
dpc-6169	154	8	age	age	NOUN
dpc-6169	154	9	and	and	CCONJ
dpc-6169	154	10	sex	sex	NOUN
dpc-6169	154	11	may	may	AUX
dpc-6169	154	12	have	have	VERB
dpc-6169	154	13	some	some	DET
dpc-6169	154	14	influence	influence	NOUN
dpc-6169	154	15	on	on	ADP
dpc-6169	154	16	relapse	relapse	NOUN
dpc-6169	154	17	dynamics	dynamic	NOUN
dpc-6169	154	18	,	,	PUNCT
dpc-6169	154	19	they	they	PRON
dpc-6169	154	20	are	be	AUX
dpc-6169	154	21	unlikely	unlikely	ADJ
dpc-6169	154	22	to	to	PART
dpc-6169	154	23	serve	serve	VERB
dpc-6169	154	24	as	as	ADP
dpc-6169	154	25	stand	stand	VERB
dpc-6169	154	26	-	-	PUNCT
dpc-6169	154	27	alone	alone	ADJ
dpc-6169	154	28	predictors	predictor	NOUN
dpc-6169	154	29	of	of	ADP
dpc-6169	154	30	treatment	treatment	NOUN
dpc-6169	154	31	response	response	NOUN
dpc-6169	154	32	.	.	PUNCT
dpc-6169	155	1	in	in	ADP
dpc-6169	155	2	addition	addition	NOUN
dpc-6169	155	3	to	to	ADP
dpc-6169	155	4	age	age	NOUN
dpc-6169	155	5	and	and	CCONJ
dpc-6169	155	6	sex	sex	NOUN
dpc-6169	155	7	,	,	PUNCT
dpc-6169	155	8	we	we	PRON
dpc-6169	155	9	investigated	investigate	VERB
dpc-6169	155	10	baseline	baseline	ADJ
dpc-6169	155	11	clinical	clinical	ADJ
dpc-6169	155	12	factors	factor	NOUN
dpc-6169	155	13	that	that	PRON
dpc-6169	155	14	might	might	AUX
dpc-6169	155	15	predict	predict	VERB
dpc-6169	155	16	early	early	ADJ
dpc-6169	155	17	treatment	treatment	NOUN
dpc-6169	155	18	response	response	NOUN
dpc-6169	155	19	to	to	ADP
dpc-6169	155	20	omalizumab	omalizumab	NOUN
dpc-6169	155	21	.	.	PUNCT
dpc-6169	156	1	our	our	PRON
dpc-6169	156	2	findings	finding	NOUN
dpc-6169	156	3	revealed	reveal	VERB
dpc-6169	156	4	that	that	SCONJ
dpc-6169	156	5	lower	low	ADJ
dpc-6169	156	6	baseline	baseline	VERB
dpc-6169	156	7	uas7	uas7	PROPN
dpc-6169	156	8	scores	score	NOUN
dpc-6169	156	9	and	and	CCONJ
dpc-6169	156	10	shorter	short	ADJ
dpc-6169	156	11	disease	disease	NOUN
dpc-6169	156	12	duration	duration	NOUN
dpc-6169	156	13	were	be	AUX
dpc-6169	156	14	both	both	PRON
dpc-6169	156	15	significantly	significantly	ADV
dpc-6169	156	16	associated	associate	VERB
dpc-6169	156	17	with	with	ADP
dpc-6169	156	18	achieving	achieve	VERB
dpc-6169	156	19	early	early	ADJ
dpc-6169	156	20	response	response	NOUN
dpc-6169	156	21	at	at	ADP
dpc-6169	156	22	four	four	NUM
dpc-6169	156	23	weeks	week	NOUN
dpc-6169	156	24	.	.	PUNCT
dpc-6169	157	1	these	these	DET
dpc-6169	157	2	observations	observation	NOUN
dpc-6169	157	3	suggest	suggest	VERB
dpc-6169	157	4	that	that	SCONJ
dpc-6169	157	5	patients	patient	NOUN
dpc-6169	157	6	with	with	ADP
dpc-6169	157	7	less	less	ADV
dpc-6169	157	8	severe	severe	ADJ
dpc-6169	157	9	disease	disease	NOUN
dpc-6169	157	10	activity	activity	NOUN
dpc-6169	157	11	and	and	CCONJ
dpc-6169	157	12	shorter	shorter	ADV
dpc-6169	157	13	-	-	PUNCT
dpc-6169	157	14	standing	stand	VERB
dpc-6169	157	15	urticaria	urticaria	NOUN
dpc-6169	157	16	may	may	AUX
dpc-6169	157	17	experience	experience	VERB
dpc-6169	157	18	faster	fast	ADJ
dpc-6169	157	19	clinical	clinical	ADJ
dpc-6169	157	20	improvement	improvement	NOUN
dpc-6169	157	21	following	follow	VERB
dpc-6169	157	22	omalizumab	omalizumab	NOUN
dpc-6169	157	23	initiation	initiation	NOUN
dpc-6169	157	24	.	.	PUNCT
dpc-6169	158	1	several	several	ADJ
dpc-6169	158	2	previous	previous	ADJ
dpc-6169	158	3	studies	study	NOUN
dpc-6169	158	4	support	support	VERB
dpc-6169	158	5	these	these	DET
dpc-6169	158	6	observations	observation	NOUN
dpc-6169	158	7	.	.	PUNCT
dpc-6169	159	1	chen	chen	PROPN
dpc-6169	159	2	et	et	PROPN
dpc-6169	159	3	al	al	PROPN
dpc-6169	159	4	.	.	PUNCT
dpc-6169	160	1	[	[	X
dpc-6169	160	2	5	5	NUM
dpc-6169	160	3	]	]	PUNCT
dpc-6169	160	4	demonstrated	demonstrate	VERB
dpc-6169	160	5	that	that	SCONJ
dpc-6169	160	6	csu	csu	NOUN
dpc-6169	160	7	rates	rate	NOUN
dpc-6169	160	8	were	be	AUX
dpc-6169	160	9	significantly	significantly	ADV
dpc-6169	160	10	higher	high	ADJ
dpc-6169	160	11	in	in	ADP
dpc-6169	160	12	male	male	ADJ
dpc-6169	160	13	patients	patient	NOUN
dpc-6169	160	14	and	and	CCONJ
dpc-6169	160	15	those	those	PRON
dpc-6169	160	16	aged	age	VERB
dpc-6169	160	17	45	45	NUM
dpc-6169	160	18	years	year	NOUN
dpc-6169	160	19	or	or	CCONJ
dpc-6169	160	20	older	old	ADJ
dpc-6169	160	21	,	,	PUNCT
dpc-6169	160	22	suggesting	suggest	VERB
dpc-6169	160	23	that	that	SCONJ
dpc-6169	160	24	these	these	DET
dpc-6169	160	25	demographic	demographic	ADJ
dpc-6169	160	26	factors	factor	NOUN
dpc-6169	160	27	may	may	AUX
dpc-6169	160	28	influence	influence	VERB
dpc-6169	160	29	disease	disease	NOUN
dpc-6169	160	30	recurrence	recurrence	NOUN
dpc-6169	160	31	after	after	ADP
dpc-6169	160	32	treatment	treatment	NOUN
dpc-6169	160	33	discontinuation	discontinuation	NOUN
dpc-6169	160	34	.	.	PUNCT
dpc-6169	161	1	these	these	DET
dpc-6169	161	2	findings	finding	NOUN
dpc-6169	161	3	support	support	VERB
dpc-6169	161	4	the	the	DET
dpc-6169	161	5	clinical	clinical	ADJ
dpc-6169	161	6	relevance	relevance	NOUN
dpc-6169	161	7	of	of	ADP
dpc-6169	161	8	baseline	baseline	NOUN
dpc-6169	161	9	disease	disease	NOUN
dpc-6169	161	10	burden	burden	NOUN
dpc-6169	161	11	and	and	CCONJ
dpc-6169	161	12	chronicity	chronicity	NOUN
dpc-6169	161	13	as	as	ADP
dpc-6169	161	14	predictors	predictor	NOUN
dpc-6169	161	15	of	of	ADP
dpc-6169	161	16	early	early	ADJ
dpc-6169	161	17	treatment	treatment	NOUN
dpc-6169	161	18	benefit	benefit	NOUN
dpc-6169	161	19	and	and	CCONJ
dpc-6169	161	20	also	also	ADV
dpc-6169	161	21	indicate	indicate	VERB
dpc-6169	161	22	that	that	SCONJ
dpc-6169	161	23	younger	young	ADJ
dpc-6169	161	24	age	age	NOUN
dpc-6169	161	25	and	and	CCONJ
dpc-6169	161	26	female	female	ADJ
dpc-6169	161	27	sex	sex	NOUN
dpc-6169	161	28	may	may	AUX
dpc-6169	161	29	be	be	AUX
dpc-6169	161	30	associated	associate	VERB
dpc-6169	161	31	with	with	ADP
dpc-6169	161	32	more	more	ADJ
dpc-6169	161	33	sustained	sustained	ADJ
dpc-6169	161	34	disease	disease	NOUN
dpc-6169	161	35	control	control	NOUN
dpc-6169	161	36	following	follow	VERB
dpc-6169	161	37	omalizumab	omalizumab	NOUN
dpc-6169	161	38	therapy	therapy	NOUN
dpc-6169	161	39	.	.	PUNCT
dpc-6169	162	1	chronic	chronic	ADJ
dpc-6169	162	2	urticaria	urticaria	NOUN
dpc-6169	162	3	,	,	PUNCT
dpc-6169	162	4	defined	define	VERB
dpc-6169	162	5	as	as	ADP
dpc-6169	162	6	urticaria	urticaria	NOUN
dpc-6169	162	7	lasting	last	VERB
dpc-6169	162	8	more	more	ADJ
dpc-6169	162	9	than	than	ADP
dpc-6169	162	10	six	six	NUM
dpc-6169	162	11	weeks	week	NOUN
dpc-6169	162	12	,	,	PUNCT
dpc-6169	162	13	is	be	AUX
dpc-6169	162	14	reported	report	VERB
dpc-6169	162	15	to	to	PART
dpc-6169	162	16	be	be	AUX
dpc-6169	162	17	2–4	2–4	NUM
dpc-6169	162	18	times	time	NOUN
dpc-6169	162	19	more	more	ADV
dpc-6169	162	20	common	common	ADJ
dpc-6169	162	21	in	in	ADP
dpc-6169	162	22	females	female	NOUN
dpc-6169	162	23	than	than	ADP
dpc-6169	162	24	in	in	ADP
dpc-6169	162	25	males	male	NOUN
dpc-6169	162	26	and	and	CCONJ
dpc-6169	162	27	is	be	AUX
dpc-6169	162	28	most	most	ADV
dpc-6169	162	29	frequently	frequently	ADV
dpc-6169	162	30	observed	observe	VERB
dpc-6169	162	31	between	between	ADP
dpc-6169	162	32	the	the	DET
dpc-6169	162	33	ages	age	NOUN
dpc-6169	162	34	of	of	ADP
dpc-6169	162	35	20	20	NUM
dpc-6169	162	36	and	and	CCONJ
dpc-6169	162	37	40	40	NUM
dpc-6169	163	1	[	[	SYM
dpc-6169	163	2	1	1	NUM
dpc-6169	163	3	-	-	SYM
dpc-6169	163	4	3	3	NUM
dpc-6169	163	5	]	]	PUNCT
dpc-6169	163	6	.	.	PUNCT
dpc-6169	164	1	in	in	ADP
dpc-6169	164	2	our	our	PRON
dpc-6169	164	3	study	study	NOUN
dpc-6169	164	4	,	,	PUNCT
dpc-6169	164	5	the	the	DET
dpc-6169	164	6	mean	mean	ADJ
dpc-6169	164	7	age	age	NOUN
dpc-6169	164	8	was	be	AUX
dpc-6169	164	9	43	43	NUM
dpc-6169	164	10	years	year	NOUN
dpc-6169	164	11	,	,	PUNCT
dpc-6169	164	12	and	and	CCONJ
dpc-6169	164	13	the	the	DET
dpc-6169	164	14	female	female	NOUN
dpc-6169	164	15	-	-	PUNCT
dpc-6169	164	16	to	to	ADP
dpc-6169	164	17	-	-	PUNCT
dpc-6169	164	18	male	male	NOUN
dpc-6169	164	19	ratio	ratio	NOUN
dpc-6169	164	20	was	be	AUX
dpc-6169	164	21	found	find	VERB
dpc-6169	164	22	to	to	PART
dpc-6169	164	23	be	be	AUX
dpc-6169	164	24	1.97:1	1.97:1	NUM
dpc-6169	164	25	,	,	PUNCT
dpc-6169	164	26	consistent	consistent	ADJ
dpc-6169	164	27	with	with	ADP
dpc-6169	164	28	previous	previous	ADJ
dpc-6169	164	29	epidemiologic	epidemiologic	ADJ
dpc-6169	164	30	data	datum	NOUN
dpc-6169	164	31	.	.	PUNCT
dpc-6169	165	1	this	this	PRON
dpc-6169	165	2	supports	support	VERB
dpc-6169	165	3	the	the	DET
dpc-6169	165	4	representativeness	representativeness	NOUN
dpc-6169	165	5	of	of	ADP
dpc-6169	165	6	our	our	PRON
dpc-6169	165	7	study	study	NOUN
dpc-6169	165	8	population	population	NOUN
dpc-6169	165	9	in	in	ADP
dpc-6169	165	10	relation	relation	NOUN
dpc-6169	165	11	to	to	ADP
dpc-6169	165	12	the	the	DET
dpc-6169	165	13	general	general	ADJ
dpc-6169	165	14	csu	csu	PROPN
dpc-6169	165	15	demographic	demographic	ADJ
dpc-6169	165	16	.	.	PUNCT
dpc-6169	166	1	di	di	PROPN
dpc-6169	166	2	bona	bona	PROPN
dpc-6169	166	3	et	et	PROPN
dpc-6169	166	4	al	al	PROPN
dpc-6169	166	5	.	.	PROPN
dpc-6169	166	6	reported	report	VERB
dpc-6169	166	7	a	a	DET
dpc-6169	166	8	mean	mean	ADJ
dpc-6169	166	9	follow	follow	VERB
dpc-6169	166	10	-	-	PUNCT
dpc-6169	166	11	up	up	ADP
dpc-6169	166	12	duration	duration	NOUN
dpc-6169	166	13	of	of	ADP
dpc-6169	166	14	91	91	NUM
dpc-6169	166	15	asthma	asthma	NOUN
dpc-6169	166	16	patients	patient	NOUN
dpc-6169	166	17	treated	treat	VERB
dpc-6169	166	18	with	with	ADP
dpc-6169	166	19	omalizumab	omalizumab	NOUN
dpc-6169	166	20	as	as	ADP
dpc-6169	166	21	45.6	45.6	NUM
dpc-6169	166	22	months	month	NOUN
dpc-6169	167	1	[	[	X
dpc-6169	167	2	10	10	NUM
dpc-6169	167	3	]	]	PUNCT
dpc-6169	167	4	.	.	PUNCT
dpc-6169	168	1	similarly	similarly	ADV
dpc-6169	168	2	,	,	PUNCT
dpc-6169	168	3	in	in	ADP
dpc-6169	168	4	our	our	PRON
dpc-6169	168	5	study	study	NOUN
dpc-6169	168	6	,	,	PUNCT
dpc-6169	168	7	the	the	DET
dpc-6169	168	8	mean	mean	ADJ
dpc-6169	168	9	follow	follow	VERB
dpc-6169	168	10	-	-	PUNCT
dpc-6169	168	11	up	up	ADP
dpc-6169	168	12	duration	duration	NOUN
dpc-6169	168	13	was	be	AUX
dpc-6169	168	14	found	find	VERB
dpc-6169	168	15	to	to	PART
dpc-6169	168	16	be	be	AUX
dpc-6169	168	17	35.5	35.5	NUM
dpc-6169	168	18	months	month	NOUN
dpc-6169	168	19	.	.	PUNCT
dpc-6169	169	1	in	in	ADP
dpc-6169	169	2	the	the	DET
dpc-6169	169	3	same	same	ADJ
dpc-6169	169	4	study	study	NOUN
dpc-6169	169	5	by	by	ADP
dpc-6169	169	6	di	di	X
dpc-6169	169	7	bona	bona	PROPN
dpc-6169	169	8	et	et	PROPN
dpc-6169	169	9	al	al	PROPN
dpc-6169	169	10	.	.	PUNCT
dpc-6169	170	1	[	[	X
dpc-6169	170	2	10	10	NUM
dpc-6169	170	3	]	]	SYM
dpc-6169	170	4	six	six	NUM
dpc-6169	170	5	patients	patient	NOUN
dpc-6169	170	6	(	(	PUNCT
dpc-6169	170	7	6.6	6.6	NUM
dpc-6169	170	8	%	%	NOUN
dpc-6169	170	9	)	)	PUNCT
dpc-6169	170	10	discontinued	discontinue	VERB
dpc-6169	170	11	treatment	treatment	NOUN
dpc-6169	170	12	due	due	ADP
dpc-6169	170	13	to	to	ADP
dpc-6169	170	14	adverse	adverse	ADJ
dpc-6169	170	15	effects	effect	NOUN
dpc-6169	170	16	,	,	PUNCT
dpc-6169	170	17	whereas	whereas	SCONJ
dpc-6169	170	18	,	,	PUNCT
dpc-6169	170	19	in	in	ADP
dpc-6169	170	20	our	our	PRON
dpc-6169	170	21	study	study	NOUN
dpc-6169	170	22	,	,	PUNCT
dpc-6169	170	23	the	the	DET
dpc-6169	170	24	rate	rate	NOUN
dpc-6169	170	25	of	of	ADP
dpc-6169	170	26	treatment	treatment	NOUN
dpc-6169	170	27	discontinuation	discontinuation	NOUN
dpc-6169	170	28	due	due	ADP
dpc-6169	170	29	to	to	ADP
dpc-6169	170	30	adverse	adverse	ADJ
dpc-6169	170	31	effects	effect	NOUN
dpc-6169	170	32	was	be	AUX
dpc-6169	170	33	lower	low	ADJ
dpc-6169	170	34	,	,	PUNCT
dpc-6169	170	35	at	at	ADP
dpc-6169	170	36	1.45	1.45	NUM
dpc-6169	170	37	%	%	NOUN
dpc-6169	170	38	,	,	PUNCT
dpc-6169	170	39	suggesting	suggest	VERB
dpc-6169	170	40	a	a	DET
dpc-6169	170	41	favorable	favorable	ADJ
dpc-6169	170	42	tolerability	tolerability	NOUN
dpc-6169	170	43	profile	profile	NOUN
dpc-6169	170	44	of	of	ADP
dpc-6169	170	45	omalizumab	omalizumab	NOUN
dpc-6169	170	46	across	across	ADP
dpc-6169	170	47	patient	patient	ADJ
dpc-6169	170	48	populations	population	NOUN
dpc-6169	170	49	.	.	PUNCT
dpc-6169	171	1	sirufo	sirufo	PROPN
dpc-6169	171	2	et	et	PROPN
dpc-6169	171	3	al	al	PROPN
dpc-6169	171	4	.	.	PUNCT
dpc-6169	172	1	[	[	X
dpc-6169	172	2	11	11	NUM
dpc-6169	172	3	]	]	PUNCT
dpc-6169	172	4	conducted	conduct	VERB
dpc-6169	172	5	a	a	DET
dpc-6169	172	6	study	study	NOUN
dpc-6169	172	7	involving	involve	VERB
dpc-6169	172	8	26	26	NUM
dpc-6169	172	9	female	female	ADJ
dpc-6169	172	10	and	and	CCONJ
dpc-6169	172	11	16	16	NUM
dpc-6169	172	12	male	male	ADJ
dpc-6169	172	13	patients	patient	NOUN
dpc-6169	172	14	and	and	CCONJ
dpc-6169	172	15	found	find	VERB
dpc-6169	172	16	that	that	SCONJ
dpc-6169	172	17	female	female	ADJ
dpc-6169	172	18	patients	patient	NOUN
dpc-6169	172	19	had	have	VERB
dpc-6169	172	20	a	a	DET
dpc-6169	172	21	better	well	ADJ
dpc-6169	172	22	response	response	NOUN
dpc-6169	172	23	to	to	ADP
dpc-6169	172	24	omalizumab	omalizumab	NOUN
dpc-6169	172	25	.	.	PUNCT
dpc-6169	173	1	additionally	additionally	ADV
dpc-6169	173	2	,	,	PUNCT
dpc-6169	173	3	at	at	ADP
dpc-6169	173	4	the	the	DET
dpc-6169	173	5	end	end	NOUN
dpc-6169	173	6	of	of	ADP
dpc-6169	173	7	the	the	DET
dpc-6169	173	8	six	six	NUM
dpc-6169	173	9	-	-	PUNCT
dpc-6169	173	10	month	month	NOUN
dpc-6169	173	11	initial	initial	ADJ
dpc-6169	173	12	treatment	treatment	NOUN
dpc-6169	173	13	cycle	cycle	NOUN
dpc-6169	173	14	,	,	PUNCT
dpc-6169	173	15	the	the	DET
dpc-6169	173	16	recurrence	recurrence	NOUN
dpc-6169	173	17	rate	rate	NOUN
dpc-6169	173	18	was	be	AUX
dpc-6169	173	19	lower	low	ADJ
dpc-6169	173	20	in	in	ADP
dpc-6169	173	21	female	female	ADJ
dpc-6169	173	22	patients	patient	NOUN
dpc-6169	173	23	(	(	PUNCT
dpc-6169	173	24	15.4	15.4	NUM
dpc-6169	173	25	%	%	NOUN
dpc-6169	173	26	)	)	PUNCT
dpc-6169	173	27	compared	compare	VERB
dpc-6169	173	28	to	to	ADP
dpc-6169	173	29	male	male	ADJ
dpc-6169	173	30	patients	patient	NOUN
dpc-6169	173	31	(	(	PUNCT
dpc-6169	173	32	50	50	NUM
dpc-6169	173	33	%	%	NOUN
dpc-6169	173	34	)	)	PUNCT
dpc-6169	173	35	.	.	PUNCT
dpc-6169	174	1	conversely	conversely	ADV
dpc-6169	174	2	,	,	PUNCT
dpc-6169	174	3	a	a	DET
dpc-6169	174	4	study	study	NOUN
dpc-6169	174	5	by	by	ADP
dpc-6169	174	6	bozat	bozat	PROPN
dpc-6169	174	7	et	et	PROPN
dpc-6169	174	8	al	al	PROPN
dpc-6169	174	9	.	.	PUNCT
dpc-6169	175	1	[	[	X
dpc-6169	175	2	12	12	NUM
dpc-6169	175	3	]	]	PUNCT
dpc-6169	175	4	on	on	ADP
dpc-6169	175	5	pediatric	pediatric	ADJ
dpc-6169	175	6	patients	patient	NOUN
dpc-6169	175	7	with	with	ADP
dpc-6169	175	8	csu	csu	PROPN
dpc-6169	175	9	suggested	suggest	VERB
dpc-6169	175	10	that	that	SCONJ
dpc-6169	175	11	sex	sex	NOUN
dpc-6169	175	12	did	do	AUX
dpc-6169	175	13	not	not	PART
dpc-6169	175	14	influence	influence	VERB
dpc-6169	175	15	treatment	treatment	NOUN
dpc-6169	175	16	response	response	NOUN
dpc-6169	175	17	.	.	PUNCT
dpc-6169	176	1	similarly	similarly	ADV
dpc-6169	176	2	,	,	PUNCT
dpc-6169	176	3	gouder	gouder	NOUN
dpc-6169	176	4	et	et	PROPN
dpc-6169	176	5	al	al	PROPN
dpc-6169	176	6	.	.	PUNCT
dpc-6169	177	1	[	[	X
dpc-6169	177	2	13	13	NUM
dpc-6169	177	3	]	]	PUNCT
dpc-6169	177	4	investigated	investigate	VERB
dpc-6169	177	5	the	the	DET
dpc-6169	177	6	effects	effect	NOUN
dpc-6169	177	7	,	,	PUNCT
dpc-6169	177	8	tolerability	tolerability	NOUN
dpc-6169	177	9	,	,	PUNCT
dpc-6169	177	10	and	and	CCONJ
dpc-6169	177	11	treatment	treatment	NOUN
dpc-6169	177	12	responses	response	NOUN
dpc-6169	177	13	of	of	ADP
dpc-6169	177	14	omalizumab	omalizumab	NOUN
dpc-6169	177	15	in	in	ADP
dpc-6169	177	16	17	17	NUM
dpc-6169	177	17	male	male	ADJ
dpc-6169	177	18	and	and	CCONJ
dpc-6169	177	19	11	11	NUM
dpc-6169	177	20	female	female	ADJ
dpc-6169	177	21	asthma	asthma	NOUN
dpc-6169	177	22	patients	patient	NOUN
dpc-6169	177	23	and	and	CCONJ
dpc-6169	177	24	found	find	VERB
dpc-6169	177	25	no	no	DET
dpc-6169	177	26	significant	significant	ADJ
dpc-6169	177	27	differences	difference	NOUN
dpc-6169	177	28	between	between	ADP
dpc-6169	177	29	the	the	DET
dpc-6169	177	30	sexes	sex	NOUN
dpc-6169	177	31	.	.	PUNCT
dpc-6169	178	1	in	in	ADP
dpc-6169	178	2	a	a	DET
dpc-6169	178	3	study	study	NOUN
dpc-6169	178	4	by	by	ADP
dpc-6169	178	5	yu	yu	PROPN
dpc-6169	178	6	et	et	PROPN
dpc-6169	178	7	al	al	PROPN
dpc-6169	178	8	.	.	PUNCT
dpc-6169	179	1	[	[	X
dpc-6169	179	2	14	14	NUM
dpc-6169	179	3	]	]	PUNCT
dpc-6169	179	4	,	,	PUNCT
dpc-6169	179	5	it	it	PRON
dpc-6169	179	6	was	be	AUX
dpc-6169	179	7	observed	observe	VERB
dpc-6169	179	8	that	that	SCONJ
dpc-6169	179	9	the	the	DET
dpc-6169	179	10	speed	speed	NOUN
dpc-6169	179	11	at	at	ADP
dpc-6169	179	12	which	which	PRON
dpc-6169	179	13	disease	disease	NOUN
dpc-6169	179	14	control	control	NOUN
dpc-6169	179	15	was	be	AUX
dpc-6169	179	16	achieved	achieve	VERB
dpc-6169	179	17	with	with	ADP
dpc-6169	179	18	omalizumab	omalizumab	NOUN
dpc-6169	179	19	was	be	AUX
dpc-6169	179	20	not	not	PART
dpc-6169	179	21	associated	associate	VERB
dpc-6169	179	22	with	with	ADP
dpc-6169	179	23	sex	sex	NOUN
dpc-6169	179	24	.	.	PUNCT
dpc-6169	180	1	in	in	ADP
dpc-6169	180	2	our	our	PRON
dpc-6169	180	3	study	study	NOUN
dpc-6169	180	4	,	,	PUNCT
dpc-6169	180	5	no	no	DET
dpc-6169	180	6	significant	significant	ADJ
dpc-6169	180	7	difference	difference	NOUN
dpc-6169	180	8	was	be	AUX
dpc-6169	180	9	found	find	VERB
dpc-6169	180	10	between	between	ADP
dpc-6169	180	11	the	the	DET
dpc-6169	180	12	two	two	NUM
dpc-6169	180	13	sexes	sex	NOUN
dpc-6169	180	14	in	in	ADP
dpc-6169	180	15	terms	term	NOUN
dpc-6169	180	16	of	of	ADP
dpc-6169	180	17	response	response	NOUN
dpc-6169	180	18	to	to	ADP
dpc-6169	180	19	the	the	DET
dpc-6169	180	20	first	first	ADJ
dpc-6169	180	21	dose	dose	NOUN
dpc-6169	180	22	or	or	CCONJ
dpc-6169	180	23	lack	lack	NOUN
dpc-6169	180	24	of	of	ADP
dpc-6169	180	25	response	response	NOUN
dpc-6169	180	26	to	to	ADP
dpc-6169	180	27	treatment	treatment	NOUN
dpc-6169	180	28	,	,	PUNCT
dpc-6169	180	29	aligning	align	VERB
dpc-6169	180	30	with	with	ADP
dpc-6169	180	31	the	the	DET
dpc-6169	180	32	general	general	ADJ
dpc-6169	180	33	literature	literature	PROPN
dpc-6169	180	34	.	.	PUNCT
dpc-6169	181	1	table	table	NOUN
dpc-6169	181	2	2	2	NUM
dpc-6169	181	3	.	.	PUNCT
dpc-6169	181	4	treatment	treatment	NOUN
dpc-6169	181	5	response	response	NOUN
dpc-6169	181	6	by	by	ADP
dpc-6169	181	7	age	age	NOUN
dpc-6169	181	8	groups	group	NOUN
dpc-6169	181	9	.	.	PUNCT
dpc-6169	182	1	age	age	NOUN
dpc-6169	182	2	groups	group	NOUN
dpc-6169	182	3	number	number	NOUN
dpc-6169	182	4	of	of	ADP
dpc-6169	182	5	patients	patient	NOUN
dpc-6169	182	6	number	number	NOUN
dpc-6169	182	7	of	of	ADP
dpc-6169	182	8	early	early	ADJ
dpc-6169	182	9	responders	responder	NOUN
dpc-6169	182	10	non	non	ADJ
dpc-6169	182	11	-	-	ADJ
dpc-6169	182	12	early	early	ADJ
dpc-6169	182	13	responders	responder	NOUN
dpc-6169	182	14	number	number	NOUN
dpc-6169	182	15	of	of	ADP
dpc-6169	182	16	female	female	ADJ
dpc-6169	182	17	early	early	ADJ
dpc-6169	182	18	responders	responder	NOUN
dpc-6169	182	19	number	number	NOUN
dpc-6169	182	20	of	of	ADP
dpc-6169	182	21	female	female	ADJ
dpc-6169	182	22	non	non	ADJ
dpc-6169	182	23	-	-	ADJ
dpc-6169	182	24	early	early	ADJ
dpc-6169	182	25	responders	responder	NOUN
dpc-6169	182	26	relapse	relapse	VERB
dpc-6169	182	27	under	under	ADP
dpc-6169	182	28	45	45	NUM
dpc-6169	182	29	years	year	NOUN
dpc-6169	182	30	151	151	NUM
dpc-6169	182	31	67	67	NUM
dpc-6169	182	32	84	84	NUM
dpc-6169	182	33	39	39	NUM
dpc-6169	182	34	65	65	NUM
dpc-6169	182	35	32	32	NUM
dpc-6169	182	36	46	46	NUM
dpc-6169	182	37	years	year	NOUN
dpc-6169	182	38	and	and	CCONJ
dpc-6169	182	39	above	above	ADP
dpc-6169	182	40	123	123	NUM
dpc-6169	182	41	36	36	NUM
dpc-6169	182	42	87	87	NUM
dpc-6169	182	43	25	25	NUM
dpc-6169	182	44	53	53	NUM
dpc-6169	182	45	42	42	NUM
dpc-6169	182	46	6	6	NUM
dpc-6169	182	47	original	original	ADJ
dpc-6169	182	48	article	article	NOUN
dpc-6169	182	49	|	|	ADV
dpc-6169	182	50	dermatol	dermatol	ADJ
dpc-6169	182	51	pract	pract	NOUN
dpc-6169	182	52	concept	concept	NOUN
dpc-6169	182	53	.	.	PUNCT
dpc-6169	183	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	183	2	risk	risk	NOUN
dpc-6169	183	3	may	may	AUX
dpc-6169	183	4	guide	guide	VERB
dpc-6169	183	5	treatment	treatment	NOUN
dpc-6169	183	6	continuation	continuation	NOUN
dpc-6169	183	7	and	and	CCONJ
dpc-6169	183	8	monitoring	monitoring	NOUN
dpc-6169	183	9	strategies	strategy	NOUN
dpc-6169	183	10	.	.	PUNCT
dpc-6169	184	1	integrating	integrate	VERB
dpc-6169	184	2	these	these	DET
dpc-6169	184	3	accessible	accessible	ADJ
dpc-6169	184	4	clinical	clinical	ADJ
dpc-6169	184	5	parameters	parameter	NOUN
dpc-6169	184	6	into	into	ADP
dpc-6169	184	7	treatment	treatment	NOUN
dpc-6169	184	8	planning	planning	NOUN
dpc-6169	184	9	could	could	AUX
dpc-6169	184	10	support	support	VERB
dpc-6169	184	11	a	a	DET
dpc-6169	184	12	more	more	ADV
dpc-6169	184	13	personalized	personalized	ADJ
dpc-6169	184	14	approach	approach	NOUN
dpc-6169	184	15	in	in	ADP
dpc-6169	184	16	csu	csu	PROPN
dpc-6169	184	17	management	management	NOUN
dpc-6169	184	18	and	and	CCONJ
dpc-6169	184	19	improve	improve	VERB
dpc-6169	184	20	patient	patient	ADJ
dpc-6169	184	21	outcomes	outcome	NOUN
dpc-6169	184	22	.	.	PUNCT
dpc-6169	185	1	references	reference	NOUN
dpc-6169	185	2	1	1	NUM
dpc-6169	185	3	.	.	PUNCT
dpc-6169	185	4	zuberbier	zuberbier	PROPN
dpc-6169	185	5	t	t	PROPN
dpc-6169	185	6	,	,	PUNCT
dpc-6169	185	7	abdul	abdul	PROPN
dpc-6169	185	8	latiff	latiff	PROPN
dpc-6169	185	9	ah	ah	INTJ
dpc-6169	185	10	,	,	PUNCT
dpc-6169	185	11	abuzakouk	abuzakouk	PROPN
dpc-6169	185	12	m	m	PROPN
dpc-6169	185	13	,	,	PUNCT
dpc-6169	185	14	et	et	PROPN
dpc-6169	185	15	al	al	PROPN
dpc-6169	185	16	.	.	PUNCT
dpc-6169	186	1	the	the	DET
dpc-6169	186	2	international	international	PROPN
dpc-6169	186	3	eaaci	eaaci	PROPN
dpc-6169	186	4	/	/	SYM
dpc-6169	186	5	ga²len	ga²len	PROPN
dpc-6169	186	6	/	/	SYM
dpc-6169	186	7	euroguiderm	euroguiderm	NOUN
dpc-6169	186	8	/	/	SYM
dpc-6169	186	9	apaaaci	apaaaci	NOUN
dpc-6169	186	10	guideline	guideline	NOUN
dpc-6169	186	11	for	for	ADP
dpc-6169	186	12	the	the	DET
dpc-6169	186	13	definition	definition	NOUN
dpc-6169	186	14	,	,	PUNCT
dpc-6169	186	15	classification	classification	NOUN
dpc-6169	186	16	,	,	PUNCT
dpc-6169	186	17	diagnosis	diagnosis	NOUN
dpc-6169	186	18	,	,	PUNCT
dpc-6169	186	19	and	and	CCONJ
dpc-6169	186	20	management	management	NOUN
dpc-6169	186	21	of	of	ADP
dpc-6169	186	22	urticaria	urticaria	NOUN
dpc-6169	186	23	.	.	PUNCT
dpc-6169	186	24	 	 	SPACE
dpc-6169	186	25	allergy	allergy	PROPN
dpc-6169	186	26	.	.	PUNCT
dpc-6169	186	27	 	 	SPACE
dpc-6169	187	1	2022;77(3):734	2022;77(3):734	NUM
dpc-6169	187	2	-	-	SYM
dpc-6169	187	3	66	66	NUM
dpc-6169	187	4	.	.	PUNCT
dpc-6169	188	1	doi	doi	NOUN
dpc-6169	188	2	:	:	PUNCT
dpc-6169	188	3	10.1111	10.1111	NUM
dpc-6169	188	4	/	/	SYM
dpc-6169	188	5	all.15090	all.15090	X
dpc-6169	188	6	.	.	PUNCT
dpc-6169	189	1	pmid	pmid	NOUN
dpc-6169	189	2	:	:	PUNCT
dpc-6169	189	3	34536239	34536239	NUM
dpc-6169	189	4	.	.	PUNCT
dpc-6169	190	1	2	2	X
dpc-6169	190	2	.	.	X
dpc-6169	190	3	de	de	PROPN
dpc-6169	190	4	martinis	martinis	PROPN
dpc-6169	190	5	m	m	PROPN
dpc-6169	190	6	,	,	PUNCT
dpc-6169	190	7	sirufo	sirufo	PROPN
dpc-6169	190	8	mm	mm	PROPN
dpc-6169	190	9	,	,	PUNCT
dpc-6169	190	10	suppa	suppa	PROPN
dpc-6169	190	11	m	m	PROPN
dpc-6169	190	12	,	,	PUNCT
dpc-6169	190	13	di	di	PROPN
dpc-6169	190	14	silvestre	silvestre	PROPN
dpc-6169	190	15	d	d	PROPN
dpc-6169	190	16	,	,	PUNCT
dpc-6169	190	17	ginaldi	ginaldi	PROPN
dpc-6169	190	18	l.	l.	PROPN
dpc-6169	190	19	sex	sex	PROPN
dpc-6169	190	20	and	and	CCONJ
dpc-6169	190	21	gender	gender	NOUN
dpc-6169	190	22	aspects	aspect	NOUN
dpc-6169	190	23	for	for	ADP
dpc-6169	190	24	patient	patient	ADJ
dpc-6169	190	25	stratification	stratification	NOUN
dpc-6169	190	26	in	in	ADP
dpc-6169	190	27	allergy	allergy	PROPN
dpc-6169	190	28	prevention	prevention	NOUN
dpc-6169	190	29	and	and	CCONJ
dpc-6169	190	30	treatment	treatment	NOUN
dpc-6169	190	31	.	.	PUNCT
dpc-6169	191	1	int	int	PROPN
dpc-6169	191	2	j	j	PROPN
dpc-6169	191	3	mol	mol	ADP
dpc-6169	191	4	sci	sci	PROPN
dpc-6169	191	5	.	.	PUNCT
dpc-6169	192	1	2020;21(4):1535	2020;21(4):1535	PROPN
dpc-6169	192	2	.	.	PUNCT
dpc-6169	193	1	doi	doi	NOUN
dpc-6169	193	2	:	:	PUNCT
dpc-6169	193	3	10.3390	10.3390	NUM
dpc-6169	193	4	/	/	SYM
dpc-6169	193	5	ijms21041535	ijms21041535	PROPN
dpc-6169	193	6	.	.	PUNCT
dpc-6169	194	1	pmid	pmid	NOUN
dpc-6169	194	2	:	:	PUNCT
dpc-6169	194	3	32102344	32102344	NUM
dpc-6169	194	4	.	.	PUNCT
dpc-6169	195	1	3	3	X
dpc-6169	195	2	.	.	X
dpc-6169	195	3	maurer	maurer	PROPN
dpc-6169	195	4	m	m	PROPN
dpc-6169	195	5	,	,	PUNCT
dpc-6169	195	6	weller	weller	PROPN
dpc-6169	195	7	k	k	PROPN
dpc-6169	195	8	,	,	PUNCT
dpc-6169	195	9	bindslev	bindslev	NOUN
dpc-6169	195	10	-	-	PUNCT
dpc-6169	195	11	jensen	jensen	PROPN
dpc-6169	195	12	c	c	PROPN
dpc-6169	195	13	,	,	PUNCT
dpc-6169	195	14	et	et	PROPN
dpc-6169	195	15	al	al	PROPN
dpc-6169	195	16	.	.	PUNCT
dpc-6169	196	1	unmet	unmet	PROPN
dpc-6169	196	2	clinical	clinical	ADJ
dpc-6169	196	3	needs	need	NOUN
dpc-6169	196	4	in	in	ADP
dpc-6169	196	5	chronic	chronic	ADJ
dpc-6169	196	6	spontaneous	spontaneous	ADJ
dpc-6169	196	7	urticaria	urticaria	NOUN
dpc-6169	196	8	.	.	PUNCT
dpc-6169	197	1	a	a	DET
dpc-6169	197	2	ga²len	ga²len	PROPN
dpc-6169	197	3	task	task	NOUN
dpc-6169	197	4	force	force	NOUN
dpc-6169	197	5	report	report	NOUN
dpc-6169	197	6	.	.	PUNCT
dpc-6169	197	7	  	  	SPACE
dpc-6169	197	8	allergy	allergy	NOUN
dpc-6169	197	9	.	.	PUNCT
dpc-6169	197	10	  	  	SPACE
dpc-6169	198	1	2011;66(3):317	2011;66(3):317	NUM
dpc-6169	198	2	-	-	SYM
dpc-6169	198	3	30	30	NUM
dpc-6169	198	4	.	.	PUNCT
dpc-6169	199	1	doi	doi	NOUN
dpc-6169	199	2	:	:	PUNCT
dpc-6169	199	3	10.1111	10.1111	NUM
dpc-6169	199	4	/	/	SYM
dpc-6169	199	5	j.1398	j.1398	NOUN
dpc-6169	199	6	-9995.2010.02496.x	-9995.2010.02496.x	ADJ
dpc-6169	199	7	.	.	PUNCT
dpc-6169	200	1	pmid	pmid	NOUN
dpc-6169	200	2	:	:	PUNCT
dpc-6169	200	3	21083565	21083565	NUM
dpc-6169	200	4	.	.	PUNCT
dpc-6169	201	1	4	4	X
dpc-6169	201	2	.	.	X
dpc-6169	201	3	okayama	okayama	PROPN
dpc-6169	201	4	y	y	PROPN
dpc-6169	201	5	,	,	PUNCT
dpc-6169	201	6	matsumoto	matsumoto	PROPN
dpc-6169	201	7	h	h	PROPN
dpc-6169	201	8	,	,	PUNCT
dpc-6169	201	9	odajima	odajima	PROPN
dpc-6169	201	10	h	h	PROPN
dpc-6169	201	11	,	,	PUNCT
dpc-6169	201	12	takahagi	takahagi	PROPN
dpc-6169	201	13	s	s	PROPN
dpc-6169	201	14	,	,	PUNCT
dpc-6169	201	15	hide	hide	VERB
dpc-6169	201	16	m	m	PROPN
dpc-6169	201	17	,	,	PUNCT
dpc-6169	201	18	okubo	okubo	PROPN
dpc-6169	201	19	k.	k.	PROPN
dpc-6169	201	20	roles	role	NOUN
dpc-6169	201	21	of	of	ADP
dpc-6169	201	22	omalizumab	omalizumab	NOUN
dpc-6169	201	23	in	in	ADP
dpc-6169	201	24	various	various	ADJ
dpc-6169	201	25	allergic	allergic	ADJ
dpc-6169	201	26	diseases	disease	NOUN
dpc-6169	201	27	.	.	PUNCT
dpc-6169	202	1	allergol	allergol	PROPN
dpc-6169	202	2	int	int	PROPN
dpc-6169	202	3	.	.	PUNCT
dpc-6169	203	1	2020;69(2):167	2020;69(2):167	NUM
dpc-6169	203	2	-	-	SYM
dpc-6169	203	3	77	77	NUM
dpc-6169	203	4	.	.	PUNCT
dpc-6169	204	1	doi	doi	NOUN
dpc-6169	204	2	:	:	PUNCT
dpc-6169	204	3	10.1016	10.1016	NUM
dpc-6169	204	4	/	/	SYM
dpc-6169	204	5	j.alit.2020.01.004	j.alit.2020.01.004	PROPN
dpc-6169	204	6	.	.	PUNCT
dpc-6169	205	1	pmid	pmid	NOUN
dpc-6169	205	2	:	:	PUNCT
dpc-6169	205	3	32067933	32067933	NUM
dpc-6169	205	4	.	.	PUNCT
dpc-6169	206	1	5	5	X
dpc-6169	206	2	.	.	X
dpc-6169	207	1	chen	chen	PROPN
dpc-6169	207	2	j	j	PROPN
dpc-6169	207	3	,	,	PUNCT
dpc-6169	207	4	ou	ou	PROPN
dpc-6169	207	5	s	s	PROPN
dpc-6169	207	6	,	,	PUNCT
dpc-6169	207	7	wu	wu	PROPN
dpc-6169	207	8	w	w	PROPN
dpc-6169	207	9	,	,	PUNCT
dpc-6169	207	10	zou	zou	PROPN
dpc-6169	207	11	h	h	PROPN
dpc-6169	207	12	,	,	PUNCT
dpc-6169	207	13	li	li	PROPN
dpc-6169	207	14	h	h	PROPN
dpc-6169	207	15	,	,	PUNCT
dpc-6169	207	16	zhu	zhu	PROPN
dpc-6169	207	17	h.	h.	PROPN
dpc-6169	207	18	omalizumab	omalizumab	NOUN
dpc-6169	207	19	in	in	ADP
dpc-6169	207	20	chronic	chronic	ADJ
dpc-6169	207	21	spontaneous	spontaneous	ADJ
dpc-6169	207	22	urticaria	urticaria	NOUN
dpc-6169	207	23	:	:	PUNCT
dpc-6169	207	24	a	a	DET
dpc-6169	207	25	real	real	ADJ
dpc-6169	207	26	-	-	PUNCT
dpc-6169	207	27	world	world	NOUN
dpc-6169	207	28	study	study	NOUN
dpc-6169	207	29	on	on	ADP
dpc-6169	207	30	effectiveness	effectiveness	NOUN
dpc-6169	207	31	,	,	PUNCT
dpc-6169	207	32	safety	safety	NOUN
dpc-6169	207	33	and	and	CCONJ
dpc-6169	207	34	predictors	predictor	NOUN
dpc-6169	207	35	of	of	ADP
dpc-6169	207	36	treatment	treatment	NOUN
dpc-6169	207	37	outcome	outcome	NOUN
dpc-6169	207	38	.	.	PUNCT
dpc-6169	208	1	clin	clin	PROPN
dpc-6169	208	2	cosmet	cosmet	PROPN
dpc-6169	208	3	investig	investig	NOUN
dpc-6169	208	4	dermatol	dermatol	NOUN
dpc-6169	208	5	.	.	PUNCT
dpc-6169	209	1	2024;17:1799	2024;17:1799	NUM
dpc-6169	209	2	-	-	SYM
dpc-6169	209	3	808	808	NUM
dpc-6169	209	4	.	.	PUNCT
dpc-6169	209	5	doi	doi	NOUN
dpc-6169	209	6	:	:	PUNCT
dpc-6169	209	7	10.2147	10.2147	NUM
dpc-6169	209	8	/ccid.s470160	/ccid.s470160	PROPN
dpc-6169	209	9	.	.	PUNCT
dpc-6169	210	1	pmid	pmid	NOUN
dpc-6169	210	2	:	:	PUNCT
dpc-6169	210	3	39132026	39132026	NUM
dpc-6169	210	4	.	.	PUNCT
dpc-6169	211	1	6	6	NUM
dpc-6169	211	2	.	.	X
dpc-6169	211	3	sánchez	sánchez	NOUN
dpc-6169	211	4	-	-	PUNCT
dpc-6169	211	5	borges	borges	PROPN
dpc-6169	211	6	m	m	PROPN
dpc-6169	211	7	,	,	PUNCT
dpc-6169	211	8	díaz	díaz	PROPN
dpc-6169	211	9	sg	sg	PROPN
dpc-6169	211	10	,	,	PUNCT
dpc-6169	211	11	ortega	ortega	PROPN
dpc-6169	211	12	-	-	PUNCT
dpc-6169	211	13	martell	martell	PROPN
dpc-6169	211	14	ja	ja	PROPN
dpc-6169	211	15	,	,	PUNCT
dpc-6169	211	16	rojo	rojo	PROPN
dpc-6169	211	17	mi	mi	PROPN
dpc-6169	211	18	,	,	PUNCT
dpc-6169	211	19	ansotegui	ansotegui	NOUN
dpc-6169	211	20	ij	ij	NOUN
dpc-6169	211	21	.	.	PUNCT
dpc-6169	212	1	current	current	ADJ
dpc-6169	212	2	and	and	CCONJ
dpc-6169	212	3	potential	potential	ADJ
dpc-6169	212	4	biologic	biologic	NOUN
dpc-6169	212	5	drugs	drug	NOUN
dpc-6169	212	6	for	for	ADP
dpc-6169	212	7	the	the	DET
dpc-6169	212	8	treatment	treatment	NOUN
dpc-6169	212	9	of	of	ADP
dpc-6169	212	10	chronic	chronic	ADJ
dpc-6169	212	11	urticaria	urticaria	NOUN
dpc-6169	212	12	.	.	PUNCT
dpc-6169	213	1	immunol	immunol	PROPN
dpc-6169	213	2	allergy	allergy	PROPN
dpc-6169	213	3	clin	clin	PROPN
dpc-6169	213	4	north	north	PROPN
dpc-6169	213	5	am	am	PROPN
dpc-6169	213	6	.	.	PUNCT
dpc-6169	214	1	2020	2020	NUM
dpc-6169	214	2	nov;40(4):609	nov;40(4):609	NOUN
dpc-6169	214	3	-	-	PUNCT
dpc-6169	214	4	23	23	NUM
dpc-6169	214	5	.	.	PUNCT
dpc-6169	215	1	doi	doi	NOUN
dpc-6169	215	2	:	:	PUNCT
dpc-6169	215	3	10.1016	10.1016	NUM
dpc-6169	215	4	/	/	SYM
dpc-6169	215	5	j.iac.2020.06.005	j.iac.2020.06.005	VERB
dpc-6169	215	6	.	.	PUNCT
dpc-6169	216	1	pmid	pmid	NOUN
dpc-6169	216	2	:	:	PUNCT
dpc-6169	216	3	33012323	33012323	NUM
dpc-6169	216	4	.	.	PUNCT
dpc-6169	217	1	7	7	X
dpc-6169	217	2	.	.	X
dpc-6169	217	3	kaplan	kaplan	PROPN
dpc-6169	217	4	a	a	PROPN
dpc-6169	217	5	,	,	PUNCT
dpc-6169	217	6	ferrer	ferrer	PROPN
dpc-6169	217	7	m	m	PROPN
dpc-6169	217	8	,	,	PUNCT
dpc-6169	217	9	bernstein	bernstein	PROPN
dpc-6169	217	10	ja	ja	PROPN
dpc-6169	217	11	,	,	PUNCT
dpc-6169	217	12	et	et	PROPN
dpc-6169	217	13	al	al	PROPN
dpc-6169	217	14	.	.	PUNCT
dpc-6169	217	15	timing	timing	NOUN
dpc-6169	217	16	and	and	CCONJ
dpc-6169	217	17	duration	duration	NOUN
dpc-6169	217	18	of	of	ADP
dpc-6169	217	19	omalizumab	omalizumab	NOUN
dpc-6169	217	20	response	response	NOUN
dpc-6169	217	21	in	in	ADP
dpc-6169	217	22	patients	patient	NOUN
dpc-6169	217	23	with	with	ADP
dpc-6169	217	24	chronic	chronic	ADJ
dpc-6169	217	25	idiopathic	idiopathic	ADJ
dpc-6169	217	26	/	/	SYM
dpc-6169	217	27	spontaneous	spontaneous	ADJ
dpc-6169	217	28	urticaria	urticaria	NOUN
dpc-6169	217	29	.	.	PUNCT
dpc-6169	217	30	 	 	SPACE
dpc-6169	218	1	j	j	PROPN
dpc-6169	218	2	allergy	allergy	PROPN
dpc-6169	218	3	clin	clin	PROPN
dpc-6169	218	4	immunol	immunol	PROPN
dpc-6169	218	5	.	.	PUNCT
dpc-6169	218	6	 	 	SPACE
dpc-6169	219	1	2016;137(2):474	2016;137(2):474	NUM
dpc-6169	219	2	-	-	SYM
dpc-6169	219	3	81	81	NUM
dpc-6169	219	4	.	.	PUNCT
dpc-6169	220	1	doi	doi	NOUN
dpc-6169	220	2	:	:	PUNCT
dpc-6169	220	3	10.1016	10.1016	NUM
dpc-6169	220	4	/	/	SYM
dpc-6169	220	5	j.jaci.2015.08.023	j.jaci.2015.08.023	PROPN
dpc-6169	220	6	.	.	PUNCT
dpc-6169	221	1	pmid	pmid	NOUN
dpc-6169	221	2	:	:	PUNCT
dpc-6169	221	3	26483177	26483177	NUM
dpc-6169	221	4	.	.	PUNCT
dpc-6169	222	1	8	8	X
dpc-6169	222	2	.	.	X
dpc-6169	223	1	proença	proença	PROPN
dpc-6169	223	2	m	m	PROPN
dpc-6169	223	3	,	,	PUNCT
dpc-6169	223	4	marcelino	marcelino	PROPN
dpc-6169	223	5	j	j	PROPN
dpc-6169	223	6	,	,	PUNCT
dpc-6169	223	7	vieira	vieira	PROPN
dpc-6169	223	8	j	j	PROPN
dpc-6169	223	9	,	,	PUNCT
dpc-6169	223	10	guimares	guimare	VERB
dpc-6169	223	11	j	j	PROPN
dpc-6169	223	12	,	,	PUNCT
dpc-6169	223	13	dias	dias	PROPN
dpc-6169	223	14	c	c	PROPN
dpc-6169	223	15	,	,	PUNCT
dpc-6169	223	16	tomaz	tomaz	PROPN
dpc-6169	223	17	e.	e.	PROPN
dpc-6169	223	18	predictors	predictor	NOUN
dpc-6169	223	19	of	of	ADP
dpc-6169	223	20	treatment	treatment	NOUN
dpc-6169	223	21	control	control	NOUN
dpc-6169	223	22	in	in	ADP
dpc-6169	223	23	severe	severe	ADJ
dpc-6169	223	24	chronic	chronic	ADJ
dpc-6169	223	25	urticaria	urticaria	NOUN
dpc-6169	223	26	treated	treat	VERB
dpc-6169	223	27	with	with	ADP
dpc-6169	223	28	omalizumab	omalizumab	NOUN
dpc-6169	223	29	.	.	PUNCT
dpc-6169	224	1	asia	asia	PROPN
dpc-6169	224	2	pac	pac	PROPN
dpc-6169	224	3	allergy	allergy	PROPN
dpc-6169	224	4	.	.	PUNCT
dpc-6169	225	1	2025	2025	NUM
dpc-6169	225	2	sep;15(3):159	sep;15(3):159	PROPN
dpc-6169	225	3	-	-	PUNCT
dpc-6169	225	4	65	65	NUM
dpc-6169	225	5	.	.	PUNCT
dpc-6169	226	1	|	|	ADV
dpc-6169	226	2	doi	doi	NOUN
dpc-6169	226	3	:	:	PUNCT
dpc-6169	226	4	10.5415	10.5415	NUM
dpc-6169	226	5	/	/	SYM
dpc-6169	226	6	apallergy.0000000000000162	apallergy.0000000000000162	PROPN
dpc-6169	226	7	.	.	PUNCT
dpc-6169	227	1	pmid	pmid	PROPN
dpc-6169	227	2	:	:	PUNCT
dpc-6169	227	3	40933429	40933429	NUM
dpc-6169	227	4	.	.	PUNCT
dpc-6169	228	1	9	9	X
dpc-6169	228	2	.	.	X
dpc-6169	228	3	marzano	marzano	PROPN
dpc-6169	228	4	av	av	PROPN
dpc-6169	228	5	,	,	PUNCT
dpc-6169	228	6	genovese	genovese	NOUN
dpc-6169	228	7	g	g	NOUN
dpc-6169	228	8	,	,	PUNCT
dpc-6169	228	9	casazza	casazza	NOUN
dpc-6169	228	10	g	g	NOUN
dpc-6169	228	11	,	,	PUNCT
dpc-6169	228	12	et	et	PROPN
dpc-6169	228	13	al	al	PROPN
dpc-6169	228	14	.	.	PUNCT
dpc-6169	228	15	predictors	predictor	NOUN
dpc-6169	228	16	of	of	ADP
dpc-6169	228	17	response	response	NOUN
dpc-6169	228	18	to	to	ADP
dpc-6169	228	19	omalizumab	omalizumab	NOUN
dpc-6169	228	20	and	and	CCONJ
dpc-6169	228	21	relapse	relapse	VERB
dpc-6169	228	22	in	in	ADP
dpc-6169	228	23	chronic	chronic	ADJ
dpc-6169	228	24	spontaneous	spontaneous	ADJ
dpc-6169	228	25	urticaria	urticaria	NOUN
dpc-6169	228	26	:	:	PUNCT
dpc-6169	228	27	a	a	DET
dpc-6169	228	28	study	study	NOUN
dpc-6169	228	29	of	of	ADP
dpc-6169	228	30	470	470	NUM
dpc-6169	228	31	patients	patient	NOUN
dpc-6169	228	32	.	.	PUNCT
dpc-6169	228	33	  	  	SPACE
dpc-6169	229	1	j	j	PROPN
dpc-6169	229	2	eur	eur	PROPN
dpc-6169	229	3	acad	acad	PROPN
dpc-6169	229	4	dermatol	dermatol	NOUN
dpc-6169	229	5	venereol	venereol	NOUN
dpc-6169	229	6	.	.	PUNCT
dpc-6169	229	7	 	 	SPACE
dpc-6169	230	1	2019;33(5):918	2019;33(5):918	PROPN
dpc-6169	230	2	-	-	PUNCT
dpc-6169	230	3	24	24	NUM
dpc-6169	230	4	.	.	PUNCT
dpc-6169	230	5	doi	doi	NOUN
dpc-6169	230	6	:	:	PUNCT
dpc-6169	230	7	10.1111	10.1111	NUM
dpc-6169	230	8	/	/	SYM
dpc-6169	230	9	jdv.15350	jdv.15350	PROPN
dpc-6169	230	10	.	.	PUNCT
dpc-6169	231	1	pmid	pmid	NOUN
dpc-6169	231	2	:	:	PUNCT
dpc-6169	231	3	30451325	30451325	NUM
dpc-6169	231	4	.	.	PUNCT
dpc-6169	232	1	10	10	NUM
dpc-6169	232	2	.	.	X
dpc-6169	232	3	di	di	PROPN
dpc-6169	232	4	bona	bona	PROPN
dpc-6169	232	5	d	d	PROPN
dpc-6169	232	6	,	,	PUNCT
dpc-6169	232	7	fiorino	fiorino	PROPN
dpc-6169	232	8	i	i	PROPN
dpc-6169	232	9	,	,	PUNCT
dpc-6169	232	10	taurino	taurino	PROPN
dpc-6169	232	11	m	m	PROPN
dpc-6169	232	12	,	,	PUNCT
dpc-6169	232	13	et	et	PROPN
dpc-6169	232	14	al	al	PROPN
dpc-6169	232	15	.	.	PUNCT
dpc-6169	233	1	long	long	ADJ
dpc-6169	233	2	-	-	PUNCT
dpc-6169	233	3	term	term	NOUN
dpc-6169	233	4	“	"	PUNCT
dpc-6169	233	5	real	real	ADJ
dpc-6169	233	6	-	-	PUNCT
dpc-6169	233	7	life	life	NOUN
dpc-6169	233	8	”	"	PUNCT
dpc-6169	233	9	safety	safety	NOUN
dpc-6169	233	10	of	of	ADP
dpc-6169	233	11	omalizumab	omalizumab	NOUN
dpc-6169	233	12	in	in	ADP
dpc-6169	233	13	patients	patient	NOUN
dpc-6169	233	14	with	with	ADP
dpc-6169	233	15	severe	severe	ADJ
dpc-6169	233	16	uncontrolled	uncontrolled	ADJ
dpc-6169	233	17	asthma	asthma	NOUN
dpc-6169	233	18	:	:	PUNCT
dpc-6169	233	19	a	a	DET
dpc-6169	233	20	nine	nine	NUM
dpc-6169	233	21	-	-	PUNCT
dpc-6169	233	22	year	year	NOUN
dpc-6169	233	23	study	study	NOUN
dpc-6169	233	24	.	.	PUNCT
dpc-6169	234	1	respir	respir	VERB
dpc-6169	234	2	med	med	ADJ
dpc-6169	234	3	.	.	PUNCT
dpc-6169	235	1	2017;130:55	2017;130:55	NUM
dpc-6169	235	2	-	-	SYM
dpc-6169	235	3	60	60	NUM
dpc-6169	235	4	.	.	PUNCT
dpc-6169	236	1	doi	doi	NOUN
dpc-6169	236	2	:	:	PUNCT
dpc-6169	236	3	10.1016	10.1016	NUM
dpc-6169	236	4	/	/	SYM
dpc-6169	236	5	j.rmed.2017.07.013	j.rmed.2017.07.013	PROPN
dpc-6169	236	6	.	.	PUNCT
dpc-6169	237	1	pmid	pmid	NOUN
dpc-6169	237	2	:	:	PUNCT
dpc-6169	237	3	29206634	29206634	NUM
dpc-6169	237	4	.	.	PUNCT
dpc-6169	238	1	11	11	NUM
dpc-6169	238	2	.	.	X
dpc-6169	238	3	sirufo	sirufo	PROPN
dpc-6169	238	4	mm	mm	PROPN
dpc-6169	238	5	,	,	PUNCT
dpc-6169	238	6	bassino	bassino	VERB
dpc-6169	238	7	em	em	PRON
dpc-6169	238	8	,	,	PUNCT
dpc-6169	238	9	de	de	PROPN
dpc-6169	238	10	pietro	pietro	PROPN
dpc-6169	238	11	f	f	PROPN
dpc-6169	238	12	,	,	PUNCT
dpc-6169	238	13	ginaldi	ginaldi	PROPN
dpc-6169	238	14	l	l	PROPN
dpc-6169	238	15	,	,	PUNCT
dpc-6169	238	16	de	de	PROPN
dpc-6169	238	17	martinis	martinis	PROPN
dpc-6169	238	18	m.	m.	NOUN
dpc-6169	238	19	sex	sex	NOUN
dpc-6169	238	20	differences	difference	NOUN
dpc-6169	238	21	in	in	ADP
dpc-6169	238	22	the	the	DET
dpc-6169	238	23	efficacy	efficacy	NOUN
dpc-6169	238	24	of	of	ADP
dpc-6169	238	25	omalizumab	omalizumab	NOUN
dpc-6169	238	26	in	in	ADP
dpc-6169	238	27	the	the	DET
dpc-6169	238	28	treatment	treatment	NOUN
dpc-6169	238	29	of	of	ADP
dpc-6169	238	30	chronic	chronic	ADJ
dpc-6169	238	31	spontaneous	spontaneous	ADJ
dpc-6169	238	32	urticaria	urticaria	NOUN
dpc-6169	238	33	.	.	PUNCT
dpc-6169	239	1	int	int	PROPN
dpc-6169	239	2	j	j	PROPN
dpc-6169	239	3	immunopathol	immunopathol	PROPN
dpc-6169	239	4	pharmacol	pharmacol	PROPN
dpc-6169	239	5	.	.	PUNCT
dpc-6169	240	1	2021;35:20587384211065870	2021;35:20587384211065870	X
dpc-6169	240	2	.	.	PUNCT
dpc-6169	240	3	doi	doi	NOUN
dpc-6169	240	4	:	:	PUNCT
dpc-6169	240	5	10.1177/20587384211065870	10.1177/20587384211065870	NUM
dpc-6169	240	6	.	.	PUNCT
dpc-6169	241	1	pmid	pmid	NOUN
dpc-6169	241	2	:	:	PUNCT
dpc-6169	241	3	35170369	35170369	NUM
dpc-6169	241	4	.	.	PUNCT
dpc-6169	242	1	12	12	NUM
dpc-6169	242	2	.	.	PUNCT
dpc-6169	243	1	özyılmaz	özyılmaz	NOUN
dpc-6169	243	2	-	-	PUNCT
dpc-6169	243	3	bozat	bozat	NOUN
dpc-6169	243	4	g	g	NOUN
dpc-6169	243	5	,	,	PUNCT
dpc-6169	243	6	şahiner	şahiner	NOUN
dpc-6169	243	7	üm	üm	NOUN
dpc-6169	243	8	,	,	PUNCT
dpc-6169	243	9	buyuktiryaki	buyuktiryaki	VERB
dpc-6169	243	10	b	b	NUM
dpc-6169	243	11	,	,	PUNCT
dpc-6169	243	12	uysal	uysal	ADJ
dpc-6169	243	13	-	-	PUNCT
dpc-6169	243	14	soyer	soyer	NOUN
dpc-6169	243	15	ö	ö	PROPN
dpc-6169	243	16	,	,	PUNCT
dpc-6169	243	17	şekerel	şekerel	NOUN
dpc-6169	243	18	be	be	VERB
dpc-6169	243	19	.	.	PUNCT
dpc-6169	244	1	children	child	NOUN
dpc-6169	244	2	with	with	ADP
dpc-6169	244	3	chronic	chronic	ADJ
dpc-6169	244	4	spontaneous	spontaneous	ADJ
dpc-6169	244	5	urticaria	urticaria	NOUN
dpc-6169	244	6	:	:	PUNCT
dpc-6169	244	7	recurrence	recurrence	NOUN
dpc-6169	244	8	patients	patient	NOUN
dpc-6169	244	9	with	with	ADP
dpc-6169	244	10	lower	low	ADJ
dpc-6169	244	11	baseline	baseline	PROPN
dpc-6169	244	12	uas7	uas7	PROPN
dpc-6169	244	13	scores	score	NOUN
dpc-6169	244	14	were	be	AUX
dpc-6169	244	15	significantly	significantly	ADV
dpc-6169	244	16	more	more	ADV
dpc-6169	244	17	likely	likely	ADJ
dpc-6169	244	18	to	to	PART
dpc-6169	244	19	achieve	achieve	VERB
dpc-6169	244	20	early	early	ADJ
dpc-6169	244	21	response	response	NOUN
dpc-6169	244	22	to	to	ADP
dpc-6169	244	23	omalizumab	omalizumab	NOUN
dpc-6169	244	24	(	(	PUNCT
dpc-6169	244	25	median	median	ADJ
dpc-6169	244	26	uas7	uas7	PROPN
dpc-6169	244	27	28	28	NUM
dpc-6169	244	28	vs.	vs.	ADP
dpc-6169	244	29	35	35	NUM
dpc-6169	244	30	,	,	PUNCT
dpc-6169	244	31	p<0.01	p<0.01	PROPN
dpc-6169	244	32	)	)	PUNCT
dpc-6169	244	33	,	,	PUNCT
dpc-6169	244	34	highlighting	highlight	VERB
dpc-6169	244	35	the	the	DET
dpc-6169	244	36	relevance	relevance	NOUN
dpc-6169	244	37	of	of	ADP
dpc-6169	244	38	initial	initial	ADJ
dpc-6169	244	39	disease	disease	NOUN
dpc-6169	244	40	severity	severity	NOUN
dpc-6169	244	41	in	in	ADP
dpc-6169	244	42	predicting	predict	VERB
dpc-6169	244	43	treatment	treatment	NOUN
dpc-6169	244	44	success	success	NOUN
dpc-6169	244	45	.	.	PUNCT
dpc-6169	245	1	similarly	similarly	ADV
dpc-6169	245	2	,	,	PUNCT
dpc-6169	245	3	cubiro	cubiro	PRON
dpc-6169	245	4	et	et	VERB
dpc-6169	245	5	al	al	PROPN
dpc-6169	245	6	.	.	PUNCT
dpc-6169	246	1	[	[	X
dpc-6169	246	2	18	18	NUM
dpc-6169	246	3	]	]	PUNCT
dpc-6169	246	4	reported	report	VERB
dpc-6169	246	5	that	that	SCONJ
dpc-6169	246	6	patients	patient	NOUN
dpc-6169	246	7	with	with	ADP
dpc-6169	246	8	shorter	short	ADJ
dpc-6169	246	9	disease	disease	NOUN
dpc-6169	246	10	duration	duration	NOUN
dpc-6169	246	11	exhibited	exhibit	VERB
dpc-6169	246	12	better	well	ADJ
dpc-6169	246	13	symptom	symptom	NOUN
dpc-6169	246	14	control	control	NOUN
dpc-6169	246	15	at	at	ADP
dpc-6169	246	16	12	12	NUM
dpc-6169	246	17	weeks	week	NOUN
dpc-6169	246	18	,	,	PUNCT
dpc-6169	246	19	suggesting	suggest	VERB
dpc-6169	246	20	that	that	SCONJ
dpc-6169	246	21	early	early	ADJ
dpc-6169	246	22	intervention	intervention	NOUN
dpc-6169	246	23	may	may	AUX
dpc-6169	246	24	enhance	enhance	VERB
dpc-6169	246	25	therapeutic	therapeutic	ADJ
dpc-6169	246	26	outcomes	outcome	NOUN
dpc-6169	246	27	.	.	PUNCT
dpc-6169	247	1	in	in	ADP
dpc-6169	247	2	a	a	DET
dpc-6169	247	3	korean	korean	ADJ
dpc-6169	247	4	cohort	cohort	NOUN
dpc-6169	247	5	,	,	PUNCT
dpc-6169	247	6	kim	kim	PROPN
dpc-6169	247	7	et	et	PROPN
dpc-6169	247	8	al	al	PROPN
dpc-6169	247	9	.	.	PUNCT
dpc-6169	248	1	[	[	X
dpc-6169	248	2	19	19	NUM
dpc-6169	248	3	]	]	PUNCT
dpc-6169	248	4	further	far	ADV
dpc-6169	248	5	confirmed	confirm	VERB
dpc-6169	248	6	that	that	SCONJ
dpc-6169	248	7	shorter	short	ADJ
dpc-6169	248	8	disease	disease	NOUN
dpc-6169	248	9	duration	duration	NOUN
dpc-6169	248	10	was	be	AUX
dpc-6169	248	11	independently	independently	ADV
dpc-6169	248	12	associated	associate	VERB
dpc-6169	248	13	with	with	ADP
dpc-6169	248	14	achieving	achieve	VERB
dpc-6169	248	15	disease	disease	NOUN
dpc-6169	248	16	control	control	NOUN
dpc-6169	248	17	at	at	ADP
dpc-6169	248	18	three	three	NUM
dpc-6169	248	19	months	month	NOUN
dpc-6169	248	20	.	.	PUNCT
dpc-6169	249	1	however	however	ADV
dpc-6169	249	2	,	,	PUNCT
dpc-6169	249	3	the	the	DET
dpc-6169	249	4	literature	literature	NOUN
dpc-6169	249	5	also	also	ADV
dpc-6169	249	6	reflects	reflect	VERB
dpc-6169	249	7	some	some	DET
dpc-6169	249	8	inconsistency	inconsistency	NOUN
dpc-6169	249	9	.	.	PUNCT
dpc-6169	250	1	in	in	ADP
dpc-6169	250	2	contrast	contrast	NOUN
dpc-6169	250	3	to	to	ADP
dpc-6169	250	4	our	our	PRON
dpc-6169	250	5	findings	finding	NOUN
dpc-6169	250	6	,	,	PUNCT
dpc-6169	250	7	tonacci	tonacci	NOUN
dpc-6169	250	8	et	et	PROPN
dpc-6169	250	9	al	al	PROPN
dpc-6169	250	10	.	.	PUNCT
dpc-6169	251	1	[	[	X
dpc-6169	251	2	20	20	NUM
dpc-6169	251	3	]	]	PUNCT
dpc-6169	251	4	and	and	CCONJ
dpc-6169	251	5	cubiro	cubiro	PRON
dpc-6169	251	6	et	et	VERB
dpc-6169	251	7	al	al	PROPN
dpc-6169	251	8	.	.	PUNCT
dpc-6169	252	1	[	[	X
dpc-6169	252	2	18	18	NUM
dpc-6169	252	3	]	]	PUNCT
dpc-6169	252	4	reported	report	VERB
dpc-6169	252	5	that	that	SCONJ
dpc-6169	252	6	baseline	baseline	NOUN
dpc-6169	252	7	disease	disease	NOUN
dpc-6169	252	8	severity	severity	NOUN
dpc-6169	252	9	did	do	AUX
dpc-6169	252	10	not	not	PART
dpc-6169	252	11	significantly	significantly	ADV
dpc-6169	252	12	influence	influence	VERB
dpc-6169	252	13	response	response	NOUN
dpc-6169	252	14	rates	rate	NOUN
dpc-6169	252	15	.	.	PUNCT
dpc-6169	253	1	moreover	moreover	ADV
dpc-6169	253	2	,	,	PUNCT
dpc-6169	253	3	marzano	marzano	PROPN
dpc-6169	253	4	et	et	PROPN
dpc-6169	253	5	al	al	PROPN
dpc-6169	253	6	.	.	PUNCT
dpc-6169	254	1	[	[	X
dpc-6169	254	2	9	9	NUM
dpc-6169	254	3	]	]	PUNCT
dpc-6169	254	4	observed	observe	VERB
dpc-6169	254	5	that	that	SCONJ
dpc-6169	254	6	while	while	SCONJ
dpc-6169	254	7	disease	disease	NOUN
dpc-6169	254	8	duration	duration	NOUN
dpc-6169	254	9	did	do	AUX
dpc-6169	254	10	not	not	PART
dpc-6169	254	11	predict	predict	VERB
dpc-6169	254	12	initial	initial	ADJ
dpc-6169	254	13	response	response	NOUN
dpc-6169	254	14	to	to	ADP
dpc-6169	254	15	omalizumab	omalizumab	NOUN
dpc-6169	254	16	,	,	PUNCT
dpc-6169	254	17	longer	long	ADV
dpc-6169	254	18	pre	pre	ADJ
dpc-6169	254	19	-	-	ADJ
dpc-6169	254	20	treatment	treatment	ADJ
dpc-6169	254	21	disease	disease	NOUN
dpc-6169	254	22	duration	duration	NOUN
dpc-6169	254	23	was	be	AUX
dpc-6169	254	24	associated	associate	VERB
dpc-6169	254	25	with	with	ADP
dpc-6169	254	26	a	a	DET
dpc-6169	254	27	higher	high	ADJ
dpc-6169	254	28	risk	risk	NOUN
dpc-6169	254	29	of	of	ADP
dpc-6169	254	30	symptom	symptom	NOUN
dpc-6169	254	31	relapse	relapse	NOUN
dpc-6169	254	32	after	after	ADP
dpc-6169	254	33	therapy	therapy	NOUN
dpc-6169	254	34	discontinuation	discontinuation	NOUN
dpc-6169	254	35	.	.	PUNCT
dpc-6169	255	1	both	both	DET
dpc-6169	255	2	baseline	baseline	ADJ
dpc-6169	255	3	disease	disease	NOUN
dpc-6169	255	4	severity	severity	NOUN
dpc-6169	255	5	(	(	PUNCT
dpc-6169	255	6	uas7	uas7	PROPN
dpc-6169	255	7	)	)	PUNCT
dpc-6169	255	8	and	and	CCONJ
dpc-6169	255	9	chronicity	chronicity	NOUN
dpc-6169	255	10	(	(	PUNCT
dpc-6169	255	11	duration	duration	NOUN
dpc-6169	255	12	in	in	ADP
dpc-6169	255	13	months	month	NOUN
dpc-6169	255	14	)	)	PUNCT
dpc-6169	255	15	showed	show	VERB
dpc-6169	255	16	strong	strong	ADJ
dpc-6169	255	17	discriminatory	discriminatory	ADJ
dpc-6169	255	18	ability	ability	NOUN
dpc-6169	255	19	in	in	ADP
dpc-6169	255	20	predicting	predict	VERB
dpc-6169	255	21	early	early	ADJ
dpc-6169	255	22	response	response	NOUN
dpc-6169	255	23	to	to	ADP
dpc-6169	255	24	omalizumab	omalizumab	NOUN
dpc-6169	255	25	.	.	PUNCT
dpc-6169	256	1	roc	roc	NOUN
dpc-6169	256	2	analysis	analysis	NOUN
dpc-6169	256	3	revealed	reveal	VERB
dpc-6169	256	4	inverted	inverted	ADJ
dpc-6169	256	5	auc	auc	NOUN
dpc-6169	256	6	values	value	NOUN
dpc-6169	256	7	of	of	ADP
dpc-6169	256	8	0.917	0.917	NUM
dpc-6169	256	9	and	and	CCONJ
dpc-6169	256	10	0.940	0.940	NUM
dpc-6169	256	11	,	,	PUNCT
dpc-6169	256	12	respectively	respectively	ADV
dpc-6169	256	13	,	,	PUNCT
dpc-6169	256	14	for	for	ADP
dpc-6169	256	15	baseline	baseline	NOUN
dpc-6169	256	16	uas7	uas7	NOUN
dpc-6169	256	17	and	and	CCONJ
dpc-6169	256	18	disease	disease	NOUN
dpc-6169	256	19	duration	duration	NOUN
dpc-6169	256	20	.	.	PUNCT
dpc-6169	257	1	these	these	DET
dpc-6169	257	2	findings	finding	NOUN
dpc-6169	257	3	suggest	suggest	VERB
dpc-6169	257	4	that	that	SCONJ
dpc-6169	257	5	initiating	initiate	VERB
dpc-6169	257	6	omalizumab	omalizumab	NOUN
dpc-6169	257	7	in	in	ADP
dpc-6169	257	8	the	the	DET
dpc-6169	257	9	earlier	early	ADJ
dpc-6169	257	10	phases	phase	NOUN
dpc-6169	257	11	of	of	ADP
dpc-6169	257	12	csu	csu	PROPN
dpc-6169	257	13	and	and	CCONJ
dpc-6169	257	14	in	in	ADP
dpc-6169	257	15	patients	patient	NOUN
dpc-6169	257	16	with	with	ADP
dpc-6169	257	17	lower	low	ADJ
dpc-6169	257	18	symptom	symptom	NOUN
dpc-6169	257	19	burden	burden	NOUN
dpc-6169	257	20	may	may	AUX
dpc-6169	257	21	substantially	substantially	ADV
dpc-6169	257	22	increase	increase	VERB
dpc-6169	257	23	the	the	DET
dpc-6169	257	24	probability	probability	NOUN
dpc-6169	257	25	of	of	ADP
dpc-6169	257	26	achieving	achieve	VERB
dpc-6169	257	27	early	early	ADJ
dpc-6169	257	28	disease	disease	NOUN
dpc-6169	257	29	control	control	NOUN
dpc-6169	257	30	.	.	PUNCT
dpc-6169	258	1	taken	take	VERB
dpc-6169	258	2	together	together	ADV
dpc-6169	258	3	,	,	PUNCT
dpc-6169	258	4	our	our	PRON
dpc-6169	258	5	findings	finding	NOUN
dpc-6169	258	6	suggest	suggest	VERB
dpc-6169	258	7	that	that	SCONJ
dpc-6169	258	8	early	early	ADJ
dpc-6169	258	9	identification	identification	NOUN
dpc-6169	258	10	of	of	ADP
dpc-6169	258	11	patients	patient	NOUN
dpc-6169	258	12	with	with	ADP
dpc-6169	258	13	favorable	favorable	ADJ
dpc-6169	258	14	baseline	baseline	NOUN
dpc-6169	258	15	characteristics	characteristic	NOUN
dpc-6169	258	16	,	,	PUNCT
dpc-6169	258	17	such	such	ADJ
dpc-6169	258	18	as	as	ADP
dpc-6169	258	19	lower	low	ADJ
dpc-6169	258	20	disease	disease	NOUN
dpc-6169	258	21	activity	activity	NOUN
dpc-6169	258	22	and	and	CCONJ
dpc-6169	258	23	shorter	short	ADJ
dpc-6169	258	24	duration	duration	NOUN
dpc-6169	258	25	of	of	ADP
dpc-6169	258	26	symptoms	symptom	NOUN
dpc-6169	258	27	,	,	PUNCT
dpc-6169	258	28	may	may	AUX
dpc-6169	258	29	allow	allow	VERB
dpc-6169	258	30	for	for	ADP
dpc-6169	258	31	a	a	DET
dpc-6169	258	32	more	more	ADV
dpc-6169	258	33	tailored	tailor	VERB
dpc-6169	258	34	approach	approach	NOUN
dpc-6169	258	35	to	to	ADP
dpc-6169	258	36	omalizumab	omalizumab	NOUN
dpc-6169	258	37	therapy	therapy	NOUN
dpc-6169	258	38	in	in	ADP
dpc-6169	258	39	csu	csu	PROPN
dpc-6169	258	40	.	.	PUNCT
dpc-6169	259	1	while	while	SCONJ
dpc-6169	259	2	sex	sex	NOUN
dpc-6169	259	3	and	and	CCONJ
dpc-6169	259	4	age	age	NOUN
dpc-6169	259	5	did	do	AUX
dpc-6169	259	6	not	not	PART
dpc-6169	259	7	independently	independently	ADV
dpc-6169	259	8	predict	predict	VERB
dpc-6169	259	9	initial	initial	ADJ
dpc-6169	259	10	response	response	NOUN
dpc-6169	259	11	,	,	PUNCT
dpc-6169	259	12	their	their	PRON
dpc-6169	259	13	influence	influence	NOUN
dpc-6169	259	14	on	on	ADP
dpc-6169	259	15	relapse	relapse	NOUN
dpc-6169	259	16	risk	risk	NOUN
dpc-6169	259	17	,	,	PUNCT
dpc-6169	259	18	particularly	particularly	ADV
dpc-6169	259	19	the	the	DET
dpc-6169	259	20	higher	high	ADJ
dpc-6169	259	21	recurrence	recurrence	NOUN
dpc-6169	259	22	observed	observe	VERB
dpc-6169	259	23	in	in	ADP
dpc-6169	259	24	older	old	ADJ
dpc-6169	259	25	and	and	CCONJ
dpc-6169	259	26	in	in	ADP
dpc-6169	259	27	male	male	ADJ
dpc-6169	259	28	patients	patient	NOUN
dpc-6169	259	29	,	,	PUNCT
dpc-6169	259	30	highlights	highlight	VERB
dpc-6169	259	31	the	the	DET
dpc-6169	259	32	importance	importance	NOUN
dpc-6169	259	33	of	of	ADP
dpc-6169	259	34	individualized	individualized	ADJ
dpc-6169	259	35	follow	follow	NOUN
dpc-6169	259	36	-	-	PUNCT
dpc-6169	259	37	up	up	NOUN
dpc-6169	259	38	and	and	CCONJ
dpc-6169	259	39	treatment	treatment	NOUN
dpc-6169	259	40	continuation	continuation	NOUN
dpc-6169	259	41	decisions	decision	NOUN
dpc-6169	259	42	.	.	PUNCT
dpc-6169	260	1	integrating	integrate	VERB
dpc-6169	260	2	simple	simple	ADJ
dpc-6169	260	3	clinical	clinical	ADJ
dpc-6169	260	4	parameters	parameter	NOUN
dpc-6169	260	5	like	like	ADP
dpc-6169	260	6	baseline	baseline	VERB
dpc-6169	260	7	uas7	uas7	NOUN
dpc-6169	260	8	and	and	CCONJ
dpc-6169	260	9	disease	disease	NOUN
dpc-6169	260	10	duration	duration	NOUN
dpc-6169	260	11	into	into	ADP
dpc-6169	260	12	treatment	treatment	NOUN
dpc-6169	260	13	planning	planning	NOUN
dpc-6169	260	14	may	may	AUX
dpc-6169	260	15	help	help	VERB
dpc-6169	260	16	clinicians	clinician	NOUN
dpc-6169	260	17	better	well	ADV
dpc-6169	260	18	predict	predict	VERB
dpc-6169	260	19	treatment	treatment	NOUN
dpc-6169	260	20	trajectory	trajectory	NOUN
dpc-6169	260	21	and	and	CCONJ
dpc-6169	260	22	optimize	optimize	VERB
dpc-6169	260	23	outcomes	outcome	NOUN
dpc-6169	260	24	for	for	ADP
dpc-6169	260	25	csu	csu	NOUN
dpc-6169	260	26	patients	patient	NOUN
dpc-6169	260	27	receiving	receive	VERB
dpc-6169	260	28	omalizumab	omalizumab	NOUN
dpc-6169	260	29	.	.	PUNCT
dpc-6169	261	1	while	while	SCONJ
dpc-6169	261	2	our	our	PRON
dpc-6169	261	3	study	study	NOUN
dpc-6169	261	4	provides	provide	VERB
dpc-6169	261	5	clinically	clinically	ADV
dpc-6169	261	6	relevant	relevant	ADJ
dpc-6169	261	7	insights	insight	NOUN
dpc-6169	261	8	,	,	PUNCT
dpc-6169	261	9	several	several	ADJ
dpc-6169	261	10	limitations	limitation	NOUN
dpc-6169	261	11	should	should	AUX
dpc-6169	261	12	be	be	AUX
dpc-6169	261	13	acknowledged	acknowledge	VERB
dpc-6169	261	14	.	.	PUNCT
dpc-6169	262	1	as	as	ADP
dpc-6169	262	2	a	a	DET
dpc-6169	262	3	single	single	ADJ
dpc-6169	262	4	-	-	PUNCT
dpc-6169	262	5	center	center	NOUN
dpc-6169	262	6	retrospective	retrospective	ADJ
dpc-6169	262	7	study	study	NOUN
dpc-6169	262	8	,	,	PUNCT
dpc-6169	262	9	generalizability	generalizability	NOUN
dpc-6169	262	10	may	may	AUX
dpc-6169	262	11	be	be	AUX
dpc-6169	262	12	limited	limit	VERB
dpc-6169	262	13	,	,	PUNCT
dpc-6169	262	14	and	and	CCONJ
dpc-6169	262	15	certain	certain	ADJ
dpc-6169	262	16	laboratory	laboratory	NOUN
dpc-6169	262	17	biomarkers	biomarker	NOUN
dpc-6169	262	18	such	such	ADJ
dpc-6169	262	19	as	as	ADP
dpc-6169	262	20	total	total	ADJ
dpc-6169	262	21	ige	ige	NOUN
dpc-6169	262	22	or	or	CCONJ
dpc-6169	262	23	autologous	autologous	ADJ
dpc-6169	262	24	serum	serum	NOUN
dpc-6169	262	25	test	test	NOUN
dpc-6169	262	26	results	result	NOUN
dpc-6169	262	27	were	be	AUX
dpc-6169	262	28	not	not	PART
dpc-6169	262	29	available	available	ADJ
dpc-6169	262	30	for	for	ADP
dpc-6169	262	31	correlation	correlation	NOUN
dpc-6169	262	32	.	.	PUNCT
dpc-6169	263	1	relapse	relapse	NOUN
dpc-6169	263	2	assessments	assessment	NOUN
dpc-6169	263	3	were	be	AUX
dpc-6169	263	4	based	base	VERB
dpc-6169	263	5	on	on	ADP
dpc-6169	263	6	clinical	clinical	ADJ
dpc-6169	263	7	follow	follow	NOUN
dpc-6169	263	8	-	-	PUNCT
dpc-6169	263	9	up	up	NOUN
dpc-6169	263	10	without	without	ADP
dpc-6169	263	11	standardized	standardized	ADJ
dpc-6169	263	12	timing	timing	NOUN
dpc-6169	263	13	,	,	PUNCT
dpc-6169	263	14	which	which	PRON
dpc-6169	263	15	may	may	AUX
dpc-6169	263	16	underestimate	underestimate	VERB
dpc-6169	263	17	late	late	ADJ
dpc-6169	263	18	recurrences	recurrence	NOUN
dpc-6169	263	19	.	.	PUNCT
dpc-6169	264	1	despite	despite	SCONJ
dpc-6169	264	2	these	these	DET
dpc-6169	264	3	limitations	limitation	NOUN
dpc-6169	264	4	,	,	PUNCT
dpc-6169	264	5	our	our	PRON
dpc-6169	264	6	findings	finding	NOUN
dpc-6169	264	7	reinforce	reinforce	VERB
dpc-6169	264	8	the	the	DET
dpc-6169	264	9	importance	importance	NOUN
dpc-6169	264	10	of	of	ADP
dpc-6169	264	11	baseline	baseline	NOUN
dpc-6169	264	12	disease	disease	NOUN
dpc-6169	264	13	severity	severity	NOUN
dpc-6169	264	14	and	and	CCONJ
dpc-6169	264	15	duration	duration	NOUN
dpc-6169	264	16	as	as	ADP
dpc-6169	264	17	strong	strong	ADJ
dpc-6169	264	18	predictors	predictor	NOUN
dpc-6169	264	19	of	of	ADP
dpc-6169	264	20	early	early	ADJ
dpc-6169	264	21	omalizumab	omalizumab	NOUN
dpc-6169	264	22	response	response	NOUN
dpc-6169	264	23	.	.	PUNCT
dpc-6169	265	1	additionally	additionally	ADV
dpc-6169	265	2	,	,	PUNCT
dpc-6169	265	3	the	the	DET
dpc-6169	265	4	observed	observed	ADJ
dpc-6169	265	5	associations	association	NOUN
dpc-6169	265	6	between	between	ADP
dpc-6169	265	7	younger	young	ADJ
dpc-6169	265	8	age	age	NOUN
dpc-6169	265	9	,	,	PUNCT
dpc-6169	265	10	female	female	ADJ
dpc-6169	265	11	sex	sex	NOUN
dpc-6169	265	12	,	,	PUNCT
dpc-6169	265	13	and	and	CCONJ
dpc-6169	265	14	reduced	reduce	VERB
dpc-6169	265	15	relapse	relapse	NOUN
dpc-6169	265	16	original	original	ADJ
dpc-6169	265	17	article	article	NOUN
dpc-6169	265	18	|	|	ADV
dpc-6169	265	19	dermatol	dermatol	ADJ
dpc-6169	265	20	pract	pract	NOUN
dpc-6169	265	21	concept	concept	NOUN
dpc-6169	265	22	.	.	PUNCT
dpc-6169	266	1	2025;15(4):6169	2025;15(4):6169	NUM
dpc-6169	266	2	7	7	NUM
dpc-6169	266	3	17	17	NUM
dpc-6169	266	4	.	.	PUNCT
dpc-6169	267	1	ghazanfar	ghazanfar	PROPN
dpc-6169	267	2	mn	mn	PROPN
dpc-6169	267	3	,	,	PUNCT
dpc-6169	267	4	sand	sand	NOUN
dpc-6169	267	5	c	c	NOUN
dpc-6169	267	6	,	,	PUNCT
dpc-6169	267	7	thomsen	thomsen	PROPN
dpc-6169	267	8	sf	sf	PROPN
dpc-6169	267	9	.	.	PROPN
dpc-6169	267	10	effectiveness	effectiveness	NOUN
dpc-6169	267	11	and	and	CCONJ
dpc-6169	267	12	safety	safety	NOUN
dpc-6169	267	13	of	of	ADP
dpc-6169	267	14	omalizumab	omalizumab	NOUN
dpc-6169	267	15	in	in	ADP
dpc-6169	267	16	chronic	chronic	ADJ
dpc-6169	267	17	spontaneous	spontaneous	ADJ
dpc-6169	267	18	or	or	CCONJ
dpc-6169	267	19	inducible	inducible	ADJ
dpc-6169	267	20	urticaria	urticaria	NOUN
dpc-6169	267	21	:	:	PUNCT
dpc-6169	267	22	evaluation	evaluation	NOUN
dpc-6169	267	23	of	of	ADP
dpc-6169	267	24	154	154	NUM
dpc-6169	267	25	patients	patient	NOUN
dpc-6169	267	26	.	.	PUNCT
dpc-6169	268	1	br	br	PROPN
dpc-6169	268	2	j	j	PROPN
dpc-6169	268	3	dermatol	dermatol	NOUN
dpc-6169	268	4	.	.	PUNCT
dpc-6169	269	1	2016;175(2):404	2016;175(2):404	NUM
dpc-6169	269	2	-	-	SYM
dpc-6169	269	3	6	6	NUM
dpc-6169	269	4	.	.	PUNCT
dpc-6169	269	5	doi	doi	NOUN
dpc-6169	269	6	:	:	PUNCT
dpc-6169	269	7	10.1111	10.1111	NUM
dpc-6169	269	8	/	/	SYM
dpc-6169	269	9	bjd.14540	bjd.14540	PROPN
dpc-6169	269	10	.	.	PUNCT
dpc-6169	270	1	pmid	pmid	NOUN
dpc-6169	270	2	:	:	PUNCT
dpc-6169	270	3	26972689	26972689	NUM
dpc-6169	270	4	.	.	PUNCT
dpc-6169	271	1	18	18	NUM
dpc-6169	271	2	.	.	PUNCT
dpc-6169	272	1	cubiró	cubiró	PROPN
dpc-6169	272	2	x	x	PROPN
dpc-6169	272	3	,	,	PUNCT
dpc-6169	272	4	spertino	spertino	PROPN
dpc-6169	272	5	j	j	PROPN
dpc-6169	272	6	,	,	PUNCT
dpc-6169	272	7	rozas	rozas	PROPN
dpc-6169	272	8	-	-	PUNCT
dpc-6169	272	9	muñoz	muñoz	PROPN
dpc-6169	272	10	e	e	PROPN
dpc-6169	272	11	,	,	PUNCT
dpc-6169	272	12	serra	serra	NOUN
dpc-6169	272	13	-	-	PUNCT
dpc-6169	272	14	baldrich	baldrich	NOUN
dpc-6169	272	15	e	e	NOUN
dpc-6169	272	16	,	,	PUNCT
dpc-6169	272	17	puig	puig	PROPN
dpc-6169	272	18	l.	l.	PROPN
dpc-6169	272	19	the	the	DET
dpc-6169	272	20	effectiveness	effectiveness	NOUN
dpc-6169	272	21	of	of	ADP
dpc-6169	272	22	omalizumab	omalizumab	NOUN
dpc-6169	272	23	treatment	treatment	NOUN
dpc-6169	272	24	in	in	ADP
dpc-6169	272	25	real	real	ADJ
dpc-6169	272	26	-	-	PUNCT
dpc-6169	272	27	life	life	NOUN
dpc-6169	272	28	is	be	AUX
dpc-6169	272	29	lower	low	ADJ
dpc-6169	272	30	in	in	ADP
dpc-6169	272	31	patients	patient	NOUN
dpc-6169	272	32	with	with	ADP
dpc-6169	272	33	chronic	chronic	ADJ
dpc-6169	272	34	urticaria	urticaria	NOUN
dpc-6169	272	35	longer	long	ADV
dpc-6169	272	36	than	than	ADP
dpc-6169	272	37	18	18	NUM
dpc-6169	272	38	months	month	NOUN
dpc-6169	272	39	’	'	PUNCT
dpc-6169	272	40	evolution	evolution	NOUN
dpc-6169	272	41	and	and	CCONJ
dpc-6169	272	42	prior	prior	ADJ
dpc-6169	272	43	immunosuppressive	immunosuppressive	ADJ
dpc-6169	272	44	treatment	treatment	NOUN
dpc-6169	272	45	.	.	PUNCT
dpc-6169	273	1	actas	actas	NOUN
dpc-6169	273	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-6169	273	3	.	.	PUNCT
dpc-6169	274	1	2019;110(4):289	2019;110(4):289	NUM
dpc-6169	274	2	-	-	SYM
dpc-6169	274	3	96	96	NUM
dpc-6169	274	4	.	.	PUNCT
dpc-6169	275	1	doi	doi	NOUN
dpc-6169	275	2	:	:	PUNCT
dpc-6169	275	3	10.1016	10.1016	NUM
dpc-6169	275	4	/	/	SYM
dpc-6169	275	5	j	j	PROPN
dpc-6169	275	6	.ad.2018.09.009	.ad.2018.09.009	PUNCT
dpc-6169	275	7	.	.	PUNCT
dpc-6169	276	1	pmid	pmid	NOUN
dpc-6169	276	2	:	:	PUNCT
dpc-6169	276	3	30360885	30360885	NUM
dpc-6169	276	4	.	.	PUNCT
dpc-6169	277	1	19	19	NUM
dpc-6169	277	2	.	.	PUNCT
dpc-6169	278	1	kim	kim	PROPN
dpc-6169	278	2	w	w	PROPN
dpc-6169	278	3	,	,	PUNCT
dpc-6169	278	4	kim	kim	PROPN
dpc-6169	278	5	sm	sm	PROPN
dpc-6169	278	6	,	,	PUNCT
dpc-6169	279	1	oh	oh	INTJ
dpc-6169	279	2	j	j	PROPN
dpc-6169	279	3	,	,	PUNCT
dpc-6169	279	4	et	et	PROPN
dpc-6169	279	5	al	al	PROPN
dpc-6169	279	6	.	.	PUNCT
dpc-6169	280	1	biomarkers	biomarker	NOUN
dpc-6169	280	2	for	for	ADP
dpc-6169	280	3	short	short	ADJ
dpc-6169	280	4	-	-	PUNCT
dpc-6169	280	5	term	term	NOUN
dpc-6169	280	6	omalizumab	omalizumab	NOUN
dpc-6169	280	7	response	response	NOUN
dpc-6169	280	8	in	in	ADP
dpc-6169	280	9	chronic	chronic	ADJ
dpc-6169	280	10	spontaneous	spontaneous	ADJ
dpc-6169	280	11	urticaria	urticaria	NOUN
dpc-6169	280	12	.	.	PUNCT
dpc-6169	280	13	  	  	SPACE
dpc-6169	280	14	ann	ann	PROPN
dpc-6169	280	15	dermatol	dermatol	NOUN
dpc-6169	280	16	.	.	PUNCT
dpc-6169	280	17	 	 	SPACE
dpc-6169	281	1	2024;36(6):367	2024;36(6):367	PROPN
dpc-6169	281	2	-	-	PUNCT
dpc-6169	281	3	75	75	NUM
dpc-6169	281	4	.	.	PUNCT
dpc-6169	282	1	doi	doi	NOUN
dpc-6169	282	2	:	:	PUNCT
dpc-6169	282	3	10.5021	10.5021	NUM
dpc-6169	282	4	/	/	SYM
dpc-6169	282	5	ad.24.004	ad.24.004	PROPN
dpc-6169	282	6	.	.	PUNCT
dpc-6169	283	1	pmid	pmid	NOUN
dpc-6169	283	2	:	:	PUNCT
dpc-6169	283	3	39623613	39623613	NUM
dpc-6169	283	4	.	.	PUNCT
dpc-6169	284	1	20	20	NUM
dpc-6169	284	2	.	.	PUNCT
dpc-6169	285	1	tonacci	tonacci	PROPN
dpc-6169	285	2	a	a	PRON
dpc-6169	285	3	,	,	PUNCT
dpc-6169	285	4	billeci	billeci	PROPN
dpc-6169	285	5	l	l	NOUN
dpc-6169	285	6	,	,	PUNCT
dpc-6169	285	7	pioggia	pioggia	NOUN
dpc-6169	285	8	g	g	NOUN
dpc-6169	285	9	,	,	PUNCT
dpc-6169	285	10	navarra	navarra	PROPN
dpc-6169	285	11	m	m	PROPN
dpc-6169	285	12	,	,	PUNCT
dpc-6169	285	13	gangemi	gangemi	PROPN
dpc-6169	285	14	s.	s.	PROPN
dpc-6169	285	15	omalizumab	omalizumab	NOUN
dpc-6169	285	16	for	for	ADP
dpc-6169	285	17	the	the	DET
dpc-6169	285	18	treatment	treatment	NOUN
dpc-6169	285	19	of	of	ADP
dpc-6169	285	20	chronic	chronic	ADJ
dpc-6169	285	21	idiopathic	idiopathic	ADJ
dpc-6169	285	22	urticaria	urticaria	NOUN
dpc-6169	285	23	:	:	PUNCT
dpc-6169	285	24	systematic	systematic	ADJ
dpc-6169	285	25	review	review	NOUN
dpc-6169	285	26	of	of	ADP
dpc-6169	285	27	the	the	DET
dpc-6169	285	28	literature	literature	NOUN
dpc-6169	285	29	.	.	PUNCT
dpc-6169	286	1	pharmacotherapy	pharmacotherapy	NOUN
dpc-6169	286	2	.	.	PUNCT
dpc-6169	287	1	2017	2017	NUM
dpc-6169	287	2	apr;37(4):464	apr;37(4):464	SYM
dpc-6169	287	3	-	-	PUNCT
dpc-6169	287	4	80	80	NUM
dpc-6169	287	5	.	.	PUNCT
dpc-6169	288	1	doi	doi	NOUN
dpc-6169	288	2	:	:	PUNCT
dpc-6169	288	3	10.1002	10.1002	NUM
dpc-6169	288	4	/	/	SYM
dpc-6169	288	5	phar.1915	phar.1915	PROPN
dpc-6169	288	6	.	.	PUNCT
dpc-6169	288	7	pmid	pmid	NOUN
dpc-6169	288	8	:	:	PUNCT
dpc-6169	288	9	28226418	28226418	NUM
dpc-6169	288	10	.	.	PUNCT
dpc-6169	289	1	after	after	ADP
dpc-6169	289	2	remission	remission	NOUN
dpc-6169	289	3	and	and	CCONJ
dpc-6169	289	4	its	its	PRON
dpc-6169	289	5	predictors	predictor	NOUN
dpc-6169	289	6	.	.	PUNCT
dpc-6169	290	1	j	j	PROPN
dpc-6169	290	2	allergy	allergy	PROPN
dpc-6169	290	3	clin	clin	PROPN
dpc-6169	290	4	immunolpract	immunolpract	PROPN
dpc-6169	290	5	.	.	PUNCT
dpc-6169	291	1	2020;8(2):796	2020;8(2):796	X
dpc-6169	291	2	-	-	PUNCT
dpc-6169	291	3	798.e1	798.e1	NOUN
dpc-6169	291	4	.	.	PUNCT
dpc-6169	292	1	doi	doi	NOUN
dpc-6169	292	2	:	:	PUNCT
dpc-6169	292	3	10.1016	10.1016	NUM
dpc-6169	292	4	/	/	SYM
dpc-6169	292	5	j.jaip.2019.08.010	j.jaip.2019.08.010	PROPN
dpc-6169	292	6	.	.	PUNCT
dpc-6169	293	1	pmid	pmid	NOUN
dpc-6169	293	2	:	:	PUNCT
dpc-6169	293	3	31425834	31425834	NUM
dpc-6169	293	4	.	.	PUNCT
dpc-6169	294	1	13	13	NUM
dpc-6169	294	2	.	.	PUNCT
dpc-6169	294	3	gouder	gouder	PROPN
dpc-6169	294	4	c	c	PROPN
dpc-6169	294	5	,	,	PUNCT
dpc-6169	294	6	asciak	asciak	PROPN
dpc-6169	294	7	r	r	NOUN
dpc-6169	294	8	,	,	PUNCT
dpc-6169	294	9	montefort	montefort	NOUN
dpc-6169	294	10	s.	s.	PROPN
dpc-6169	294	11	sex	sex	NOUN
dpc-6169	294	12	differences	difference	NOUN
dpc-6169	294	13	in	in	ADP
dpc-6169	294	14	the	the	DET
dpc-6169	294	15	efficacy	efficacy	NOUN
dpc-6169	294	16	,	,	PUNCT
dpc-6169	294	17	safety	safety	NOUN
dpc-6169	294	18	,	,	PUNCT
dpc-6169	294	19	and	and	CCONJ
dpc-6169	294	20	tolerability	tolerability	NOUN
dpc-6169	294	21	of	of	ADP
dpc-6169	294	22	omalizumab	omalizumab	NOUN
dpc-6169	294	23	after	after	ADP
dpc-6169	294	24	1	1	NUM
dpc-6169	294	25	year	year	NOUN
dpc-6169	294	26	in	in	ADP
dpc-6169	294	27	maltese	maltese	ADJ
dpc-6169	294	28	patients	patient	NOUN
dpc-6169	294	29	with	with	ADP
dpc-6169	294	30	asthma	asthma	NOUN
dpc-6169	294	31	.	.	PUNCT
dpc-6169	295	1	ann	ann	PROPN
dpc-6169	295	2	allergy	allergy	PROPN
dpc-6169	295	3	asthma	asthma	PROPN
dpc-6169	295	4	immunol	immunol	PROPN
dpc-6169	295	5	.	.	PUNCT
dpc-6169	296	1	2017;118(4):513	2017;118(4):513	NUM
dpc-6169	296	2	-	-	SYM
dpc-6169	296	3	4	4	NUM
dpc-6169	296	4	.	.	PUNCT
dpc-6169	296	5	doi	doi	NOUN
dpc-6169	296	6	:	:	PUNCT
dpc-6169	296	7	10.1016	10.1016	NUM
dpc-6169	296	8	/	/	SYM
dpc-6169	296	9	j.anai.2017.01.019	j.anai.2017.01.019	PART
dpc-6169	296	10	.	.	PUNCT
dpc-6169	297	1	pmid	pmid	NOUN
dpc-6169	297	2	:	:	PUNCT
dpc-6169	297	3	28283278	28283278	NUM
dpc-6169	297	4	.	.	PUNCT
dpc-6169	298	1	14	14	NUM
dpc-6169	298	2	.	.	X
dpc-6169	298	3	yu	yu	PROPN
dpc-6169	298	4	m	m	PROPN
dpc-6169	298	5	,	,	PUNCT
dpc-6169	298	6	terhorst	terhorst	NOUN
dpc-6169	298	7	-	-	PUNCT
dpc-6169	298	8	molawi	molawi	VERB
dpc-6169	298	9	d	d	NOUN
dpc-6169	298	10	,	,	PUNCT
dpc-6169	298	11	altrichter	altrichter	PROPN
dpc-6169	298	12	s	s	PART
dpc-6169	298	13	,	,	PUNCT
dpc-6169	298	14	et	et	PROPN
dpc-6169	298	15	al	al	PROPN
dpc-6169	298	16	.	.	PROPN
dpc-6169	298	17	omalizumab	omalizumab	NOUN
dpc-6169	298	18	in	in	ADP
dpc-6169	298	19	chronic	chronic	ADJ
dpc-6169	298	20	inducible	inducible	ADJ
dpc-6169	298	21	urticaria	urticaria	NOUN
dpc-6169	298	22	:	:	PUNCT
dpc-6169	298	23	a	a	DET
dpc-6169	298	24	real	real	ADJ
dpc-6169	298	25	-	-	PUNCT
dpc-6169	298	26	life	life	NOUN
dpc-6169	298	27	study	study	NOUN
dpc-6169	298	28	of	of	ADP
dpc-6169	298	29	efficacy	efficacy	NOUN
dpc-6169	298	30	,	,	PUNCT
dpc-6169	298	31	safety	safety	NOUN
dpc-6169	298	32	,	,	PUNCT
dpc-6169	298	33	predictors	predictor	NOUN
dpc-6169	298	34	of	of	ADP
dpc-6169	298	35	treatment	treatment	NOUN
dpc-6169	298	36	outcome	outcome	NOUN
dpc-6169	298	37	and	and	CCONJ
dpc-6169	298	38	time	time	NOUN
dpc-6169	298	39	to	to	PART
dpc-6169	298	40	response	response	VERB
dpc-6169	298	41	.	.	PUNCT
dpc-6169	298	42	  	  	SPACE
dpc-6169	298	43	clin	clin	PROPN
dpc-6169	298	44	exp	exp	NOUN
dpc-6169	298	45	allergy	allergy	PROPN
dpc-6169	298	46	.	.	PUNCT
dpc-6169	298	47	  	  	SPACE
dpc-6169	298	48	2021;51(5):730	2021;51(5):730	NUM
dpc-6169	298	49	-	-	SYM
dpc-6169	298	50	4	4	NUM
dpc-6169	298	51	.	.	PUNCT
dpc-6169	298	52	doi	doi	NOUN
dpc-6169	298	53	:	:	PUNCT
dpc-6169	298	54	10.1111	10.1111	NUM
dpc-6169	298	55	/	/	SYM
dpc-6169	298	56	cea.13838	cea.13838	X
dpc-6169	298	57	.	.	PUNCT
dpc-6169	299	1	pmid	pmid	NOUN
dpc-6169	299	2	:	:	PUNCT
dpc-6169	299	3	33522024	33522024	NUM
dpc-6169	299	4	.	.	PUNCT
dpc-6169	300	1	15	15	NUM
dpc-6169	300	2	.	.	PUNCT
dpc-6169	300	3	kitao	kitao	PROPN
dpc-6169	300	4	r	r	PROPN
dpc-6169	300	5	,	,	PUNCT
dpc-6169	300	6	oda	oda	PROPN
dpc-6169	300	7	y	y	PROPN
dpc-6169	300	8	,	,	PUNCT
dpc-6169	300	9	washio	washio	VERB
dpc-6169	300	10	k	k	PROPN
dpc-6169	300	11	,	,	PUNCT
dpc-6169	300	12	et	et	PROPN
dpc-6169	300	13	al	al	PROPN
dpc-6169	300	14	.	.	PROPN
dpc-6169	301	1	lower	low	ADJ
dpc-6169	301	2	efficacy	efficacy	NOUN
dpc-6169	301	3	of	of	ADP
dpc-6169	301	4	omalizumab	omalizumab	NOUN
dpc-6169	301	5	in	in	ADP
dpc-6169	301	6	older	old	ADJ
dpc-6169	301	7	adults	adult	NOUN
dpc-6169	301	8	with	with	ADP
dpc-6169	301	9	chronic	chronic	ADJ
dpc-6169	301	10	spontaneous	spontaneous	ADJ
dpc-6169	301	11	urticaria	urticaria	NOUN
dpc-6169	301	12	.	.	PUNCT
dpc-6169	301	13	  	  	SPACE
dpc-6169	302	1	j	j	PROPN
dpc-6169	302	2	dermatol	dermatol	NOUN
dpc-6169	302	3	.	.	PUNCT
dpc-6169	302	4	 	 	SPACE
dpc-6169	303	1	2022;49(7):729	2022;49(7):729	NUM
dpc-6169	303	2	-	-	SYM
dpc-6169	303	3	31	31	NUM
dpc-6169	303	4	.	.	PUNCT
dpc-6169	304	1	doi	doi	NOUN
dpc-6169	304	2	:	:	PUNCT
dpc-6169	304	3	10.1111/1346	10.1111/1346	NUM
dpc-6169	304	4	-	-	SYM
dpc-6169	304	5	8138.16370	8138.16370	NUM
dpc-6169	304	6	.	.	PUNCT
dpc-6169	305	1	pmid	pmid	NOUN
dpc-6169	305	2	:	:	PUNCT
dpc-6169	305	3	35352836	35352836	NUM
dpc-6169	305	4	.	.	PUNCT
dpc-6169	306	1	16	16	NUM
dpc-6169	306	2	.	.	PUNCT
dpc-6169	307	1	korn	korn	PROPN
dpc-6169	307	2	s	s	PROPN
dpc-6169	307	3	,	,	PUNCT
dpc-6169	307	4	schumann	schumann	PROPN
dpc-6169	307	5	c	c	PROPN
dpc-6169	307	6	,	,	PUNCT
dpc-6169	307	7	kropf	kropf	PROPN
dpc-6169	307	8	c	c	AUX
dpc-6169	307	9	,	,	PUNCT
dpc-6169	307	10	et	et	PROPN
dpc-6169	307	11	al	al	PROPN
dpc-6169	307	12	.	.	PROPN
dpc-6169	307	13	effectiveness	effectiveness	NOUN
dpc-6169	307	14	of	of	ADP
dpc-6169	307	15	omalizumab	omalizumab	NOUN
dpc-6169	307	16	in	in	ADP
dpc-6169	307	17	patients	patient	NOUN
dpc-6169	307	18	50	50	NUM
dpc-6169	307	19	years	year	NOUN
dpc-6169	307	20	and	and	CCONJ
dpc-6169	307	21	older	old	ADJ
dpc-6169	307	22	with	with	ADP
dpc-6169	307	23	severe	severe	ADJ
dpc-6169	307	24	persistent	persistent	ADJ
dpc-6169	307	25	allergic	allergic	ADJ
dpc-6169	307	26	asthma	asthma	NOUN
dpc-6169	307	27	.	.	PUNCT
dpc-6169	307	28	 	 	SPACE
dpc-6169	308	1	ann	ann	PROPN
dpc-6169	308	2	allergy	allergy	PROPN
dpc-6169	308	3	asthma	asthma	PROPN
dpc-6169	308	4	immunol	immunol	PROPN
dpc-6169	308	5	.	.	PUNCT
dpc-6169	308	6	 	 	SPACE
dpc-6169	309	1	2010;105(4):313	2010;105(4):313	NUM
dpc-6169	309	2	-	-	SYM
dpc-6169	309	3	9	9	NUM
dpc-6169	309	4	.	.	PUNCT
dpc-6169	309	5	doi	doi	NOUN
dpc-6169	309	6	:	:	PUNCT
dpc-6169	309	7	10.1016	10.1016	NUM
dpc-6169	309	8	/	/	SYM
dpc-6169	309	9	j.anai.2010.07.007	j.anai.2010.07.007	PROPN
dpc-6169	309	10	.	.	PUNCT
dpc-6169	310	1	pmid	pmid	NOUN
dpc-6169	310	2	:	:	PUNCT
dpc-6169	310	3	20934632	20934632	NUM
dpc-6169	310	4	.	.	PUNCT